N E W !!!
Frustrated by Ineffective
Cancer Therapies ? Do you know any terminally ill cancer patient ?
Suffering from Chemotherapy
side effects ? Do not lose Hope !
Safe Herbal Cancer
Treatment is here. Treat Cancer, Naturally with CARCTOL - The Ray of Hope.
It all started around 1968, when a young man working with
tribals of Assam(India) discovered astonishing properties of some herbs ,those when ingested, produced miraculous results
in world healing. This young man, Dr. Nandlal Tiwari has been since then continuously experimenting this natural formulation
among cancer patients.
CARCTOL is a thoroughly researched herbal cancer therapy
produced from Natural herbs made into a powerful herbal dietary supplement.
Safe and harmless, CARCTOL treats all types of cancer which
includes Cancer of the Esophagus, Ear, Nose Throat, Brain, Breast, Lymphoma, Lungs, Blood, Kidney, Cervix, Stomach, Colorectal,
Pancreas and Hepatobilliary Cancer.
Testimonial - " My mother Aged 60 now was suffering from
Diabetes and Malignant Melanoma in ascending colone, in the year of 1996. Her platelet count was decreasing day by day. At
All India Institute of Medical Sciences (New Delhi) she was advised to operate and with an external bag for faeces and life was counted for only
3 months. One of the doctor from AIIMS had suggested to see Dr. Tiwari. we met him and my mother was undergoing treatement
with the carctol for about three years. Just after one year of administration of the CARCTOL under the medical supervision
of Dr. Tiwari, my mother was again taken to AIIMS for checking. It was miracle that she didn't had any traces of cancer.As
per the advice of Dr. Tiwari she took medicines for another two years. She is quite healthy now. My sincere Gratitude to Dr.
Tiwari"
- Dr. S. Sen, New Delhi INDIA
Cancer Treatment
using Carctol : How does Carctol Work?
What is CARCTOL
?
CARCTOL is a gift of timeless knowledge of Ayurveda. What
started as a precious mix of herbs in powdered form, has been refined over the years as a Herbal Dietary Supplement (in capsules).
Today CARCTOL is a herbal compound containing only rare,
natural and indigenous Indian Herbs mixed together with proportional strength to treat and heal all types of Cancer.
This Herbal Cancer Treatment, CARCTOL is distinguished from
other conventional anti-cancer drugs for the fact that it does not cause any side effects, has ZERO Toxicity and is backed
by Pharmacological data. Besides healing Cancer, it also neutralises toxicity produced by chemotherapeutic agents.
CARCTOL Treats CA-Cervix, Ca Esophagus, Leukaemia Myoblastic
and Lymphoblastic and other Cancers of Soft Tissues.
Composition of CARCTOL
Each CARCTOL capsule of 500 mg contains :
Hemidesmus Indicus - 20 mg
Tribulus Terrestris - 20 mg
Piper Cubeba Linn - 120 mg
Ammani Vesicatoria - 20 mg
Lepidium Sativum Linn - 20 mg
Blepharis Edulis - 200 mg
Smilax China Linn
- 80 mg
Rheumemodi Wall - 20 mg
Advantages of CARCTOL
Oral Administration
Effective against multi-drug resistance
Well Tolerated
Cost Effective
Prevents Recurrences of Secondaries.
Relieves Despondency
Also effective for those patients who are troubled by the
side-effects of chemo-therapy and radiotherapy
Dosage Instructions
Adult (Stage
1 or 2) 1 capsule 4 times a day
Adult (Chronic/Terminal Cases) 2 Capsules 4 times a day
Child 1/2 * 4 times a day
Infant 1/4 * 4 times a day
* In cases of Children and Infants, capsule has to be opened,
and the contents inside have to be divided as per dosage. For example in case of a child, 1/2 of the content of a capsule
has to be given each time , 4 times in a day. The contents can ideally be fully dissolved in milk and then given.
In chronic cases, the dosage can be also be increased to
6 to 8 capsules a day, in proportion or as recommended by the physician.
Duration
An adult has to take one CARCTOL capsule normally four times
a day i.e. at 8 AM - 12 Noon - 4 pm - 8 pm strictly after meals or light refreshments with milk or
water. You can vary the above times giving a strict 4 hour gaps as per your meal schedule. For any clarifications, click here
to write to us.
The dosage may be increased upto 6 to 8 capsules a day considering the advancement of malignancy in the patient. Since CARCTOL capsule contains herbs, it
has a slow action. To be assured of its efficacy, one should continue it strictly as per dosage schedule for atleast 60 days
(2 months) for the Initial Response and then to continue as per physician's advise. CARCTOL capsules are to be continued for
six more months even after obtaining "No Evidence of Maligancy" report from a reputed diagnostic laboratory. It is important
not to interrupt the daily dosage in any case. During the treatment, if any other ailment develops, required treatment can
be taken by consulting your family physician. CARCTOL does not interfere or cross-react with any medicine.
Precautions
Anything that tastes sour must be avoided. Read our FAQ
here for more details.
Sufficient quantity of "Boiled and then cooled" water should
be taken during the administration of CARCTOL.
It is also advised that consumption of liquor, tobacco in
any form and non-vegetarian food should be avoided.
© IvyComm Systems
1405, Sector 14, Faridabad HR 121007,
India.
Tel : 00 91 9818181405
Fax : 00 91 129 5003781
Dr. Nandlal Tiwari
Internationally acclaimed ayurvedic specialist Dr. Nandlal
Tiwari has been treating terminally cancer patients with his special herbal cancer therapy for the past 20 years with a fair
measure of success.
He invented CARCTOL from experiments done on valuable information
he gathered from the tribals in ASSAM forests in India during his research on
herbs there. He claims that his findings proved effective in almost all types of cancer.
Dr. Tiwari, is from Jaipur, Rajasthan, India treats only terminally ill patients and claims to have success rate of between 30 to 40 percent.
Dr. Tiwari feels that modern medical practitioners should
take up research projects to understand how CARCTOL, the alternative cancer treatment works on the body.
Dr. Tiwari has been receiving recognition from all over
the world and Central governments of various countries have been asked to test and work on this formulation to refine it even
further.
He has travelled and treated patients worldwide, including
Germany, Australia, Sweden, Britain and Kenya. CARCTOL, his invention
is a blend comprising eight herbal ingredients, which he said he came up with after much rigorous trial and experiment.
"Ayurvedic treatment works because of the correct mixture
of the herbs. It is different from the medicines prescribed by general practitioners because of their chemical ingredients."
Dr. Tiwari who has appeared on BBC television in a documentary
and several other documentaries in India to report on his herbal cancer treatment said, he provided, "A Ray of Hope" for
patients, who sought him as a last resort.
Q : What is Carctol?
A : Carctol
is a herbal remedy made from pure Indian Herbs for treating all types of Cancer. You can find all information about it by
clicking here. Browse through this FAQ for more common questions. If you still have some query unanswered, write to us.
Q : Who all can
take CARCTOL? Does it benefit only people with Cancer?
A : CARCTOL is a herbal remedy for cancer as well as a powerful
general tonic. Though it is generally taken by people with cancer or tumors, it is very safe and harmless that even non-cancer
patients can also take it. So much so EVEN if a person having no disease whatsoever may safely take it for 6 months with no
harm done.
Those patients who have been taking Tobacco or having whooping
cough or difficulty in swallowing food may take CARCTOL. In such cases, carctol treats these problems with positive results.
Even women who are victims of semenal passing, monthly gynaecological disorders, falling appetite, liver damage due to access
of alcohol OR any type of vaginal disorders may also take CARCTOL with good results.
Q : What are the
dosage instructions of taking CARCTOL?
A : Detailed dosage Instructions can be read here. If you
still have any queries, do write to us.
In brief, Adult 1 capsule 4 times a day
Child 1/2 * 4 times a day
Infant 1/4 * 4 times a day
* In cases of Children and Infants, capsule has to be opened,
and the contents inside have to be divided as per dosage. For example in case of a child, 1/2 of the content of a capsule
has to be given each time , 4 times in a day. The contents can ideally be fully dissolved in milk and then given.
Q : Can we take
CARCTOL in the morning or with an empty stomach?
A : CARCTOL should not be taken in the morning with an empty
stomach. CARCTOL capsule should generally be taken 4 times a day with a little water. It is advisable to take a cup of milk
immediately after each dose however not necessary. If there be any difficulty in swallowing the capsule, the contents of the
capsule may be mixed in milk and then taken. The number of doses may be increased from 4 times a day to 6 times a day or even
8 times a day depending upon the chronicity and malignancy of patient's cancer.
Q : How long does
CARCTOL take to act or show its effects?
A : CARCTOL generally takes around 60 days or approximately
2 months for an INITIAL RESPONSE. As CARCTOL is a sum-total or a combination of only pure herbs, its effect will be slow and
steady. Hence it should be taken regularly for two months. If the medicine proves to be effective within two months, continue
the medicine. If there is no sign of improvement within two months, the medicine may be discontinued.
Note : In any case if the patient thinks of discontinuing
the medicine in less than two months, he/she might as well not take it at all.
Q : How will the
patient know whether CARCTOL is working or not? How can we be sure that the cancer is healing due to its action?
A : Sometimes the patient would like to know the efficacy
of the medicine. Many people think as to how will they be able to know whether CARCTOL is working or not. Dr. Tiwari believes
that if the medicine is working, then patient will feel the improvement within. This can be ascertained and observed within
two months by the general feeling of the patient. Only when the patient feels satisfied of the improvement, should the medicine
be continued beyond two months or else it must be stopped henceforth.
Q : While taking
CARCTOL, if there is some other disease, what should be done? Can I take other medicines along with CARCTOL without adverse
effects?
A : While undergoing the "CARCTOL" treatment, if the patient
is struck by any other disease or physical difficulty apart from cancer, he /she may be taken to the concerned doctor for
consultation. Any medicines prescribed by Doctor may be taken without discontinuing the "CARCTOL" capsules provided that a
gap of half an hour is given between these two medicines. It means that CARCTOL never reacts with any of the other medicines
being taken by the patient. T
Q : Is CARCTOL harmful?
Does it cause any side effects ?
A : CARCTOL is absoloutely safe and harmless. Whether "CARCTOL"
cures your cancer or not, one must remember that IT WILL NOT do any harm to the patient. Obtained and made from completely
natural resources, it can never cause any harm or side effects. So much so EVEN if a person having no disease whatsoever may
safely take it for 6 months with no harm done.
Q : Is CARCTOL toxic?
Has it been tested for toxicity?
A : CARCTOL is made from pure herbs. It has already been
tested at All India Institute of Medical Sciences Laboratory New Delhi and has been cleared of causing any side effects on
human body. Carctol was also tested at Lyne, Martin and Radford Laboratory at London. These Certificate
of Analysis and other relevant test reports are available upon request.
CARCTOL is a product prepared on the guidelines laid down
by the Drugs Act in India. CARCTOL has no metal, remains of any burnt objects/herbs , intoxicating elements,
poison, juices of chemicals of any kind that may injur or impair human life. It is an absoloutely SAFE medication and can
be taken as a WHOLE HERBAL FOOD OR DIETARY SUPPLEMENT.
Q : What are the
DOs and DONTs while taking CARCTOL? Are there any dietary restrictions while taking it?
A : "Pre-boiled and then cooled" water should be given to
the patient. As far as it is practical, the patient should avoid plain water. The patient must be given as much as possible
in order to create more urine. This process is beneficial in curing the patient.
The patient should avoid ALL SOUR things during the treatment.
However, in case of sickness, if the Doctor prescribes a medicine which is sour or Vitamin "C", there is no bar to that. But
in no case, sour things are not to be taken by the patient. There are certain things which are sour in the beginning or in
course of eating towards the end. For example - Mango. Mango is sour when raw but sweet when ripe. Another example is CURD.
In the beginning it is sweet but after a few hours it becomes sour. So things or foods like these should not be taken. Sour
things contain acids which are already present in the body. Taking sour things unnecessarily adds more acids to the body which
are not needed and will only hamper the progress made by CARCTOL. However, fruits like bananas, papaya and vegetables like
carrot or its juice, coconut juice can be taken. Any food which cannot be digested easily by the patient should not be given.
Milk should only be taken depending upon the patient's digestion capacity and power.
Patients should be able to digest all food intake well.
If their digestion is not upto the mark as is the case with 70% of the people in this world, they should consult their physician
and take some appropriate medicine for improving digestion. CARCTOL works better when the digestion capacity of the patient
is good.
Q : Why should not
I take Sour things(food that is sour in nature or have sour properties) while taking CARCTOL?
A : According to Dr. Tiwari, "Foods taste Sour till the
time they are tasted by your tongue. Once they are digested and assimilated, you cannot tell whether it is sour or sweet.".
As to why foods having SOUR properties should not be taken is because All things sour in taste or nature are acidic. They
release acids when taken and these unnecessary acids get accumulated into the body. Many of these acids are already present
in the body and your body does not need any additional acids. These acids affect the efficacy and action of CARCTOL and are
not good for healing tumors and cancers. Hence, we strictly advise not to take foods with Sour properties.
Examples of SOUR food are : Tomato, tangerine, plum, lemon,
grape, haw, cherry apple, pomegranate, vinegar, curd, Mango. Some doctors may advise any of these foods, but please bear in
mind that these sour foods may hamper the action and effect of CARCTOL.
Q : Can I take non-vegetarian
food while taking carctol? Is it mandatory to take vegetarian food?
A : It is advised that a patient should maintain a vegetarian
diet. However, if you are taking any non-vegetarian food, please make sure that it is easily digested and that it is not sour
in any form.
Q : What are the
other benefits of CARCTOL besides healing Cancer?
A : CARCTOL is a general healer of all kinds of tumors.
It also treats and removes all the symptoms and side effects caused by Chemotherapy and RadioTherapy. Those patients who have
been taking Tobacco or having whooping cough or difficulty in swallowing food may take CARCTOL. In such cases, carctol treats
these problems with positive results. Even women who are victims of semenal passing, monthly gynaecological disorders, falling
appetite, liver damage due to access of alcohol OR any type of vaginal disorders may also take CARCTOL with good results.
Q : Will everyone
be fully cured off Cancer by using CARCTOL? Do you make any claims or guarantees for Cure with CARCTOL?
A : One should not be under any misconception that 100%
patients would be fully cured by CARCTOL. We have clearly mentioned that we have seen a 30% to 40% success rate with CARCTOL
in cancer patients. This success rate is considered to be very high particularly when the disease we deal with is CANCER (even
malign CANCER). Hence only 30% to 40% patients who come under CARCTOL's control are generally cured and the rest do not. In
other cases, where there might not be a complete healing of cancer, there are strong chances of a significant improvement.
Hence, please do not associate words like "Assurance", "Guarantee" , "Surety" , "Claim" with this medicine. We believe that
even if 30 out of 100 patients are benefitted, CARCTOL has played its part well in healing the world. Patients who feel despondent,
frustrated, give up hopes of their lives, or to whom doctors have refused for any further treatment are advised to try CARCTOL
for 2 months.
Q : Will CARCTOL
help me if I have Ascites i.e. accumulation of fluid in abdominal cavity?
A : It is seen that CARCTOL is not very effective in those
patients who have ASCITES. But it is observed that it still works in 5% of cases which have ASCITIS involved. Read below for
definition of ASCITES.
Q : What is Ascites?
A : Inside the abdomen there is a membrane called the peritoneum
which has two layers. One layer lines the abdominal wall and the other layer covers the organs inside the abdominal cavity.
The peritoneum produces a fluid that acts a lubricant and allows the abdominal organs to glide smoothly over one another.
Sometimes an excess of this fluid can build up between the two layers and this is called ascites. Ascites can be a symptom
of many types of cancer. The types of cancer that are more likely to cause ascites are: cancer of the ovary, lining of the
womb (endometrium), breast, bronchus (main airway), large bowel (colon), stomach and pancreas.
Q : Why do you advise
buying a 2 month supply for newer patients. Why should not I try for only 1 month?
A : CARCTOL is a sum-total or a combination of only pure
herbs, its effect will be slow and steady. Hence it should be taken regularly for two months. If the medicine proves to be
effective within two months, continue the medicine. If there is no sign of improvement within two months, the medicine may
be discontinued. In any case if the patient thinks of discontinuing the medicine in less than two months, he/she might as
well not take it at all.
Please Note : CARCTOL has been economically priced to help
cancer patients. It is way below the costs that an average cancer patient incurs on chemotherapy, and other conventional methods
of treatment and paying for their medical bills.
Between 1985 to
1989, 1900 patients with terminal stage were treated.
The success of this
trial is depicted below :
Grade A = 80-100%
symptome free upto 2yrs then left the follow up
Grade B = 50-80%
symptomatic improvement, then left the follow up
Grade C = 5-50%
improvement, then left the follow up
Grade D = Those
who took it for two months only
Zero Toxicity Report
CARCTOL has been tested for Zero Toxicity at All India Institute
of Medical Sciences and also at -
Lyne, Martin & Radford, UK. Both these toxicity test
reports are available upon request to patients and researchers.
Severn Trent Laboratories in Coventry, UK has also issued
a Lab Test Report after doing a thorough Compound and Multiresidue Analysis. All these reports are also available upon request.
PREVENTION IS BETTER THAN CURE
For individuals with potential hazard of cancer like smokers,
tobacco addicts, drug addicts, alcoholics, residents of highly polluted areas, patients of chronic coughs, ulcers, women with
consistent leucorrhoea problems and such other health hazards are strongly recomended to take CARCTOL regularly.
In addition families with history of cancer patients are
also advised to use CARCTOL as a preventive meassure.
Over the years, during Dr. Tiwari's research, he has received
many worthy mentions in various newspapers, magazines and health publications.
We attempt to launch CARCTOL publicly through this website
and we would be updating this section as and when there are more press releases outside India.
Outside India
Dr. Tiwari has appeared in numerous interviews in United
Kingdom in both print and television including a BBC Documentary.
In print, here is a writeup published in The Sunday Tribune
in South Africa.
Download as Text | Download as Scanned Image(Jpeg)
Till now, CARCTOL has received mentions in numerous publications
(most of them which are Indian). Listed below are few of these. We will be updating this section with English versions of
these writeups very soon.
The Assam Tribune - Feb 27, 1990
The Hitavada - November 10, 1984
United News of India - March 12, 1994
Indian Express - Feb 27, 1990
Hindustan Times - Feb 26, 1990
Dainik NavJyoti - 17 April 2001
Patheya Kan - November 1998
Kadambari - January 1994
Vishwa Rakshak - 5th April 2001
Ranchi Express - 1 June 2001
Sanmarg - 14 June 1999
CARCTOL is now available for ordering and can be shipped
to all parts of the world. We have designed ergonomical packs for all the patients for ease of use.
*Note* : For initial trial purposes, we strongly advise
that CARCTOL must be taken for atleast 60 days or 2 months for it to show effects. CARCTOL, made from pure natural herbs takes
atleast 60 days for the INITIAL RESPONSE.
Dosage Instructions
Adult
(Early Stage :I,II) 1 capsule 4 times a day
Adult (Chronic/Terminal Cases) 2 Capsules 4 times a day
Child 1/2 * 4 times a day
Infant 1/4 * 4 times a day
* In cases of Children and Infants, capsule has to be opened,
and the contents inside have to be divided as per dosage. For example in case of a child, 1/2 of the content of a capsule
has to be given each time , 4 times in a day. The contents can ideally be fully dissolved in milk and then given.
Each Box of CARCTOL contains 120 capsules. Each box is priced
uniformly throughout the world for USD 69.95. We accept all major credit cards and we use 2Checkout.com Payment Gateway for
Secure 128 bit encrypted transactions)
Following packs
are available :
>> 2 boxes of 120 capsules = 240 Capsules : US$ 124.95
Click here to buy
(You save $15 here)
>> 4 boxes of 120 capsules = 480 capsules : US$ 209.95
Click here to buy
(You save $70 here)
>> 6 boxes of 120 capsules = 720 capsules : US$ 299.95
Click here to buy
(Super Saver Pack. It saves you $120)
>> 1 box of 120 Capsules (Not Recommended for new
patients)
US$ 69.95 each. Click here to buy.
Shipping Information
All orders are shipped within 72 hours by EMS or Airborne
Express. Expected time of Delivery is within 8 days of ordering.
Refund Policy
- In case the customer is dissatisfied with the product,
we will accept the product back within 30 days of ordering and refund the amount back to your credit card. However, shipping
charges are not refundable and a fixed $15 charge as shipping will be deducted from the refund amount.
- In case the product ordered by you is never received,
please write to us. We will let you know the status within 48 hours. In case we are not able to produce the proof of delivery,
we will be happy to refund the full amount.
- We resolve all refund inquiries within 72 hours and maintain
a shopper-friendly refund policy.
Go to >>
>> Read about Dr. Nandlal Tiwari
>> Frequently Asked Questions
>> About the Medicine
>> Clinical Trials of CARCTOL
>> Press Releases
>> Questions? Give us your feedback
>> Sign up for our Newsletter
"God has not given us any disease for which he has not provided
a remedy." - Paracelsus
Call us at : (+91) 981 8181405
Fax : +91 129 5003781 (India)
Secure Online shopping with CCAvenue.com
CCAvenues.com is our online retailer. Our shopping-cart
software runs in Secure Mode on the Online Shopper's browser, using SSL (Secure Sockets Layer) to encrypt sensitive data such
as credit card numbers. All charges will be billed and appear as "CCAvenues.com" on your credit card statement.
While selecting products and adding them to the Shopping
Cart, the Online Shopper is in Non-Secure Mode. After he/she presses the Checkout button, we switch to Secure Mode in order
to collect the billing and shipping information. All modern Web browsers support
the SSL standard, but the Online Shopper can choose to checkout using Non-Secure Mode if necessary.
Waging War On Lung Cancer
Five years ago, when Ken Giddes was vacationing with his wife in Vancouver, British Columbia, the 61-year-old resident of Atlanta began feeling short of breath. But since he was "running around quite a bit," Giddes chalked up
his problem to being an overachieving tourist. When he returned home, though, his shortness of breath persisted. The cause--uncovered
by an x-ray--was a collapsed lung.
But it wasn't until he underwent surgery to repair his lung, that the cause of the collapse was clear: lung cancer
had eaten a hole in the air sack of his lung. After surgeons removed his lung in an effort to contain the cancer, they checked
Giddes for any traces of cancer every three months. Within a year there was more bad news: a CT scan revealed 13 spots on
his remaining lung.
Surgery revealed the cancer had spread throughout his remaining lung. Giddes recalled that he was given less than a
30 percent chance of living another two years. But he decided to battle the cancer "with all the energy, hope and positive
attitude I could muster." After 30 weeks of chemotherapy, he was told his cancer was in remission.
Today, he's glad he didn't give up because he's beaten the odds, surviving five years since his cancer was diagnosed.
And as the head of the Caring Ambassador Program, sponsored by Republic Financial Corporation, he's helping other cancer survivors
wage war on lung cancer, too.
Survival and Detection
Lung cancer is the leading cause of cancer deaths among both men and women, according to the American Cancer Society.
Since 1987, more women have died each year of lung cancer than of breast cancer.
Detecting lung cancer in its early stages is difficult in some cases because the disease spreads very quickly and symptoms
often don't appear until the disease is advanced. Only about 15 percent of lung cancers are found before the cells have spread
to lymph nodes or distant organs.
Still, the survival rate for the disease has improved over the years. The one-year survival rate for patients is about
40 percent today compared with 32 percent in 1973. And five-year survival is up from 8 percent in the 1960s to 14 percent
today. Improvement in survival rates can be attributed, at least partially, to diagnostics and new drugs that the Food and
Drug Administration has approved.
Lung cancer can be diagnosed by:
a chest x-ray or CT scan to check for spots on the lungs
a microscopic analysis of phlegm cells
a bronchoscopy, which involves passing a lighted tube through the tubes that carry air to the lungs to see if tumors
or blockages exist.
If suspicious tissue or spots are detected, a needle biopsy is typically performed, so that a sample of the tumor can
be obtained to confirm the diagnosis of lung cancer.
There also are two other diagnostic tools that may be used in place of a biopsy.
The Xillix LIFE-Lung Fluorescence Endoscopy System is a medical device FDA approved in 1996 for detecting bronchial
tissue abnormalities in patients with previous, current or suspected lung cancer. A tube inserted through a patient's mouth
into the bronchi (tubes leading from the trachea to the lungs) delivers a blue laser light to the bronchial tissue. The image
the laser reveals is projected onto a video monitor. While normal tissue appears green, abnormal tissue will appear reddish
brown. Suspicious areas can then be biopsied. The system was approved for use in conjunction with conventional white light
bronchoscopy. While the illumination provided by the white light helps doctors identify tissue that looks abnormal, the new
blue laser system detects more tissue changes than can be seen with the white light alone.
The approval of this device is significant, says Harry Sauberman, chief of the ear, nose and throat devices branch
in FDA's Center for Devices and Radiological Health. It can spot moderate to severe dysplasia (irregular tissue), "some of
which may turn out to be malignant and you'll have a case of lung cancer," he explains. Patients with dysplasia can then be
closely monitored, and if cancer appears, it can be treated in its earliest stages.
The second diagnostic tool is an imaging agent called Nofetumomab (verluma). Approved by FDA in 1996, it can determine
the extent of disease in patients already diagnosed with small cell lung cancer through a biopsy but who have not yet been
treated. Nofetumomab is a fragment of a monoclonal (synthetic) antibody that, when tagged with a radioisotope, can detect
a protein found on the surface of most small cell lung cancers. The antibody collects in tumor sites and other areas of the
body where protein is detected and, using special cameras, doctors can see the areas as "hotspots." This information helps
physicians see how far the cancer has spread without exploratory surgery or other diagnostic tests and allows them to develop
a more effective treatment plan.
According to Patricia Keegan, M.D., deputy director for the division of clinical trials design and analysis in FDA's
Center for Biologics Evaluation and Research, the major advantage of using the imaging agent is that it allows doctors to
do a full body scan of a patient. "The disadvantage is that it isn't as sensitive in any one area as other scans," she says.
"It's not as good as a CT scan for picking up every liver metastasis. And it isn't as good as an MRI or CT scan of the head
to pick up brain metastasis. But if all you want is a quick and dirty answer about whether the cancer is widely disseminated
or not, it's a relatively simple test to do."
Treatment
About 75 percent of lung cancer cases are categorized as non-small cell lung cancer, and the other 25 percent are small
cell lung cancer. Lung cancer can multiply quickly and form large tumors, which sometimes spread to lymph nodes and other
organs.
Once lung cancer is detected, a treatment plan is developed based on the patient's physical health, whether the lung
cancer is small cell or non-small cell and how extensively the cancer has spread. (See "Stages of Lung Cancer.") Treatment
may include surgery, chemotherapy, radiation, or a combination of two or more of these therapies.
FDA recently approved three therapies to treat non-small cell lung cancer: Photofrin (porfimer sodium), Taxol (paclitaxel)
in combination with the commonly used cancer drug cisplatin, and Gemzar (gemcitabine hydrochloride) in combination with cisplatin.
Photofrin, a light-activated drug, was approved in January 1998 for patients with early stage, non-small cell lung
cancer who cannot undergo surgery or radiotherapy due to other medical conditions. Administered intravenously, Photofrin accumulates
in the tumor cells. A laser, directed toward the cancerous tissue, then activates the drug. A significant side effect is extreme
photosensitivity, making it necessary for patients to stay out of the sun "almost completely for about a month," says Grant
Williams, M.D., a medical team leader in the division of oncology drug products in FDA's Center for Drug Evaluation and Research.
Williams admits that the number of patients with early stage lung cancer who will be helped by Photofrin will be quite
limited. "We're talking about a very small number of patients compared to the number of lung cancer patients who have extensive
cancers that can't be operated on," he says.
Williams notes, however, that Photofrin may also be able to relieve symptoms in some patients with advanced non-small
cell lung cancer. He explains that Photofrin has been demonstrated to be helpful in relieving breathing difficulties caused
by tumors that are obstructing the flow of air through patients' bronchial tubes. Approval for this use was recommended by
an FDA advisory committee in September 1998. Final FDA action is pending.
Taxol (paclitaxel), already approved to treat other cancers, was approved last year for use in combination with cisplatin
for the first-line treatment of non-small cell lung cancer in patients who are not candidates for surgery or radiation therapy.
Gemzar (gemcitabine hydrochloride), another already approved cancer drug, received an additional approval in August
for use in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced or metastatic
non-small cell lung cancer.
Although results of some studies have shown that new treatments may only give patients an additional month or two to
live, "there are not a lot of effective treatments for advanced stage non-small cell lung cancer," says Isagani Chico, M.D.,
a medical officer in FDA's division of oncology drug products.
Because small cell lung cancer has typically spread by the time it's detected, it generally cannot be cured by surgery.
Treatment usually begins with a combination of two or more drugs to kill cancer cells throughout the body. Later, treatment
with more drugs combined with radiation therapy or radiation alone, is often prescribed. Chemotherapy (drugs) and radiation
therapy shrink tumors in most patients, and sometimes the disease goes into remission. But in many cases the cancer begins
to grow again when it becomes resistant to treatment.
The Road Ahead
The future and course of lung cancer research seems to vary tremendously depending on who you talk to. Some experts
believe prevention and early detection are the best bet. Others insist that improved treatments and gene therapy will be the
answer. Paul Bunn Jr., M.D., believes that more research needs to be conducted to see if it's feasible to use x-rays to screen
cigarette smokers and people exposed to asbestos, who are at highest risk of developing the disease. Bunn, the director of
the University of Colorado Cancer Center and past chairman of FDA's Oncologic Drugs Advisory Committee, believes that the
increased use of tobacco among teenagers and adults must be curtailed and that one of the best weapons against lung cancer
is prevention.
As for lung cancer patient Ron Norgord, he's banking on a drug that's intended to cut off the blood
supply to tumors using molecular technology. The 63-year-old resident of Pasadena, Calif., who has been on a variety of chemotherapy and radiotherapy treatments since he was diagnosed
about a year and a half ago, was accepted in September into a clinical trial of a drug that inhibits the growth of tumor blood
vessels at UCLA's Cancer Center. "I'm quite encouraged by the results so far," Norgord says. "It's too early to see yet, but I see some positive things
coming out of the treatment." One positive sign came after his first treatment, when his chances for fighting infections improved
because his white blood cell count finally came up into the normal range.
Researchers are currently studying a variety of drugs and drug combinations designed to extend patients' lives and
improve their quality of life. They are also studying various aspects of the disease in the hope of someday developing more
effective treatments. Here are just a few of the recent findings, studies and developments related to lung cancer:
Researchers at the Dana-Farber Cancer Institute and the Brigham and Women's Hospital in Boston have identified six factors
that place patients with early-stage lung cancer at risk for recurrence. These factors include: large tumor size, a specific
tumor subtype of adenocarcinoma (a type of lung cancer), evidence that the cancer has entered the channels of the lymph system,
and the presence of certain proteins commonly associated with cancers. Patients with two or more of these risk factors have
an increased chance of their cancers recurring. This knowledge may help doctors decide which patients would benefit most from
chemotherapy after surgery.
The Radiation Therapy Oncology Group, a federally funded cancer clinical trials cooperative group, which carries out
multi-disciplinary research nationwide, recently began a randomized clinical trial that will evaluate whether amifostine,
a radio-protective agent, can effectively reduce some side effects in certain lung cancer patients treated with combined radiation
therapy and chemotherapy. The trial, which will study patients with inoperable non-small cell lung cancer, is important because
lung cancer patients who are treated with radiation and chemotherapy sometimes develop inflammation of the esophagus, making
it difficult for them to swallow.
At an American Association for Cancer research meeting in March, E. Premkumar Reddy, Ph.D., director
of the Fels Institute for Cancer Research at Temple University School of Medicine in Philadelphia, reported that discovery of a new pathway
for tumor growth may help researchers develop new types of diagnostic tests and anti-cancer agents. The new pathway, Src-Stat-3,
is believed to play a critical role in the proliferation of cancer cells in the lung, breast, prostate, and ovary.
Meanwhile, lung cancer survivor Ken Giddes, who is also a voting patient representative on FDA's Oncology Drug Advisory
Committee, continues to spread a message of hope to people throughout the country. "I want people to know that the diagnosis
of cancer is not an automatic death sentence and to inform people of the many options available to them," he says. "I also
want people to know that just because they have lung cancer they shouldn't be written off or forgotten. People try to make
you feel bad, especially if you smoked, like it's your own fault. But I see plenty of people who have lung cancer and haven't
smoked. And even if they did smoke, they didn't plan to get lung cancer."
Ellen Brown is a writer in Lakewood, Ohio.
The Risks of Smoking
You have undoubtedly heard the warnings: if you smoke cigarettes, stop now, and if you don't smoke,
don't start. Why? Because cigarette smoke is made up of over 4,000 chemicals, including 43 known to cause cancer. According
to the American Cancer Society, tobacco use accounts for 30 percent of all cancer deaths in the United States, and smoking
is responsible for 90 percent of lung cancers in men and more then 70 percent in women. The ACS estimates that 28 percent
of men, 23 percent of women, and about 30 percent of adolescents smoke.
According to the American Lung Association, the more you smoke and the longer you smoke, the more likely you are to
develop lung cancer. But the ACS contends that if you quit smoking when precancerous signs are found, the damaged lung tissue
often may return to normal, oftentimes within five years.
There has been some debate, however, on this subject. In 1997, researchers at the University of Pittsburgh Cancer Institute
concluded after a preliminary study, that just because people quit smoking doesn't mean they won't develop lung cancer at
some point in their lives. The study, which was published in the American Journal of Respiratory and Critical Care Medicine,
determined that 77 percent of the people who smoked at least a pack of cigarettes a day for 25 years had irregularities in
their lung cells even if they weren't smoking at the time the lung tissue was examined. While those who smoked fewer cigarettes
weren't home free, they were less likely to develop abnormal lung cells. Only about 15 percent of the people who smoked for
less than 25 years showed similar cellular changes.
More research still needs to be conducted on this topic, and most doctors still recommend that people stop smoking,
no matter how long they've been keeping up the habit. This is especially true for people who have been diagnosed with lung
cancer. "People with lung cancer who stop smoking live longer and have higher cure rates and lower rates of second cancers,
which is a major problem for these patients," says Paul Bunn Jr., M.D., director of the University of Colorado Cancer Center
and past president of the International Association for the Study of Lung Cancer. "They also have lowered risk of death from
other problems such as heart disease." Bunn says it's a myth that most lung cancer patients don't quit smoking; in fact, they
have a much higher quit rate, he says.
For more information on how to quit smoking, see "It's Quittin' Time" in the November-December 1997 FDA Consumer.
Lung Cancer Warning Signs
Detecting lung cancer in its early stages can lead to a cure for some people and extend the life of others, according
to the American Cancer Society. So, if you are experiencing any of the following problems or symptoms, seek medical attention
at once:
a persistent cough
chest pain
weight loss and/or decreased appetite
bloody phlegm
shortness of breath
hoarseness
a fever for an unknown reason
recurring infections, such as bronchitis and pneumonia.
Some of these symptoms may be related to another disease or condition. The only way to know if you have lung cancer
is for a doctor to perform the necessary tests.
Stages of Lung Cancer
Lung cancer treatment depends on tumor size and on how far the cancer has spread. To help doctors decide on the best
treatment plan for their patients, a system of stages that describes the growth and spread of the cancer has been developed.
There are two stages for small cell lung cancer. In the limited stage, the tumor is usually confined to one lung and
lymph nodes on the same side of the chest. In the extensive stage, the cancer has spread to the other lung and to lymph nodes
on the other side of the chest, or to distant organs.
The stages of non-small cell lung cancer are:
Occult Stage:
Cancer can be detected in patient's saliva, but tumors cannot be found in the lungs.
Stage 0:
Cancer is localized in a few layers of cells and has not grown through the lung's top lining.
Stage I:
The tumor is only in the lung and surrounded by normal tissue.
Stage II:
Cancer has spread to nearby lymph nodes.
Stage III:
Cancer has spread to the chest wall or diaphragm near the lung, or to the lymph nodes in the mediastinum (the area
that separates the two lungs), or to the lymph nodes on the other side of the chest or in the neck. This stage is divided
into IIIA, which can usually be operated on, and stage IIIB, which usually cannot withstand surgery.
Stage IV:
The cancer has spread to other parts of the body.
Recurrent:
Cancer has returned after treatment.
by Ellen Brown
The Cancer Network ( Green tea)
Green tea is widely consumed in Asian countries, especially China and Japan. It has been suggested
that green tea has a protective effect against the development of stomach adenocarcinoma, the second leading cause of cancer
death throughout the world. Although laboratory experiments and some case-control studies have shown that some chemicals extracted
from green tea may inhibit development of several types of cancer, a recent study published in the New England Journal of
Medicine did not confirm such preventive effects.
Dr. Yoshitaka Tsubono and colleagues from the Department of Public Health and Forensic Medicine
at Tohoku University Graduate School of Medicine conducted a large population-based, prospective cohort study in three municipalities
in northern Japan. A total of 26,611 individuals were studied between January 1988 and December 1992. The majority
of the studied subjects were 40 years of age or older. All patients were required to complete a self- administered questionnaire
that included questions about the frequency and amount of green tea consumed, and were followed up with screening examinations
for adenocarcinoma of the stomach for at least 8 years.
During the 8-year follow-up, approximately 420 patients were diagnosed with stomach cancer. Of these patients, 296
were men and 123 were women. The incidence of stomach cancer among all the studied subjects was analyzed by utilizing several
sophisticated statistics models, and the relative risk of gastric cancer according to the consumption of green tea was estimated.
The researchers found that green tea consumption does not decrease the risk of gastric cancer. Individuals who drink one or
two, three or four, and five or more cups of green tea daily have a similar risk of developing stomach carcinoma as people
who drink less than one cup per day.
"In conclusion, in a prospective cohort study, we found no association -- inverse or otherwise
-- between the consumption of green tea and the risk of gastric cancer in Japan," said Dr. Tsubono.
Reference: Green tea and the risk of gastric cancer in Japan. New England Journal of Medicine 2001 Mar 1;
344 (9):632-6
This article is copyrighted by The Cancer Information NetworkTM -- a leading national organization dedicated to cancer
patients and their caregivers. This article may be transmitted freely with this contact and attribution information. For more
information on cancer, cancer diagnosis and treatment, visit http://www.thecancer.info.
Deborah Shaffer had metastatic Lung Cancer, but her tumors are shrinking
Alimta: An Emerging Treatment Option for Relapsed Lung Cancer
Iressa
Approval of
First Targeted Drug for Lung Cancer
Lung Cancer Treatments
New Lung Cancer Therapies
by Cathy Dunn & Amy DOrazio, PhD
Deborah Shaffer is playing a lot these days, enjoying her family, and riding horses on her farm
in Cleveland,
Texas,
outside Houston. Shes just following doctors orders, she says. The doctor told me in January to go home and play, says Shaffer, who
is 52.
For Shaffer it was good news. A smoker for 30 years, Shaffer was diagnosed with stage IV (metastatic)
lung cancer in April 2002. She had brain surgery to remove a metastatic tumor, and in January 2003 tests showed that the tumors
in her lungs were continuing to shrink after her six-month chemotherapy regimen of Paraplatin® (carboplatin) and Taxotere®
(docetaxel) that ended in October 2002. Physicians would like to see success stories like Shaffer more often. Lung cancer
is one of the most common cancers in the United Statesand, by far, the most deadly. In fact, more people die from lung cancer than from colon, prostate,
and breast cancer combined.
A Difficult Cancer
Nobody knows for sure why lung cancer is so difficult to treat effectively. But the answer may
be inherent in the structure of lung cells, says Alex Adjei, MD, faculty member at the Mayo Clinic, Rochester, Minnesota.
Because the lungs are important for breathing and are frequently exposed to unhealthy environmental elements, nature
has made the cells lining the lungs extremely resistant to damage and death, Dr. Adjei says. When these cells become cancerous,
their survival properties are magnified, making them very difficult to kill with chemotherapy.
Complicating matters is the fact that the disease is often difficult to diagnose in its early stages. Although many
people undergo high-resolution spiral CT to screen for lung cancer, so far, the U.S. Food and Drug Administration (FDA) has
not approved a screening method for lung cancer.
Adding to the complexity are the numerous types of the disease. Even the most common type, nonsmall-cell lung cancer
(NSCLC), is further divided into three categories: 1) squamous cell (similar to cells of the skin); 2) adenocarcinoma (a cancer
of the mucous glands); and 3) large cell. A less common subtype of adenocarcinoma, called bronchoalveolar carcinoma, is seen
more commonly in women and people who have never smoked. If that isnt confusing enough, NSCLC is defined by stages using the
International Staging System for Lung Cancer. The system classifies a tumor according to size (T), involvement of lymph nodes
(N), and amount and location of cancer spread (metastasis) to other parts of the body (M). Different treatment options are
prescribed for each stage.
Many people who have undiagnosed lung cancer dont know anything is wrong; others experience symptomssuch as a nagging
cough or hoarsenessthat may be explained by other causes such as upper respiratory problems. By the time a diagnosis is made,
the disease may have spread to other organs. In fact, about 85% of lung cancer cases are not identified until the later stages.
Finding the Good News
Thats the bad news. The good news is that lung cancer patients are beating the odds by working closely with their doctors,
educating themselves about innovative treatments, and acting quickly to combat the disease. In some cases, that means undergoing
traditional treatment such as surgery, radiation, or chemotherapy. In other cases, participation in a clinical trial testing
a new medication may be a patients best chance for survival.
Doctors have an arsenal of chemotherapy drugs to treat lung cancer, with each stage and type responding differently
to various drugs. For Shaffer the carboplatin/Taxotere combination worked.
Even as recently as the 1980s, doctors were unsure whether it was worthwhile to treat patients with advanced lung cancer
with chemotherapy. However, after a series of clinical trials showed that chemotherapy with Platinol® (cisplatin) could prolong
life and relieve symptoms, chemotherapy became more widely accepted.
Since that time several new agents have been developed (see sidebar, page 23). These include Taxol® (paclitaxel), Taxotere,
Navelbine® (vinorelbine), Gemzar® (gemcitabine), and Camptosar® (irinotecan). With the exception of Camptosar, each has FDA
approval for use in lung cancer patients. It has been found that these agents are most effective when combined as a doublet
with cisplatin or carboplatin, a modified form of cisplatin that is better tolerated by most patients.
Shaffer found her treatment with carboplatin/Taxotere tolerable. The first treatment I didnt have any side effects,
but the second one I was nauseated and had diarrhea, she explains. But it was manageable. I knew when I was being treated
and planned for it.
Analysis of numerous trials involving thousands of patients has shown that each of these agents alone leads to tumor
shrinkage in about 20-25% of patients. When combined as a doublet with cisplatin or carboplatin, that figure increases to
around 30%. The most well-known trial comparing these regimens was conducted by Eastern Cooperative Oncology Group (ECOG),
which compared Gemzar/cisplatin, Taxol/carboplatin, and Taxotere/cisplatin to Taxol/cisplatin. The study found that each regimen
was approximately equal in its ability to shrink the tumor and prolong time to relapse. An informal analysis of the ECOG trial
and an additional 11 clinical trials that enrolled a total of almost 4,100 patients showed the same thing: Many of the regimens
that combined Taxol, Taxotere, Navelbine, or Gemzar with either cisplatin or carboplatin had similar effectiveness.
Choosing a treatment
How then do a physician and patient decide on a treatment plan? Corey Langer, MD, director of thoracic
oncology, Fox Chase
Cancer Center, Philadelphia, Pennsylvania, says other health conditions such as
diabetes or heart disease (called co-morbidities) may impact the decision as does overall health and fitness.
For instance, in individuals with pre-existing peripheral nerve damage, we are loath to consider Taxol at conventional
doses. By the same token, pre-existing kidney disease or hearing loss will preclude cisplatin, Dr. Langer says.
Other side effects such as hair loss can also influence treatment choice. In the randomized trials mentioned above,
80% of those patients treated with Taxol/carboplatin experienced total or near-total hair loss. In comparison, only 10% of
patients treated with Gemzar/cisplatin or Navelbine/cisplatin experienced significant hair loss. But Gemzar and Navelbine
both require weekly clinic visits compared to Taxol and Taxotere, which only require a clinic visit every three weeks.
For patients who cannot tolerate one treatment, other options remain. Physicians continue to prefer the doublet that
contains Taxol, Taxotere, Navelbine, or Gemzar with either cisplatin or carboplatin because the clinical trial data show effectiveness,
but if treatment with cisplatin or carboplatin is not possible, regimens such as Taxol/gemcitabine or Taxotere/gemcitabine
are effective and more tolerable than the platinum-based therapy.
The Older Patient
Age must also be taken into consideration when planning treatment.
Interestingly, although 58% of patients with lung cancer are over 70, the median age of the patients enrolled in most
clinical trials is only 59. However, Dr. Langer says age alone is not a deterrent to treatment because elderly patients who
are fit do as well or nearly as well as younger, fit patients.
Dr. Langer distinguishes between patients in their 70s who appear to tolerate chemotherapy reasonably well and those
over 80 because, he says, the data are extraordinarily sparse on patients over 80.
The little data that exist suggests that they do considerably worse. We must also respect the potential for increased
toxicity in older individuals, although we need to acknowledge that the fit elderly do as well as younger individuals from
a therapeutic standpoint.
The elderly may also be restricted by the availability of caregivers, financial concerns, or by reluctance to pursue
more aggressive treatment. And physicians who believe treatment will not be as successful in the elderly patient might treat
less aggressively.
Yet, growing evidence shows there are feasible and successful treatment options for the elderly patient. A large Italian
study compared chemotherapy with Navelbine to supportive care without chemotherapy in elderly lung cancer patients and determined
that survival was prolonged in those who received chemotherapy.
A second trial conducted in Tennessee showed that Taxotere was able to induce tumor shrinkage in 26% of lung cancer patients who were
elderly and had medical conditions that would have otherwise precluded treatment. This rate is approximately equal to that
seen in other Taxotere trials in younger lung cancer patients.
Lastly, a large clinical trial recently compared chemotherapy with the combination of Gemzar and Navelbine to either
Gemzar or Navelbine alone. Administration of two agents is the prevailing preference among lung cancer patients as a whole,
but in this group of patients over age 70, Gemzar or Navelbine as single agents worked as well and had fewer side effects
than the doublet.
Dr. Langer says the key to making treatment choices is fitness and potential for physical vulnerability. Frail patients
are best served by single agents; the fit can tolerate combination regimens.
Since no one treatment regimen is suitable for every lung cancer patient, the patient and physician must consider medical
history, overall health, age, and lifestyle.
Hope for Breaking the Plateau
The combination of Taxol/carboplatin is one of the most widely used regimens in the United States for patients with
newly diagnosed advanced lung cancer, but many other drugs appear to have equal effectiveness for these patients. Frustrated,
many physicians have termed this the therapeutic plateau, because although significant progress has been made, theyd like
to see even greater strides.
Many physicians and patients are banking on a new class of therapeutics known as targeted therapies to break the plateau
and take lung cancer treatment one step further. Among the most promising of these new agents are Iressa (gefitinib), Tarceva
(erlotinib), Erbitux (cetuximab or C225), ABX-EGF, and Avastin (bevacizumab). It is hoped that these agents can either improve
the effectiveness of chemotherapy or help patients for whom chemotherapy has failed.
When Gary Lougher was a teenager, he decided not to start smoking because he didnt want to risk developing lung cancer.
He stayed true to that decision throughout his 24-year stint in the U.S. Navy. Ultimately, though, the career he loved brought
on the disease he dreaded.
As a Navy electronics technician during the 1970s, I was frequently exposed to nuclear radiation,
asbestos, and a variety of chemicals, says the 48-year-old from Chesapeake, Virginia, who has bronchoalveolar carcinoma, a rare form of lung cancer. The Navy has determined that my
particular kind of cancer has been linked specifically to nuclear radiation exposure.
Once known as a disease plaguing only those who smoke, lung cancer is increasingly affecting nonsmokers as well. Bronchoalveolar
carcinoma in particular is unique because 30% of patients affected with this subtype of lung cancer have never smoked. Other
carcinogens, such as secondhand smoke, radon, and asbestos, play a role in the development of lung tumors.
When Lougher was diagnosed in 1998, his cancer had already spread to surrounding lymph nodes, causing severe chest
pain. He had surgery to remove part of his lung, underwent radiation therapy, and was treated with three different chemotherapies.
But nothing seemed to slow the disease.
I had terrible side effects, including complete hair loss, severe diarrhea to the point of dehydration, and extreme
weakness, Lougher explains. I had reached the point where I couldnt even shower without my oxygen tank nearby. I thought I
had about three months to live, so I called my family and asked them to visit me one last time.
Thats when Lougher heard about a new drug called Iressa (see sidebar) from an online lung cancer support group. He
decided to try it.
I started taking Iressa in April 2001, and I saw miraculous effects overnight, he says. I literally skipped into the
kitchen the next morning, amazing my family. I am very thankful for every extra day Ive been given to spend with my family
and friends. Taking Iressa has made that possible for me.
New Hope With Targeted Therapies
Iressa is taken in pill form and is the first drug available in the United States from a new
class of anticancer drugs called selective epidermal growth factor receptor (EGFR) inhibitors, which target signaling pathways
necessary to the growth and survival of cancer cells. By blocking these pathways, Iressa helps stop tumor growth. In phase
II trials, Iressa reduced disease-related symptoms with relatively minor side effects in patients with NSCLC who had progressed
after previous treatment.
NSCLC accounts for up to 80% of lung cancer cases, so finding an effective treatment is of utmost
importance, says Roy Herbst, MD, PhD, chief of the section of thoracic medical oncology, M. D. Anderson Cancer Center, Houston.
In U.S. clinical trials, Iressa seems to have improved the quality of life for many patients. About 10%
of the participants have experienced tumor shrinkage of 50% or more in large phase II studies with previously treated patients,
he adds.
Dr. Herbst says Iressa is still effective as a single agent, and further studies will be needed to find other combinations
that will enhance that effectiveness.
Tarceva is another EGFR inhibitor that is undergoing clinical trials in lung cancer. Three large trials of Tarceva,
either by itself or in combination with chemotherapy, have completed accrual. Results should be available later this year.
Chandra Belani, MD, co-director of the Lung and Thoracic Program at the University of Pittsburgh Cancer Institute,
is involved in clinical testing of ABX-EGF, another drug that, like Iressa, targets EGFRs. ABX-EGF, a fully human monoclonal
antibody, is given by infusion.
ABX-EGF is well tolerated and produced relatively mild side effects such as rash and diarrhea in phase I trials, says
Dr. Belani. Were now moving forward with phase II trials, testing ABX-EGF in combination with standard chemotherapy. Although
we dont have all of the data yet, were optimistic about this drugs impact on lung cancer treatment.
Targretin® (bexarotene) is another novel agent being evaluated in combination with chemotherapy
for lung cancer patients. In the United States, Targretin plus Taxol/carboplatin is under evaluation. Targretin, an oral agent that was first
evaluated in lymphoma patients, showed some activity in lung cancer patients in phase I trials, leading to both the U.S. trial and one in
Europe evaluating Targretin
with Navelbine/cisplatin.
Avastin, another monoclonal antibody playing a significant role in novel lung cancer therapies, is known as an anti-VEGF
because it has the potential to block vascular endothelial cell growth factors, one of the key proteins providing blood supply
and nutrients to cancer cells, thereby stimulating tumor growth. In late June 2003, Avastin was given fast-track designation
from the FDA for treatment of advanced colon cancer.
Side effects from the infusions tend to be mild, although earlier trials showed bleeding and blood clots as risk factors.
Avastin isnt a cure, says Alan Sandler, MD, medical director of thoracic oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee. But it may one day help us control lung cancer to the point where it becomes more of a chronic
disease. Then we can concentrate on controlling problem symptoms while we continue to search for a cure.
Dr. Sandler says this is where clinical trials play a crucial role because they often provide better care with more
individual attention from some of the best doctors, nurses, and technicians in the profession.
Patients sometimes tell me they want to participate in clinical trials to help save the lives of those who will have
the disease in the future, Dr. Sandler remarks.
Thats a very noble thing to do, but I tell them to get involved to help themselves first. I encourage them to be selfish
for a very simple reason: I want them to get better.
Editors note: Gary Lougher passed away Feb. 10, 2003. CURE is proud to honor his memory.
Treatment
As is true of many cancers, the treatment of lung cancer depends upon a variety of factors. The most important factors
are the histopathologic (diseased tissue) type of tumor that is present and its stage. Once a lung cancer has been staged,
the physician and patient can discuss treatment options. An individual then has a better idea of the value of different forms
of therapy. Other factors that are taken into account include the person's general health, medical problems that may affect
treatment (such as chemotherapy), and tumor characteristics.
The characteristics of the lung tumor help to separate individuals into two groups: (1) those who are at low risk of
cancer recurrence and (2) those who are at high risk of cancer recurrence. Specific prognostic - disease-forecasting - factors
place patients in either of these groups. In particular, the histopathologic groupings of small cell lung carcinoma (SCLC)
versus non-small cell lung carcinoma (NSCLC) may be used to better predict a patient's prognosis and response to therapy.
Surgical resection, or cutting away, of the tumor generally is indicated for disease that has not spread beyond the
lung. Such resection may be conducted using a variety of techniques. Thoracotomy - the opening of the chest wall for surgical
procedures - and median sternotomy - surgery performed by cutting through the breastbone - are standard methods used for lung
cancer surgery. Alternative approaches include anterior limited thoractomy (ALT), thoractomy performed on the frontal chest
using a small incision; anterioraxillary thoracotomy (AAT), thoracotomy performed on the frontal chest near the underarm),
and posterolateral thoracotomy (PLT) thoracotomy performed on the back/side region of the trunk. ALT, in particular, is less
invasive than standard thoractomy - that is, it involves less disturbance of the body by incisions or other intrusive measures.
ALT may result in less surgical blood loss, less postoperative drainage, and less postoperative pain than standard thoracotomy.
Recently, surgeons have developed other less invasive procedures for the removal of tumorous tissue. For example, video-assisted
thoracoscopy (VAT), otherwise known as video-assisted thoracic surgery (VATS), uses a video camera to help visualize and operate
upon the lung within the chest cavity. The surgical incisions made during VAT are much smaller than those needed for thoracotomy
or sternotomy. However, some physicians caution that VAT does not allow complete lung examination to identify and remove metastases
that are not detected by preoperative chest X-ray. VAT is perhaps most appropriate for Stage 1 and Stage 2 cancers that require
lobectomy (surgical removal of a lung lobule) with lymphadenectomy (removal of one or more lymph nodes) and for peripheral
(outer edge) lung tumors that can be removed by wedge resection. In such cases, follow-up is required to establish a long-term
prognosis.
Computed tomography (CT) scans also have been added to VAT technology to improve lung cancer surgery. Experts have
found that percutaneous (through the skin) CT-guided localization wires help to identify tumorous lung nodules. In this way,
wires can be used to assist VAT in cases that need sublobectomy resection (partial removal of a lung lobe).
Unfortunately, surgical procedures may cause lymphocytopenia - low number of lymphocytes (white blood cells) in the
blood - which is linked with shorter survival times among patients with advanced lung cancer. Lymphocytopenia may be related
to a deficiency in interleukin-2 (IL-2), a hormone that controls the activity of T lymphocytes (thymus-dependent lymphocytes).
Preoperative treatment with recombinant human interleukin-2 (rhIL-2) may help to prevent the lymphocyte decrease that occurs
after surgery for operable lung cancer.
If the tumor is more aggressive and/or widespread, chemotherapy and radiotherapy (radiation therapy) also may be necessary.
In addition to chemotherapy and radiotherapy, other treatments are now available for the management of lung cancer.
Photodynamic therapy (PDT) may be especially useful for the care of persons
with inoperable lung cancer. Photodynamic therapy begins with the injection of a light-activated drug (e.g., photofrin/polyhaematoporphyrin,
lumin). Then, during bronchoscopy (examination of the airways using a flexible scope), the lung tumor is illuminated by a
laser fiber that transmits light of a specific wavelength. At that time, the laser light is used to destroy the sensitized
tumor tissue. Skin photosensitivity (light sensitivity) is a side effect of PDT. The curative potential of PDT is the most
exciting aspect of this therapy in lung cancer patients whose tumors are occult (hidden, unseen) on chest X-ray. The tissue-sparing
effects of PDT may be particularly important for individuals with limited lung function.
Electrosurgery Elecctrosurgery is surgery performed using a needle, bulb, or disk electrode, Nd-YAG laser therapy (neodymium-yttrium/argon
laser that concentrates high-energy electromagnetic radiation to destroy tissue), cryotherapy (destruction of tissue using
extreme cold), and brachytherapy (treatment with ionizing radiation) are additional tumor debulking, or size-reducing, techniques
that may be performed during bronchoscopy. Such methods are especially useful for obstructive, inner cavity (intraluminal)
lung tumors.
Radiotherapy (Radiation Therapy)
Radiotherapy - otherwise known as radiation therapy - is a treatment method that uses high-energy, ionizing radiation
(e.g., gamma rays) to kill cancer cells. Ionizing radiation is produced by a number of radioactive substances, such as cobalt
(60Co), radium (228Ra), iodine (131I), radon (221Rn), cesium (137Cs), phosphorus (32P), gold (198Au), iridium (192Ir), and
yttrium (90Y). Radiotherapy may be applied to shrink a tumor that is later removed by surgery, to relieve symptoms, or to
destroy malignant cells in a tumor that cannot be removed surgically.
Because cancer
cells usually multiply faster than most bodily tissues, they are especially affected by radiation, which prevents cell division
and the formation of DNA (deoxyribonucleic acid; human genetic material). Yet the bodily tissues that also divide rapidly
- such as hair and skin - are particularly vulnerable to radiotherapy. The specific side effects of radiotherapy include hair
loss and skin disorders (e.g., erythema, skin redness due to blood vessel congestion; puritis, itching; desquamation, sloughing-off
of outer skin layers; pain; atrophy, shrinking; increased pigmentation; edema, swelling), as well as fetal damage, increased
susceptibility to infection, tachycardia (increased heart rate), changes in taste perception, anorexia (loss of appetite),
malaise, nausea, and vomiting.
Lung Cancer Cure: Natural, Safe,
Effective & Scientifically Proven Results ---Cure for Lung Cancer!
Cancer Hope Reborn & Proven!
Two Canadian herbal remedies, after three years extensive clinical testing under
the supervision of the Ministry of Health of China, were proven to be extremely effective and safe to unleash your healing power
(see clinical data).
Are you looking for a truly effective cure for lung cancer? Look no further because
you already have it. Your own immune system is the most powerful cancer curing machine!
However, you need the right tools to initiate your self-healing power. Getting
the right tools is essential. They will assist your body's powerful healing functions which will help you correct your health
problem.
Your immune system is the best medicine you have for many degenerative diseases,
including lung cancer. Natural cancer treatments will not harm your body. Alternative medicine may provide a better solution.
Building up your health naturally is what your body needs. However, you may be worried about alternative treatments because
they do not have any scientific proof. You may not be sure whether they really work......whether they are really an effective
natural lung cancer treatment......
If you are searching for an answer for your lung cancer, look no further. Your
body already has it.
Surgery, Chemotherapy, Radiation ....... invasive treatments with serious side
effects.
Alternative treatments --- no scientific proof of effectiveness. NOW, you can
have a better choice!
Learn more about how CESSIAC & YUCCALIVE,
these two time-tested and scientifically proven herbal products, can help you initiate your own cancer curing functions. These
Canadian herbal formulas are exceptionally safe, fast, effective, and they are scientifically proven by extensive studies
in China under the strict supervision of the Ministry of Health of China.
CESSIAC and YUCCALIVE are time tested and scientifically proven!
These two herbal formulas have a long history in North America. Originally passed
down to us from the native Indians, there have been numerous reported cases showing wonderful positive results. From 1993-1996,
the Ministry of Health of China appointed three of the most reputable hospitals in China to conduct scientifically controlled tests on these formulas as well as on their individual ingredients. The results
stirred a lot of interest in China. The effectiveness of the combined use of these two formulas was clearly demonstrated.
Extensive use in Hong Kong and North America also showed how the combined use of these two formulas could positively impact
the immune system.
Knowledge will not help your condition.
Only action will. No matter how powerful our products are, if you do not
use them you will not get the benefits. Still doubtful? Enter to win a free month
supply of our CESSIAC and YUCCALIVE and see the results.
Powerful tools for you to unlock your
self-healing power. Strong evidence throughout the past 80 years. Clinically proven under strict supervision of the Ministry of Health of China. Let your immune system
take care of your lung cancer!
Tests in China included toxicity test,
tumor inhibition test, medicinal test, immunological test, and a large scale clinical test. Visit our "Clinical" page to learn
more about all these tests.
These herbal formulas are now being manufactured in British Columbia, Canada under a GMP (Good manufacturing practice -- medicine manufacturing standards)
environment.
The production is carefully monitored; the finished products are fully controlled
and measured with the specifications and standards set up by the Chinese Ministry of Health. In other words, professional
quality control ensures consistent & effective products.
Safe, fast, effective, and PROVEN! CESSIAC and YUCCALIVE are powerful tools to
help your body release and enhance its self-healing function. These products are not just folklore remedies. These are scientifically
proven and extensively tested formulas that really work by helping you build up your immune system. As a result, your self-healing
power will start to work and will be able to correct many of your degenerative problems. The combined use of CESSIAC and YUCCALIVE
will restore your internal environment and provide the proper conditions for your body to regain health.
Breast cancer, prostate cancer, colon cancer, lung cancer, ovarian cancer, leukemia,
lymphoma, diabetes, arthritis, Alzheimer, Parkinson... they are just signals from your body. Treat your body instead of your
symptoms. Rebuild your health instead of suppressing your immune system. What you need is just the right tools to unlock your
own healing power.
(CESSIAC ®) Chinese "Kang Ji" means Foundation of Health
(YUCCALIVE ®) Chinese "Yu Kang" means Health's Nourishment
These North American native Indian herbal remedies were introduced into China, the herbal kingdom, in 1993. There were several ingredients in the remedies
that even the Chinese did not have any information on them. At the requirement
of the Ministry of Health of China, numerous tests and studies were conducted by three major hospitals in China. These hospitals included the Beijing
Chinese Medicine University East Gate Hospital, the People's Hospital of Gunagdong Province, and the Guangzhou
City Cancer Hospital. The tests and studies included medicinal
test, toxicity test, immunological test, tumor inhibition test, and a 245 cases clinical study. Import permits were finally granted in 1996 by the Ministry of Health of China for these two herbal formulas
to be imported into China as the first ever non-traditional Chinese medicine for a Class A disease. The reports here show the results of the tests and studies done in China. It was based on these results that the effectiveness of these herbal
formulas were confirmed and the import permits were granted.
Since the Ministry of Health of China recognizes
herbs as powerful medicines and the Chinese has an organized set of regulations to control herbal medicines, these two herbal formulas are treated as medicines in China. However, the health regulatory bodies in North America (FDA & Health
Canada) have different sets of regulations toward the use of herbs. These formulas
then shall not be promoted as "medicines" in North America nor any medical claims shall be made. That
is why we are very careful in releasing this information to the general public in order to avoid violation of any regulations. The manufacturer in fact always emphasizes that the products are just powerful tools
that can assist us to get rid of the wastes and toxins accumulated in our bodies.
Once our internal environments become clean again, our immune systems will function properly as they were designed
to and our own healing power will be unlocked.
Note: CESSIAC ®& YUCCALIVE ® are
registered trademarks of MPS International Marketing Inc., The Chinese Names "Kang Ji" and "Yu Kang" are registered trademarks
of the MPS Group in China and Hong Kong and are also being registered in Canada. "Kang Ji" and "Yu Kang" are the official names of the formulas used in the Chinese
studies.
CESSIAC
For every problem, there is always a solution.
For every health challenge, there is always a relief.
Now we have the chance to derive the benefits from this God-sent herbal mixture
to revitalize our health.
CESSIAC® is now made in Canada under
a GMP standard (medicine manufacturing) environment according to the specifications set by the Chinese Ministry of Health.
To enjoy better results, use together with YUCCALIVE®.
It is not just the ingredients that count.
Ingredients: Sheep Sorrel
Burdock Root
Slippery Elm
Rhubarb Root
YUCCALIVE
Healing should have no geographical or cultural boundaries.
The effectiveness of the treatment method used, the drugs or natural remedies
taken, should be judged according to the final result on the user's health.
Yucca Schidigera has been used by the American Indians for thousands of years.
To enjoy better result, use together
with CESSIAC®.
It is not just the ingredients that count.
Ingredients:
Yucca
Schidigera Licorice Root
Fennel
Seed Clove
Buds
Anise
Seed Cinnamon
Bark
Honey
ORDER INFORMATION:
CESSIAC Case 6 x 909ml CESSIAC US$168
YUCCALIVE Case 6 x 909ml YUCCALIVE US$168
Combo Pak Case
4 x 909ml CESSIAC
2 x 909ml YUCCALIVE
US$168
Each case weighs 22 lbs. Shipping
cost for North America is US$25. One Combo Pak case will last 21-25 days for people with serious conditions and 75-80 days
for prevention purpose. 90-Day Satisfaction Guarantee
CESSIAC
According to naturopathic medicine and traditional Chinese medicine TCM, the
degeneration of our body system is the main source of our chronic diseases. We continue to accumulate toxins in our body from
our environment through food that we eat, water that we drink, air that we breathe, and stress that we create. We are suffering
from the consequences of human race's "effort" in polluting our planet. There is no way that we can avoid the contact of chemicals
in our food chain, carcinogenic agents in our water system, and disease-causing pollutants in the air that we breathe. These
toxins are choking our body on the cellular level. Therefore our organs do not function properly, our immune system suppressed,
and our total body function out of balance. Then we have cancer, MS, diabetes, arthritis, lupus, gall stones, hyperthyrodism,
sleeping disorder, heart disease, stroke, high blood pressure, Alzheimer's disease, dementias, cirrhosis...... and we try
to get rid of these symptoms by putting more poisons (man-made medication) into our body.
Getting rid of the toxins in our system is the first step we should take in order
to correct the degenerative health conditions that we have. No matter how much nutrients we dump into our system, how positive
our attitudes are, how much exercises we do, and how much we rest, if we do not unplug our system and flush out the toxins
we have, the correction will not happen. Only by eliminating the toxins in our body, our immune system will resume its proper
function. Our immune system is the best medicine that we have to fight against degenerative diseases. Detoxification is the
key to unlock the door to supreme immune system, hence optimal health.
According to the Chinese studies, the CESSIAC formula is a powerful tool to do
this. The Ojibway tribe in Ontario, Canada, had used a special herbal remedy for treating their ailments for hundreds of
years. In 1922, Nurse Rene Caisse introduced the herbal remedy into the White society. Throughout the past seven decades,
thousands of people in North America benefited from it. From 1993 to 1996, a group of Chinese herbal experts worked
on the remedy extensively. Extensive studies were conducted in China under
the strict supervision of the Ministry of Health of China. Specifications to determine
the effectiveness of the herbal remedy were set and the original Ojibway formula was modified with the Chinese herbal wisdom.
Now we have a much more potent and effective formula. This is CESSIAC - the Chinese improved Rene Caisse formula.
CESSIAC is now manufactured in British Columbia,
Canada, according to the specifications set up by the Chinese herbal experts in the Ministry
of Health of China after the extensive tests and studies were conducted in China. These specifications are also enforced by the Ministry of Health of China for
the importation of the herbal remedy into China. The raw materials used
for the manufacturing of the herbal remedy are selected under strict scrutiny and organic herbs are used whenever they can
be obtained. The production is under a strict GMP (drug manufacturing) standard environment. The high quality standard warrants
the greatest benefits that users can get from the herbal remedy.
The Chinese studies showed that CESSIAC serves as a powerful and effective tool
to help us detoxify the toxins in our blood and in our cells. The powerful cleansing effect results in dramatic change in
the users' health conditions. The herbal remedy will wake up the immune system and allow the body to function properly again.
Ingredients:
CESSIAC contains the same four herbs as in the old Ojibway remedy and Nurse Rene
Caisse's formula. However, it has a different ratio mix of herbs and a different method of preparation. Thanks to the Chinese
herbal experts: the result of the remedy is greatly amplified. The difference can be very obvious on people who have been
using other similar products. No other similar products has gone through that many extensive scientific testing and no other
similar products has a set of specifications established by top herbal experts of China to determine their quality and effectiveness.
Sheep Sorrel (Rumex acetosella)
Burdock Root (Arctium lappa)
Slippery Elm (Ulmus fulva)
Rhubarb Root (Rheum palmatum)
Results:
According to the Chinese studies, CESSIAC provides a powerful cleansing effect
to our blood and cells. It greatly enhances the healing force of our immune system. It works magically with the liver, pancreas,
and endocrine system. In the clinical studies in China and clinical applications
in Hong Kong, users always took both CESSIAC and YUCCALIVE (a Yucca base product which is for cleansing the intestines)
together. Both herbal products work perfectly together to give our body a complete cleansing.
In addition to its cleansing power, CESSIAC is also believed to be a very powerful
antioxidant and contains a lot of plant enzymes with great therapeutic results.
Are You Facing a major health challenge?
Your immune system is the answer ---
it is the real CURE for your health problem!
There is no magic bullet!
No drugs, therapies, supplements, or surgeries alone can correct a major illness. They may be able to alleviate or cover the symptoms temporarily. However, for every illness, the final healing has to come from within us.
From a minor cut on the finger to a life-threatening disease such as cancer, our own immune system is the only answer.
Most of our degenerative diseases begin with the improper functioning of our
immune systems. The malfunction of the immune system in many times is due to
the imbalance of nutrients in our bodies. Under-supply and over-supply of nutrients
cause some of our cells out of balance. These cells will become unable to repair
the damages they suffer due to metabolism and free radicals. Without a proper
source of a balanced nutrients, the cells will not be able to repair themselves. If
the imbalance is not corrected in time, the health problem will gradually become worse and will finally become untreatable.
If you are searching for an answer for a cure for your health problem, look no
further.
Your body already has it.
It's YOUR IMMUNE SYSTEM
In order to put your immune system in action again, you must take a holistic
approach. Detoxification-Nutrients-Positive Attitude-Exercise-Rest are the five
major factors that you have to pay attention to in order to rebuild your health. There
is no single treatment or health product that can provide you with all these five factors can bring you.
Getting to and maintaining a healthy state is an educational process. You have to educate yourself of why and how something can help you.
In this informational generation, you can easily collect information to help you make correct health decisions.
Let Our Powerful Food/Herb Combination Be Part of Your Health Rebuilding Program
Our products CESSIAC and YUCCALIVE has a long time origin from the North American
native Indians. The ingredients in these two products provide a large spectrum
of nutrients that our bodies need in order to maintain a functional immune system. The
health benefits of the ingredients of CESSIAC and YUCCALIVE have been clearly demonstrated in the native Indian communities
for thousands of years as well as in people who used these products in recent years.
They are real POWER FOODS.
CESSIAC ®
Ingredients:
Sheep Sorrel
Burdock Root
Slippery Elm
Rhubarb Root
YUCCALIVE ®
Ingredients:
Yucca
Schidigera Licorice Root
Fennel
Seed Clove
Buds
Anise
Seed Cinnamon
Bark
New Approach To Lung Cancer Treatment
Jan. 13 Lung cancer is our deadliest cancer and often difficult to treat. Now
researchers say, a new drug is showing real promise for certain patients. Dr. Dean Edell reports.
Watch this report
More recent stories...
When Elizabeth went for her annual checkup, she thought she was the picture of perfect health, but a routine x-ray
showed a spot on her lung.
Elizabeth Aviles, lung cancer patient: "I had no symptoms, nothing, absolutely
nothing, so I was quite surprised."
Elizabeth has non-small cell lung cancer. Treating the disease usually means rounds of chemotherapy delivered intravenously.
But Elizabeth's oncologist suggested something new - a pill called Iressa taken once or twice
a day.
Alex Adjei, M.D., medical oncologist: "It's a treatment that's convenient, it's
taken by mouth, the side effect profile seems to be less than regular chemotherapy, so a patient's quality of life is going
to be better."
Instead of killing all cells - like chemo does - Iressa specifically targets
cancer cells. It's part of a new group of drugs called EGFR inhibitors. A tumor forms when normal cell growth is interrupted
and cells divide uncontrollably. Iressa blocks the growth process.
Laeeq Ahmed, M.D., research oncologist: "It is not, at the present a homerun.
But it is a very exciting development."
In phase 2 clinical trials, more than 50 percent of lung cancer patients taking
Iressa had the disease stabilize. Elizabeth was one of them.
Elizabeth: "The Iressa had me cancer-free for about three months."
Experts say it's too early to tell what impact Iressa will have on survival rates.
What is clear is that the pill is making a dramatic difference in a patient's quality of life.
One problem with Iressa is that it only works well in certain lung cancer patients. Doctors are trying to find the
best way to predict which patients will respond. Iressa is also being investigated in head and neck cancer, as well as prostate
cancer, breast and colorectal cancers.
New Results Published in the Journal of Clinical
Oncology
January 8, 2004 - Wilmington, DE - New data published this week in the Journal of Clinical Oncology (JCO) highlight
the first Phase II clinical trial of IRESSA® (gefitinib) Tablets in patients with recurrent glioblastoma. Glioblastoma is
the most common of the primary malignant brain tumors and is one of the most challenging to treat effectively, with a 5-year
survival rate of approximately 5 percent.
We continue to look for better treatments for those diagnosed with this lethal
cancer, said Judith Ochs, MD, Senior Medical Director of Clinical Research for IRESSA at AstraZeneca.
The open-label, single-center Phase II trial included 57 patients with first
recurrence of a glioblastoma who were previously treated with surgical resection, radiation, and usually chemotherapy. These
patients underwent an open biopsy or resection at evaluation for confirmation of tumor recurrence. Each patient received 500 mg of IRESSA orally, once daily.
Dose escalation to 750 mg and 1000 mg occurred if a patient received enzyme-inducing antiepileptic drugs or dexamethasone.
The primary endpoint of the study was 6-month progression-free survival, with
secondary endpoint measurements of tumor response rate, event-free survival, overall survival, and drug toxicity. No patient
had either complete response or partial response, and 31 patients had radiographic progressive disease (58.4%) within the
first two months. In total, 51 of the 53 assessable patients eventually developed progressive disease, with two patients remaining
on therapy at the time of manuscript preparation; 21 percent of patients (11 of 53) had measurable disease at treatment initiation.
Seventeen percent of patients (nine of 53) underwent at least six 4-week cycles of IRESSA. The 6-month event-free survival
was 13 percent (seven of 53) and the median duration of event-free survival was 8.1 weeks.
The median overall survival time from treatment initiation was 39.4 weeks.
Adverse events were generally mild to moderate (grade 1 or 2) and consisted mainly
of skin reactions (60%) and diarrhea (40%). Other toxicities that were encountered that were felt to be possibly related to
the use of IRESSA included conjunctivitis, onycholysis, anorexia, weight loss, and AST and ALT elevation. Drug-related toxicities
were more frequent at higher doses. Patient withdrawal caused by drug-related
adverse events occurred in 6 percent (three of 53) of patients receiving 500-1000 mg/day of IRESSA.
Glioblastoma represents approximately 20 percent of all primary tumors found in the brain. Each year approximately 5 of every 100,000 individuals in the United States are diagnosed with glioblastoma. The disease is typically found in people 40 to 60 years of age and occurs
slightly more often in males than in females. Glioblastoma is considered an aggressive
tumor; it usually recurs within 1-2 cm of the original tumor site. While it may
spread to surrounding tissue within the brain, it rarely spreads to other parts of the body. Due to its location in the brain,
however, it is usually rapidly fatal.
Lung cancer now is the most common cancer-related
cause of death among men and women. In 2002 there will be about 169,400 new cases of lung cancer in the U.S, among which,
154,900 will die, including 89,200 men and 65,700 women.
The
two main types of lung cancer are non-small cell lung cancer and small cell lung cancer. Small cell lung cancer is highly
associated with smoking and grows and spreads quickly.
Orthodox
lung cancer treatment (surgery, radiation & chemotherapy) has showed, in some cases, potential in relieving symptoms and
improving the patient's quality of life. But in most other cases, the death rate of surgery, the side effects of radiation
and chemotherapy are always beyond that patients can tolerate.
Canelim Capsules, the medicine we recommended here, is the only Chinese anti-cancer medicine listed
in Class A of the National Basic Insurance Catalog, China. It is of high efficiency in killing cancer cells, boosting immunity and thus
reducing cancer body, inhibiting cancer growth and metastasis, alleviating clinical symptoms and pain, prolonging life expectancy
and improving life quality. It fits for all stages of lung cancer, either be applied alone or in combination with standard
treatments:
"
as forerunner of surgery to shrink the cancer, so that it is easier to be removed.
"
To be applied together with surgery, chemotherapy and radiation therapy.
"
as maintenance in the inermission of treatment or after surgery, or
"
as the main treatment when the cancer comes to a terminal stage that none of conventional treatments is applicable.
For
anyone who has radiation or chemotherapy or both, additional A-L Tonic Capsules is recommended
Canelim Capsules Permission No. (1995)-zz-5772, #000313 Description Capsule
Main Ingredients
Radix Curcume, Herba Agrimonia, Fructus Aurantii etc
Main function
1. Kill the cancer cells and inhibit the growth
of tumor, has significant therapeutic effect on common solid carcinoma
2. Strengthening body resistance, raising body
immunologic function
3. Ideal complex effects:a. specially enhance
sensitivity of anoxic cells to chemical medicine and radiotherapy. b. rapidly release the side effects of radiotherapy and
chemotherapy.
4. Raising patient's living quality and prolonging
patient's life
Therapeutic Range
1. Lung cancer, gastric cancer, esophagus cancer
etc
2. Lung cancers include small cell lung cancer,
non-small cell lung cancer, squamous cell carcinoma of lung, pulmonary carcinoma, large cell lung cancer, etc.
Administration & Dosage
take orally, 6cap*3 times/day, 33days/course generally,
a total of 3 courses needed, long term useage encouraged.
Adverse Reactions
1. No toxicity and side effect, can be used in
a long term.
2. Slight stomach upset occasionally seen. No
need to stop.
Stands on TCM
Theory
1. Resolve mass and swelling
2. Remove the phlegm and detoxicate
3. Promote blood circulation to stop pain
4. Exert tonic effect on the heart and strengthen
the body
Animal Test
1. Tumor inhibition--S180 tumor
2. Life extension--H22 tumor
3. Immune enhancement--S180 tumor
4. Pain relief
Clinical Reports
A. 500 cases studied by the First Attached
Hospital of the Fourth Millitary University in the last 20 years showed that this product can not only greatly relieve symptoms
and improve life quality, but also disperse majore sufferings from malignant tumors, especially for those with pulmonary cancer.
Follow-up survey of 22 patients with lung cancer, 6 lived over 15 years.
B. Review--therapeutic effects of Canelim Capsules
on malignant tumors
C. A statistical data of 24771 patients with different
types of cancers show that total effective rate varies from 53.2% to 89% respectively.
D. Clinical observation of Canelim Capsules combined
with chemotherapy on 86 cases terminal stage primary lung cancer
Price
RMB2088/course (100 cap*6 bottle for 33days),
US$254 Buy now!
Disclaimer: This information is for educational purposes only, It
is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of
a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster
assume no responsibility.
Lung
Cancer Survivor : I only Relied on Tian Xian Liquid Philippines, Mr. Sing Kio, 58
April
23, 1998 - Century Park Sheraton Hotel, Manila Philippines (Translated from Chinese)
Last June 1991, there were
nights while I was sleeping that I would cough very hard, and throw up phlegm. Like normal procedure, I took common western
& chinese herbal medicines to cure my simple disease.
But, this did not solve the
problem. I then consulted a physician named Doctor Ang. He's an old doctor and thus, have a lot of experience. After taking
an X-RAY (Figure 1), the doctor noted a slight enlargement near my left lung as compared to a normal X-RAY (Figure 2). "This
is a very suspicious area, you'll have to go get a CT-SCAN.", the doctor suggested. I hesitated to have my CT-SCAN and just
asked the doctor to prescribe some medicine. He prescribed some antibiotics, but unfortunately, it didn't work. I visited
him again, and he gave me another similar set of antibiotics, only the name have been changed. But still, nothing worked.
By November, I already have
a fever. After realizing that the medicine have no effect. I went to see another
doctor, coincidentally, his name is Doctor Ang. The second doctor was older than the first and was very popular during the
1950's. After showing my previous X-RAY to the second doctor, he also gave me the same explanation and prescription. The medicine
didn't work out again. The second time I went back to the doctor, he prescribed me a new set of antibiotics. This time around,
the medicine didn't conform with my body and hence, I lost 8 pounds.
I took the medicine from November 11 to December 10, 1991. But, my fever worsen, my phlegm already contained blood, and my cough worsen.
So, I went out to look for another doctor in a big hospital. This time around, the doctor (although named Doctor Ang again)
was a young doctor. On December
10, 1991, the third doctor advised me to have another X-RAY
and CT-SCAN. Two days later, I saw the result (Refer to Figure 3). The result was worse. The doctor didn't even believe that
the man to whom the X-RAY belonged to was still alive.
X-RAY CONSULTATION REPORT : Chinese General Hospital and Medical Center. Case No. 360114. Name : Sing Kio. Referred by : Dr. R. Ngo. Date
: 12-10-91. Clinical Data : CHEST. Compared with the previous examination taken outside dated 11-11-91 shows
interval progression of the atelectasis and infiltrates in the left lung base.
The right lung is clear. Heart is not enlarged. Diaphragm is intact. IMPRESSION: Atelectasis and pneumonia
infiltrates, left lung base showing interval progression. Possibility of this
being secondary to hilar compression cannot be ruled out.
By : E. Dy M.D. (Radiologist)
The doctor said that the tumor
is way too close to the heart. Hence, surgery, chemotheraphy, cobalt therapy is not possible even if the tumor was benign
or malignant. To me, it was more of like a death sentence.
The CT-SCAN results (Refer
to Figure 4 & 5) showed that the tumor was 9.4 cm X 6.4 cm. On that same day, the doctor didn't want to prescribe any
medicine and advised me to consult a TEMT specialist to find out if there is something wrong with my throat. Result showed
that there is an inflammation in my esophagus. The TEMT specialist recommended to perform a surgery within three days. I hesitated
because I think there was nothing wrong with my throat (I had voice, I can eat, etc).
CT-SCAN details : Chinese General Hospital & Medical Center, Section of Computed Tomography. Name : Sing Kio. Age : 58. CT No. : 91-1870. Referred by : Dr. R. Ngo. Date : 12-20-91.
Consultation Report : C.T.
SCAN OF THE CHEST. Contrast study of the chest shows a huge pulmonary mass in
the left lower lobe measuring 9.4 X 6.4 cm. This is attached to the hilum
and pleura. Nodular densities are seen in the hilum. Acinar infiltrates are noted in the left upper lobe. Fibrotic
densities are seen in both apices. The heart is lightly enlarged. No lytic changes demonstrated. IMPRESSION: Pulmonary mass,
left lower lobe, malignancy is highly considered. Attachment to the hilum and
pleura is demonstrated. Left hilar lymphadenopathy. Fibrosis, both apices.
By : Cesar S. Co. M.D.
After that, the doctor advised
to me to go back after 2 days to withdraw and analyze some liquids from my backbone. I went back and the doctor withdrew some
liquid from my backbone using a large needle. Result showed that I was cancer negative. The doctor thought that he didn't
place the needle at the correct location, thus, he tried again with a second needle. Result also showed that I didn't have
cancer. He immediately congratulated me because according to his findings, I didn't have cancer. To further confirm his findings,
he suggested that a tube should be inserted through my nose to pull out some more liquids. I refused to do so. Still, the
doctor doesn't want to prescribe any medicine because the disease was still unknown.
I went to look for another
doctor. His name is Dr. Tan. He also said the same thing as what Doctor Ang claimed since they got the same education. He
asked me to go to a Filipino hospital to withdraw some more liquids.
I went to the Filipino hospital.
He inserted a tube to my mouth for five times and pulled out some more liquids from my lungs for analysis.
After three days, it was found
out that I had malignant tumor. The doctor said that I can't be operated on, nor use chemotherapy nor cobalt therapy since
it was near my heart. Thus, I don't have any other alternative except to take Chinese medicine.
X-RAY CONSULTATION REPORT : Chinese General Hospital and Medical Center. Case No. 360114. Name : Sing Kio. Referred by : Dr. R. Ngo. Date
: 2-15-92. Clinical Data : CHEST. Compared with the previous examination dated 12-10-91 shows marked interval
decrease in the size of the atelectatic segment previously noted along the left paracardiacarea. The rest of the lungs remain
clear except for some pulmonary scarring in the left apex. The heart is not enlarged. Costrophrenic angles are well-defined.
By : T.U. Pastrana M.D. (Radiologist)
At that time, someone recommended
the use of some basic Chinese medicine. Nothing changed in 20 days. Someone then recommended Tian Xian Liquid. After taking
Tian Xian Liquid from January 10 to the end of February 1992 (approximately a month and a half), I had another X-RAY (Refer
to Figure 6). The doctor said that the results was much better than the previous one (Refer to Figure 3), but still, this
was a serious condition. My fever and cough improved, and vanished eventually.
Analysis of X-RAY:
Name : Sing Kio. Age : 58.
X-Ray No. : 5619. Date : 6-29-92.
Examination : CHEST. Examination of the chest shows the heart to be normal in size. The aorta is slightly dilated. Blunting of the left costophrenic
sulcus is noted. Apical pleural thickening is noted on the right. Minimal fibrosis is noted in both upper lung fields, more on the right. The finding appears to be inactive Koch's lesion. Comparison
with previous study will be of help. Minimal fibrosis is also seen at the left
base and could be due to residual change from previous pneumonia.
Summary : Examination of the
chest shows minimal scar, both upper lung fields, appears to be inactive Koch's lesion.
Minimal fibrosis at the left base is also noted.
By : Lorna S. Yiu Yap, M.D. Diplomate, American Board of Radiology and Nuclear Medicine. 645 Condesa Street, Binondo, Manila.
Along with Tian Xian Liquid,
I also take fruit and vegetable juices (half slice carrots, apple, one third of a cucumber, long celery, 2-3 leaves of lettuce,
sugar beet). After extracting the juices, I drank 3 glasses per day. I continued to take the Tian Xian Liquid until June (1992)
before I had another X-RAY. My fever and cough got better. I took another X-RAY(Figure 7) showed that there was nothing wrong
with me. I took the X-RAY on a commercial firm, not in the hospital. My tumor has vanished. The doctor said that it looked
like a dry scar of tuberculosis. Then, I stopped taking the Tian Xian Liquid until now.
Sonographic/Radiographic Report : ACCUVISION DIAGNOSTIC CENTER, INC. Name : Sing Kio. Date : 03/09/1998. File No. : 980645. Sonographic/Radiographic Report : Chest X-Ray : Fibrohazed
infiltrates noted in both upper lung fields. Rest of the lungs are clear. Hear and the rest of the chest findings are unremarkable. Impression: MINIMAL : PTB. BOTH UPPER LOBES, ACTIVITY UNDETERMINED.
By : Ma. Teresa D. Fontillas.
M.D.
Last month (March 1998), I
took another X-RAY (Refer to Figure 8). The X-RAY further confirmed that there is nothing wrong with me.
Recently, I have been diagnosed with colon cancer.
So, in April 1998, I started taking up the Tian Xian Liquid again. The doctor advised me to undergo operation for my colon
cancer. I refused and wanted to rely only on the Tian Xian Liquid. I hope by next year, I could be here again and testify
to the wonders of Tian Xian Liquid.
Tian Xian
Liquid
What is Tian Xian Liquid?
China No. 1 Tian Xian
Liquid is the latest contribution of the International
Rehabilitation of Cancer Association to all cancer patients in the world. It
represents a new breakthrough in mans struggle against cancer and is yet the best news for cancer patients.
The clinical experiments conducted on over more than 10,000 cancer patients in over 20 nations proved
that the latest discovery of a Chinese medical researcher, Wang Zhen Guos China No. 1 Tian Xian Liquid has an efficacy rate
of 80.7%. This is especially true for cancer patients in the middle or late stages
of illness. This treatment is more effective when compared against other anti-carcinogens.
(Please refer to the life stories of the cancer survivors).
This product was awarded by the State Ministry of Health and the State
Medical Administration of China. Some of its achievements include: The Highest
Honors in the 38th World Eureka Invention Expo, including the Award for the Worlds Best Individual Invention, Medal
of Honor from the King of Belgium, the Generals Medal and the Knights Medal. (Full details on his awards and recognition can
be found in the Wang Zhen Guo awards gallery).
Tian Xian Liquid is made with purely natural substances with no trace
of any chemical composition. It has anti-oxidant qualities scavenging for harmful free radicals. It is non-toxic. It increases
the anti-cancer function of the bodys defense system. Therefore, stimulating and strengthening the immune systems anti-cancer
function of the human body and inhibits the tumor growth. (See the Ingredients of Tianxian Liquid).
Tian Xian Liquid comes in 10cc vials and 280cc bottles for oral
consumption. Each course lasts 28 days.
The best time to take the dosage are 9 am, 3pm, 9pm, 3am, 10cc consumed each time. A total of 40cc is to be taken per day. It can also be taken as a health drink (10cc per day) for the prevention of cancer. (Details can
be found in the Tianxian product information).
After taking the Tian Xian Liquid, conditions of hair loss,
falling teeth, insomnia, anemia, etc., will be minimize. Clinical experiments
showed that significant results will be achieved after continuous dosage from 7 to 21 days. After taking 4 to 6 courses, the cancerous cells in the human body will be under control. They may cease to multiply rapidly and at times diminishes. Thus, extending the life span of the patients and eliminating the threat of death. It is necessary to avoid ingesting or exposure to carcinogenic substances, such as insecticides, pesticides,
herbicides, nitrosamines, etc.
The Tian Xian (pronounced "Dianne Sean") products are herbal dietary supplements. The active
herbal ingredients aims to control, inhibit and destroy cancer cells. It's function is complementary to that of western
therapies.
Testimonials of cancer survivors are from USA, Japan, Hong Kong, India, China, Philippines, Taiwan, Thailand, and Malaysia. The list of testimonials are added regularly.
Two books were already published detailing how Tian Xian
was invented, it's function and numerous cancer survivors stories. The publications, beside English, are available in
Chinese, Japanese, and Korean.
INDICATION
All kinds of cancer, the curative effect will be better if
matched with Tian Xian Capsule and Tian Xian Suppository.
APPLICATION AND DOSAGE
In the first two months, oral administration, 10 c.c. 6 times
daily, 6 and 9 o'clock in the morning, 12 o'clock in the noon, 3,6, and 9 o'clock in the afternoon. From the beginning of
the third month (or the state of illness has been improved) oral administration, 10 c.c. 4 times daily, 9 o'clock in the morning
3 o'clock in the afternoon, 9 o'clock in the evening and 3 o'clock before dawn.
PRICE
US$890 (For 28 days treatment)
MAJOR FUNCTIONS
1. BLOCK CANCER CELLS
The contents of China No. 1 Tian Xian Liquid block the growth
and multiplication cancer cells.
To block the multiplication of cancer cells at a certain stage and thereby to kill them.
To stop cancer cells breathing at the metabolism.
To damage cancer cells and let them dissolve.
[Raw Medicines that block cancer cells growth] : Rhizoma
Arisaematis, Rhizoma Curcumae, Radix Aconiti, Radix Aucklandiae, Radix Scrophulariae, Resina Garciniae, Sophora Alopecuroides,
Herba Rabdosiae,Rubescentis.
2. ADJUST METABOLISM
To change all kinds of metabolisms that cancer cells require
and thereby to suppress their multiplication. To improve the body invaded by cancer cells, to improve immunity against cancer
cells, and thereby to suppress the multiplication of cancer cells.
[Raw Medicines that adjust metabolism] : Black Nightshade,
Solanum Lyratum Thunb, Herba Sarcandrae, Radix Angelicae, Sincensis, Radix Salviae Miltiorrhizae, tulip.
3. IMPROVE IMMUNITY
To suppress cancer cell multiplication and to produce immunity,
to control easy-to-increase environment, and to promote killer cell activities.
[Raw Medicines that improves immunity] : Radix Rehmanniae,
fungi, Radix Acanthopanacis Senticosi, Radix Astragali, Ginseng, Poria Polysaccharide, Ginsen Soapgenein, Radix Astragali
Polysaccharide, Radix Trichosanthis.
4. MICROELEMENT EFFECT
To improve the physiological aspect of the body through microelement
activities, to promote genes activities, and to kill cancer cells.
(1) Selenium
To suppress cancer cells entering to genes; to suppress cancer
cells in liver, and to block cancer cells from split at the middle stage.
(2) Germanium
To promote the excretion of lymph soluble substance II and
interference enzyme I, to stimulate parasites to resist cancer cells, and subsequently to suppress tumor growth and spread.
LABORATORY TESTS RESULTS
With a view to understand the effect of Tian Xian Liquid in
an objective and accurate way, Taipei FRC Biology Study Center carried out experiments to have further scientific verification of Tian Xian Liquid. The experiments lasted for two years under 15 items of experimental topics and in
the name of FRC001 (the laboratories not being aware of Tian Xian Liquid for the sake of fairness) and were designed in 4
main directives. The experiment results are briefly described as follows. Detailed experimental contents are also available for reference to the academe:
EXPERIMENTS ON REMOVAL OF
FREE RADICAL
Tian Xian Liquid is able to effectively remove different
free radicals
can remove superoxide free radical, with clearance capacity of 300,000 units of SOD activity per c.c.
can remove free radical generated by white blood cells, which vitamin E fails to effectuate
can remove hydroxyl free radical, which vitamin E fails to effectuate
capacity to remove lipide peroxide is much stronger than that of vitamin E
TOXICOLOGY EXPERIMENTS
From animal experiments to mice, Tian Xian Liquid was able
to pass stringent acute toxicity test, micro-nuclear of bone marrow cell test, sperm distortion test and Ames test respectively.
IMMUNIZATION FUNCTION TESTS
Passing of animal experiments on mice, it was individually
proven that:
Tian Xian Liquid may increase the phagocytosis of macrophage
Greatly strengthened lymphatic conversion for the spleen
It raised the serum homolysis reaction and anti-host reaction, indicating significant benefits to immunization
INHIBITION EFFECT ON TUMOUR
As evidenced in a test on mice in sarcoma and hepatocele,
inhibition effect shown was not inferior to chemical (5-Fu) and also quantum effect reaction was observed, i.e. larger is
dosage better is the inhibition effect, which was greatly superious when comparing to reference group of glossy ganoderma
and green algaes, etc.
The above 4 groups of experiments indicated that Tian Xian
Liquid has passed the fundamental scientific tests in general.
INGREDIENTS
Radix Ginseng
10%
Margarita
2.5%
Radix Astragalt
10%
Borneolum Syntheicum
2.5%
Rhizoma Atractylodis Macrocephalae 5%
Radix Trichosanthis
5%
Clematis Root
5%
Heyotis Diffuse Wild
15%
Solanum Nigrum L.
5%
Indigot Naturalis
15%
Ligustrum Lucidum AIT
2.5%
Radix Glycyrrhizae
2.5%
Polyporus
10%
Pei
Ursi
5%
Pogostemon Cablin
5%
The following are some of the major components of the Tian
Xian Liqiud and their respective effects in the body. They are:
Rhizoma Atractylodis Macrocephalae - It is refined from the stems and roots of Rhizoma Atractylodis, and is an aroma,
stomachics and has diuresis effect.
Radix Glycyrrhizae - It is refined from the roots, root skin, stems of liquorice, and has the effect of immunity, inhibition,
relieving cough and phlegm removing.
Radix Ginseng - It is refined from medicinal ginseng root and has the effects of stomach strengthening, stomach support
and nourishment.
Radix Trichosanthis - It is refined from the roots of tang wu gua and has anti-tumor and anti-bacteria effects.
Radix Clematidis - It is refined from the roots of radix clematidis, and has pain relief and anti-cancer effects to
digestive organs.
Tian Xian complements Western Medicine Treatment
Western cancer treatment has been in the forefront with it's surgery, chemo and
radiation therapies. The concept of Chinese natural and herbal supplements emphasizes on the universal improvement of the
immune system. Regulating the physiology enabling the cells to repair, regenerate and restore functions.
Tian Xian Liquid is the latest contribution of the International Rehabilitation
of Cancer Association to all cancer patients in the world. It represents a new
breakthrough in man's struggle against cancer and is yet the best news for cancer patients.
The clinical experiments conducted on over more than 10,000 cancer patients in
over 20 nations proved that the latest discovery of a Chinese medical researcher, Wang Zhen Guo's China No. 1 Tian Xian Liquid
has an efficacy rate of 80.7%. This is especially true for cancer patients in
the middle or late stages of illness. This treatment is more effective when compared
against other anti-carcinogens. (Read more...)
WARNING: We found
counterfeits of Tian Xian Liquid present in several countries. Please make sure
that you buy the genuine product to ensure that you get the full effectivity of the medicine.
Contact us at the cancer hotline to confirm your local distributor.
NEWS: "Thailand Cancer Patient bought a Fake Tian Xian Liquid"
Warning on Counterfeits
We found out that many customers were able to buy counterfeits/fake products of
Tian Xian Products in Hong Kong, Taiwan, Philippines, China, Japan, USA, and South East Asian countries.
We have invested on the development of a new package to combat against counterfeits.
The design and the materials of the new packaging focuses on the presentation, convenience, safety and environmental protection.
The Lymph Tumor was Reduced by Tian Xian Liquid
I went to the hospital for a throat problem. The doctor said it was just a minor
inflammation and he gave me some antibiotics.
However, the problem did not go away and since I needed to take care of my children,
I just lived with it.
In September 1995, my neck began itching. I continued to scratch it and it began
bleeding uncontrollably.
I rushed to the hospital and I was diagnosed with lymph cancer. Surgery followed
the next month to remove two lymph tumors in three areas.
The doctor had to leave one of them as it was very close to the main artery.
We then learned about Tian Xian Liquid on the Internet, so we went to a drugstore
in Bangkok to buy some.
Although I recovered a bit after using it, the pain increased severely. The condition
got worse and I could still feel the depression.
One day I was able to browse through an advertisement of Tian Xian Liquid in
the newspaper. I compared the picture with the Tian Xian Liquid I recently bought,
they were DIFFERENT! The Tian Xian Liquid I bought was fake! According to the news, there are so many counterfeits in the
market.
I immediately ordered a new set of Tian Xian Liquid from a verified distributor. Certainly, the effect of the authentic product was true.
My pain disappeared in a month, and after 6 months, the tumor was much smaller.
I think it maybe the effect of both the chemotherapy and Tian Xian Liquid.
Just when I thought I could stop using it and rely on mere chemotherapy, I immediately
lost my energy, my condition worsened, and the pain returned. Examinations showed that the tumor grew back, so I immediately
started using Tian Xian Liquid again.
Now, I will never stop using it until I am sure that it is completely gone. The
lymph tumor reduced to the point that I can hardly feel it. (Editor's Note: It is advised to take Tian Xian Liquid continually
for a period of time, even in smaller dosage, as to prevent any recurrence)
Ms. Ma Mi Yu (46, Thailand)
Lung Cancer Survivor : Forever Grateful to Tian
Xian Liquid
Ms. Watanabe Yuki (58, Japan)
I began coughing severely in November 1997 and I thought it was just a flu. I
went to the hospital and they prescribed some cough medicine. But still, coughing
did not stop.
After two weeks, I had an X-ray
examination and it showed the accumulation of liquid in my lung. It was the cause of my cough. They were able to drain 4.5
liters of the liquid.
The severe cough recurred in April 1998, and water accumulation in my lung was
confirmed. After draining the water in the left lung, I thought I could go home.
But water began to accumulate in the right lung as well. I had another operation and they injected medicine to my lungs to
prevent further water accumulation.
However, my body rejected the medication and I suffered a high fever and had
difficulty breathing. I already felt that my life was in jeopardy. The treatment for the right lung was suspended and the
cough still wouldn't go away. Then, I lost my appetite. The cough grew worse after I went home.
It was even difficult for me to climb the stairs. I suffered greatly from the
severe coughing during the three weeks at home. Then I went back to the hospital again.
The final test results on July 15 confirmed lung cancer. The sever cough made
it difficult for me to speak, breathe, and walk, so I was bedridden. Fortunately, the patient beside me told me about Tian
Xian Liquid.
I began taking 4 bottles a day (1 bottle = 10cc). In just three days, the severe
cough was slightly relieved. I even had enough strength to walk to the toilet.
On September 13, I was relying on Tian Xian Liquid to improve my health so I
could attend my daughter's upcoming wedding. Starting September 23, the doctors placed me on the anti cancer drip treatment.
Many people did warned me about the severe side effects of the treatment.
My dream came true, the doctor allowed me to leave the hospital on October 15
and I was able to attend my daughter's wedding.
A follow-up X-ray examination showed that the lung cancer had disappeared, and
there was no more water accumulation.
Lung Cancer Survivor : I Went to Work Right After
Recovery
Mr. Yamdad Kimihiko (41, Japan)
(Wife speaking): "My husband received a surgery for thyroid cancer in November
1983. In 1992, it was revealed that the cancer had spread to his lungs, brain and neck.
Surgery followed, however, it was simply impossible to remove the cancer cells
as it has already infected both lungs. The doctor told me that my husband could only live for 3 to 4 years more.
Since 1995, he was able to gain back some energy, but he lost his voice sometime
during winter. February 1996, blood was discovered in his phlegm and he was then confined in the hospital.
I kept thinking of other ways to help my husband.
I then remembered Tian Xian Liquid, so I quickly looked into the details. After discovering that the rate of effectiveness
of Tian Xian Liquid was 80%, I decided to place all of my hope on it.
My husband had no faith in this medicine and he simply refused to try any Chinese
medicine as he already had a lot of it. Tian Xian Liquid became my last hope,
so I really urged him to try this treatment.
Finally, he agreed and started to take eight bottles a day during his stay in
the hospital (1 bottle = 10cc). Noticeably, his condition began to improve and
we were able to leave the hospital.
After 10 days of continuous usage, the bloody phlegm ceased, chest pain then
disappeared after another week. He regained both his voice and his energy and
he was able to went back to work very soon. Although the cancer is still there, his condition is very stable." (Note: No recent news yet about the status of Mr. Kimihiko's cancer)
Lung Cancer Survivor : I can now say that Tian
Xian Liquid is Really Effective
Ms. Ishikawa Hideko (67, Japan)
(Husband speaking) My wife was diagnosed with lung cancer in July 1997 and according
to the doctor, surgery was not possible.
She underwent chemotherapy and radiotherapy treatment. The doctor then said that she had no more than a year to live.
After undergoing stage four chemotherapy in October, my wife grew weaker from
the side effects to the extent that she could not withstand it. Approximately
20% of the cancer was still left.
Radiotherapy treatment was resumed in late October when there were signs of recurrence.
The therapy continued until December, however, the cancer was still there.
Her condition improved and she was released from the hospital late December.
In May 1998, an examination showed cancer cells had already spread to her brain. She was hospitalized immediately to receive
chemotherapy and radiotherapy treatment.
After the treatment (June), the cancer was still in her lung and brain. In consideration
of my wife's physical condition, the doctor told us that no more therapy should be given. In other words, it was hopeless.
We learned about Tian Xian Liquid from a news report and I immediately got into
the details. After a quick order, I gave my wife 2 bottles (1 bottle = 10cc) a day.
The reason why I gave her only half of the standard dosage was because she suffered from gastritis which resulted from
building pressure.
I increased the dosage to four bottles in June and her stomach pain receded.
An examination in July examination concluded that her lung cancer was still present
but the brain cancer had disappeared. Frankly speaking, China No. 1 Tian Xian Liquid was not the only medication we had tried.
For my wife, I had tried almost everything, but the result was in vain.
China No. 1 Tian Xian Liquid is really amazing: it destroy and inhibit the growth
of cancer. Based on what happened to my wife, I can now say that Tian Xian Liquid is really effective.
After a month or so, we were really surprised to find out that the cancer on
her brain has already disappeared.
To date, the brain cancer is gone, but the lung cancer is still there (Editor's
note: No recent news about the status of the lung cancer).
We still continue to use Tian Xian Liquid to prevent the regression of the cancer
and to improve energy. Starting August, we also included Tian Xian Capsule No.
3 to her medication.
She left the hospital in mid August and we took the doctor's advice to use stomach
medication in combination with China No. 1 Tian Xian products.
I thank Tian Xian for saving the life of my wife!
A Soldier's Experience with Lung Cancer
Mr. Jian Yong Guang (70, China)
A medical check up in April 1995 confirmed that I have stage 2 lung cancer. Immediate
surgery was necessary or I would not live longer than 5 years, the doctor said.
The news was so sudden that no one in the family could accept the reality. I
jog for 10 kilometers daily to keep my health in top condition and I do have regular medical check ups.
I was a soldier before and I was never afraid to die. But when I learned that
I have cancer, I kept asking, "Why me?" There were no apparent symptoms at all.
I was then hospitalized and underwent surgery in May. Although they removed a
part of my left lung, the surgery did not completely remove the cancer. The doctor then advised me to undergo chemotherapy
to prevent it from spreading.
I refused, not because I'm afraid of death, but because I prefer to just wait
for my time than undergo such treatment.
Later, I realized that I can accept death, but I can never surrender to cancer.
My condition grew worse after the surgery. The wounds hurt badly and a lump was
developed. I lost my energy, appetite, and weight.
Then I heard that my friend's wife (who had cancer before) was cured by a Chinese
medicine, so I quickly looked into it. She explained the details of Tian Xian Liquid to me and because of her acquaintance
with Mr. Wang, she could ask him about my condition directly.
Mr. Wang encouraged me, "Don't feel hopeless, you can be cured!" He also sent
me instructions on how to use Tian Xian Liquid and I began taking the treatment immediately.
The pain went away after using it for just a short time, but I began itching
and had diarrhea for 2 months.
Honestly, I was beginning to doubt the efficiency of Tian Xian Liquid. But, according
to Mr. Wang, the condition I was in was normal and I did trust his opinion.
An examination seven months after the surgery showed that the cancer cells have
disappeared and there was nothing wrong with me. I still use Tian Xian Liquid and I enjoy a happy and healthy life. (Editor's Note: Mr. Jian still take Tian Xian Liquid in smaller dosage so as to prevent any recurrence)
Lung Cancer Survivor : I Regained my Life Through
the Internet
Mr. Liu Wai (55, Hong Kong)
I am a healthy person and I just can't believe that I have lung cancer. A medical
checkup because of excessive cough revealed this reality in September 1996. I underwent surgery only because I don't have
any other choice.
They placed me on radiotherapy and chemotherapy treatment. I almost lost all
of my hair because of the side effects, but, the doctor still continued both therapies.
My son then learned about Tian Xian Liquid from the Internet. Since the doctors
do not recognize Chinese medicine, I have to use it secretly.
It was expensive to maintain both therapies at the same time so I asked the doctor
to stop the chemotherapy treatment for a while. I still continued taking Tian Xian Liquid. My condition grew better and my
hair began to grow again.
I told my doctor about my secret only after when I stopped coughing, but he had
already suspected it even from the start. It was difficult for him to approve it.
The miracle was brought by from Tian Xian Liquid in combination with chemotherapy,
and radiotherapy treatment. I began using Tian Xian suppository in June 1998 with excellent results.
The lung cancer receded and I went back to work. My overall condition is getting
tremendously better. To relieve the pain caused by the wounds from the surgery, I also use Tian Xian Plaster.
My inspiration to get well is because of my family's well-being. The doctor said
the tumor condition was stable and I only need to have a monthly checkup.
Later, I also found out that I was the only one who survived cancer in that hospital
among the others that were confined during the time that I was there.
Thanks to Tian Xian Liquid for saving my life. I would like to add that Chinese
people should not discriminate Chinese medicine. When it is used in conjunction with western medicine, the effective rate
is also increased.
I started smoking when I was ten years old and lung cancer seemed unavoidable.
Because of what I went through, I'm able to quit the smoking habit!
After using Tian Xian Liquid for 1 year, the Lung
Cancer Completely Disappeared
Mr. Zhu Yu Lan (49, China)
On December 3, 1995, I started to experience
fever, cough, and chest pains. Also, blood was present in my phlegm.
Medical checkups concluded that there was a 3 x 4 cm tumor in my left lung and
cancer cells were also found in my phlegm.
I received radiotherapy treatment at the hospital, but, I've to admit that it
was not effective. I left the hospital on February 8. I was very anxious at this time.
In July 1996, a friend of mine (who just recovered from stomach cancer using
Tian Xian Liquid) introduced this medicine.
I started with the Tian Xian treatment only after two months. Since then, the symptoms were relieved and the tumor was reduced
in size to 2x3 cm.
I continued using it and an X-ray examination in August 1997 showed that the
cancer was completely gone. The CEA was also negative. Also, there was no sign of recurrence.
In less than 5 Months the Tumor Disappeared and I'm back to Normal
Mr. Wang Zhou Hong (63, Malaysia)
I had several examinations (including X-ray) in March '97 and it concluded that
I have lung cancer. They found a benign 3 x 2cm tumor.
The necessity of surgery was dependent on the results of further examinations.
I remembered that surgery is not good for old people like me, so I only took medicine.
In May, my son learned from the Internet that Mr. Wang (Inventor of Tian Xian Liquid)
was coming to Malaysia to give a free consultation. I went
to see him, he immediately confirmed that I have lung cancer and prescribed a one month Tian Xian treatment program which
consisted of Tian Xian Liquid, Capsule, and Plaster.
An checkup in June showed that the tumor reduced by half. The effect is truly
amazing. Then an examination in October 25, showed that it was completely gone.
I was tremendously happy. It was Tian Xian Liquid that took me away from the
horror of death and pain. Now, the tumor is gone and I still continue to use Tian Xian Liquid to prevent any recurrence. An
examination in March 1998 reconfirmed that everything is normal.
Lung Cancer Survivor : I only Relied on Tian Xian
Liquid
Mr. Sing Kio (58, Philippines)
April 23, 1998 - Century Park Sheraton Hotel, Manila Philippines (Translated from
Chinese)
Good Day to Everyone. Today, I am here to share on how the Tian Xian Liquid cured
my cancer. First things first, I would like to make known that I don't have any relation with Professor Wang Zhen Guo (Inventor
of Tian Xian Products) nor Mr. Manuel Kiok (General Manager of Green & Gold International Exports).
I would also like to say that it is not Professor Wang nor Mr. Kiok who asked
me to share. In fact, I volunteered myself. My primary motive in testifying here today is to hear the lecture of Wang Zhen
Guo on Cancer. Secondly, I wish to personally thank Professor Wang Zhen Guo for his invention (China No. 1 Tian Xian Liquid)
which cured my cancer disease.
Let me tell you how I was able to come to speak before you today. Sometime ago,
I saw an advertisment of the Tian Xian Liquid and the Anti-Cancer Seminar (April 23, 1998) in a Chinese newspaper. I decided
to call up the office of the distributor (Green & Gold International Exports). I was able to talk to Mr. Kiok personally.
Eventually, I told him that I was cured of cancer 7 years ago due to my intake of the Tian Xian Liquid. I said I could share
my testimony on the lecture day provided that my transportation should be met.
Before I continue, I would like to testify that I wasn't able to undergo any surgery,
chemotheraphy, cobalt therapy or any other solution/medicine due to the position of the cancer (near my heart). I was left with no option but to depend on Chinese herbal medicine. (China No. 1 Tian Xian Liquid) Please see note below.
Last June 1991, there were nights while I was sleeping that I would cough very
hard, and throw up phlegm. Like normal procedure, I took common western & chinese herbal medicines to cure my simple disease.
But, this did not solve the problem. I then consulted a physician named Doctor
Ang. He's an old doctor and thus, have a lot of experience. After taking an X-RAY (Figure 1), the doctor noted a slight enlargement
near my left lung as compared to a normal X-RAY (Figure 2). "This is a very suspicious area, you'll have to go get a CT-SCAN.",
the doctor suggested. I hesitated to have my CT-SCAN and just asked the doctor to prescribe some medicine. He prescribed some
antibiotics, but unfortunately, it didn't work. I visited him again, and he gave me another similar set of antibiotics, only
the name have been changed. But still, nothing worked.
By November, I already have a fever. After
realizing that the medicine have no effect. I went to see another doctor, coincidentally, his name is Doctor Ang. The second
doctor was older than the first and was very popular during the 1950's. After showing my previous X-RAY to the second doctor,
he also gave me the same explanation and prescription. The medicine didn't work out again. The second time I went back to
the doctor, he prescribed me a new set of antibiotics. This time around, the medicine didn't conform with my body and hence,
I lost 8 pounds.
I took the medicine from November 11 to December 10, 1991.
But, my fever worsen, my phlegm already contained blood, and my cough worsen. So, I went out to look for another doctor in
a big hospital. This time around, the doctor (although named Doctor Ang again) was a young doctor. On December 10, 1991, the third doctor advised me to have another X-RAY and CT-SCAN. Two days later, I saw the result
(Refer to Figure 3). The result was worse. The doctor didn't even believe that the man to whom the X-RAY belonged to was still
alive.
X-RAY CONSULTATION REPORT : Chinese General Hospital and Medical Center. Case No. 360114. Name : Sing Kio. Referred by : Dr. R. Ngo. Date
: 12-10-91. Clinical Data : CHEST. Compared with the previous examination taken outside dated 11-11-91 shows
interval progression of the atelectasis and infiltrates in the left lung base.
The right lung is clear. Heart is not enlarged. Diaphragm is intact. IMPRESSION: Atelectasis and pneumonia
infiltrates, left lung base showing interval progression. Possibility of this
being secondary to hilar compression cannot be ruled out.
By : E. Dy M.D. (Radiologist)
The doctor said that the tumor is way too close to the heart. Hence, surgery,
chemotheraphy, cobalt therapy is not possible even if the tumor was benign or malignant. To me, it was more of like a death
sentence.
The CT-SCAN results (Refer to Figure 4 & 5) showed that the tumor was 9.4
cm X 6.4 cm. On that same day, the doctor didn't want to prescribe any medicine and advised me to consult a TEMT specialist
to find out if there is something wrong with my throat. Result showed that there is an inflammation in my esophagus. The TEMT
specialist recommended to perform a surgery within three days. I hesitated because I think there was nothing wrong with my
throat (I had voice, I can eat, etc).
CT-SCAN details : Chinese General Hospital & Medical Center, Section of Computed Tomography. Name : Sing Kio. Age : 58. CT No. : 91-1870. Referred by : Dr. R. Ngo. Date : 12-20-91.
Consultation Report : C.T. SCAN OF THE CHEST.
Contrast study of the chest shows a huge pulmonary mass in the left lower lobe measuring 9.4 X 6.4 cm. This is attached to the hilum and pleura. Nodular densities
are seen in the hilum. Acinar infiltrates are noted in the left upper lobe. Fibrotic densities are seen in both apices.
The heart is lightly enlarged. No lytic changes demonstrated. IMPRESSION: Pulmonary mass, left lower lobe, malignancy is highly considered. Attachment to the hilum and pleura is demonstrated. Left
hilar lymphadenopathy. Fibrosis, both apices.
By : Cesar S. Co. M.D.
After that, the doctor advised to me to go back after 2 days to withdraw and
analyze some liquids from my backbone. I went back and the doctor withdrew some liquid from my backbone using a large needle.
Result showed that I was cancer negative. The doctor thought that he didn't place the needle at the correct location, thus,
he tried again with a second needle. Result also showed that I didn't have cancer. He immediately congratulated me because
according to his findings, I didn't have cancer. To further confirm his findings, he suggested that a tube should be inserted
through my nose to pull out some more liquids. I refused to do so. Still, the doctor doesn't want to prescribe any medicine
because the disease was still unknown.
I went to look for another doctor. His name is Dr. Tan. He also said the same
thing as what Doctor Ang claimed since they got the same education. He asked me to go to a Filipino hospital to withdraw some
more liquids.
I went to the Filipino hospital. He inserted a tube to my mouth for five times
and pulled out some more liquids from my lungs for analysis.
After three days, it was found out that I had malignant tumor. The doctor said
that I can't be operated on, nor use chemotherapy nor cobalt therapy since it was near my heart. Thus, I don't have any other
alternative except to take Chinese medicine.
X-RAY CONSULTATION REPORT : Chinese General Hospital and Medical Center. Case No. 360114. Name : Sing Kio. Referred by : Dr. R. Ngo. Date
: 2-15-92. Clinical Data : CHEST. Compared with the previous examination dated 12-10-91 shows marked interval
decrease in the size of the atelectatic segment previously noted along the left paracardiacarea. The rest of the lungs remain
clear except for some pulmonary scarring in the left apex. The heart is not enlarged. Costrophrenic angles are well-defined.
By : T.U. Pastrana M.D. (Radiologist)
At that time, someone recommended the use of some basic Chinese medicine. Nothing
changed in 20 days. Someone then recommended Tian Xian Liquid. After taking Tian Xian Liquid from January 10 to the end of
February 1992 (approximately a month and a half), I had another X-RAY (Refer to Figure 6). The doctor said that the results
was much better than the previous one (Refer to Figure 3), but still, this was a serious condition. My fever and cough improved,
and vanished eventually.
Analysis of X-RAY: Name : Sing Kio. Age : 58. X-Ray No. : 5619. Date : 6-29-92.
Examination : CHEST. Examination
of the chest shows the heart to be normal in size. The aorta is slightly dilated. Blunting of the left costophrenic sulcus is noted.
Apical pleural thickening is noted on the right. Minimal fibrosis
is noted in both upper lung fields, more on the right. The finding appears to
be inactive Koch's lesion. Comparison with previous study will be of help. Minimal fibrosis is also seen at the left base and could be due to residual change
from previous pneumonia.
Summary : Examination of the chest shows minimal scar, both upper lung fields,
appears to be inactive Koch's lesion. Minimal fibrosis at the left base is also
noted.
By : Lorna S. Yiu Yap, M.D. Diplomate,
American Board of Radiology and Nuclear Medicine. 645 Condesa Street, Binondo, Manila.
Along with Tian Xian Liquid, I also take fruit and vegetable juices (half slice
carrots, apple, one third of a cucumber, long celery, 2-3 leaves of lettuce, sugar beet). After extracting the juices, I drank
3 glasses per day. I continued to take the Tian Xian Liquid until June (1992) before I had another X-RAY. My fever and cough
got better. I took another X-RAY(Figure 7) showed that there was nothing wrong with me. I took the X-RAY on a commercial firm,
not in the hospital. My tumor has vanished. The doctor said that it looked like a dry scar of tuberculosis. Then, I stopped
taking the Tian Xian Liquid until now.
Sonographic/Radiographic Report : ACCUVISION
DIAGNOSTIC CENTER, INC. Name : Sing Kio.
Date : 03/09/1998. File No. : 980645. Sonographic/Radiographic Report : Chest X-Ray : Fibrohazed
infiltrates noted in both upper lung fields. Rest of the lungs are clear. Hear and the rest of the chest findings are unremarkable. Impression: MINIMAL : PTB. BOTH UPPER LOBES, ACTIVITY UNDETERMINED.
By : Ma. Teresa D. Fontillas. M.D.
Last month (March 1998), I took another X-RAY (Refer to Figure 8). The X-RAY
further confirmed that there is nothing wrong with me.
Recently, I have been diagnosed with colon cancer. So, in April 1998, I started
taking up the Tian Xian Liquid again. The doctor advised me to undergo operation for my colon cancer. I refused and wanted
to rely only on the Tian Xian Liquid. I hope by next year, I could be here again and testify to the wonders of Tian Xian Liquid.
My contact number is with Mr. Manuel Kiok. Should you be interested to get any help or any comment, please don't hesitate
to contact me.
MY SECRET MEDICINE
Aside from the Tian Xian Liquid , I also used my very own secret medicine. This
medicine can't be bought anywhere. You can't ask your friends to look for it. We need to depend on ourself in order to use
this secret medicine. I know everybody is interested to know my secret medicine. 1.
Strong determination, 2. Courageous spirit, 3. Optimistic, 4. Don't worry too much, 5. Don't be afraid
This secret that you've heard is very easy for some of you. But it is hard to
apply it in the lives of the cancer patients. We know that in our environment, we have a lot of viruses. But thankfully, our
body has antibodies which deals with these viruses. When we are healthy, our antibodies are strong, thus virus can't enter
our body. But, when we have a lot of work, or we are over-tense, fatigue, stress-out, our antibody will get low, thus our
body is vulnerable to viruses.
Thus, if a cancer patient is not tense and not nervous, he'll be able to maintain
his antibodies. Afterwards, when we drink the medicine, the antibodies will be able to work together with the medicine. On
the other hand, if a cancer patinet is tensed, scared or afraid, he'll be weak and the medicine won't have any effect on him.
This is the primary reason on why some of the cancer patients doesn't get cured by the Tian Xian Liquid.
Comment by the International Distribution Manager to Mr. Sing Kio's testimony
:
* I want to comment on the testimony of Mr. Sing Kio. There are some things I
would like to bring to everyone's attention. This medicine (Tian Xian Liquid) is most effective when used together with western
medicine. Mr. Sing Kio said that he didn't use any western practice (i.e. surgery, chemo), is 'lucky'. It is not safe to say
that we should only depend on the Tian Xian Liquid. With western treatment and the full support of Tian Xian Liquid, the result
will be at its best.
Lung Cancer Disappeared in 5 Months
Mr. Heng Chew Hong (63, Malaysia)
In March 1997, my doctor urged me to have my annual checkup. He said that it is a good habit for elderly people to maintain a regular annual medical check up.
It was during this check up that a 3 X 2 cm 'shadow' was found in my left lung.
The doctor suspected that it was a tumor and a biopsy is necessary to find out whether it was benign or malignant. The result of the biopsy would also determine if a surgery is necessary.
I was worried that I'm not strong enough to undergo surgery. Hence, I started
to look for a medicine treatment in order to prevent surgery.
In May 1997, I heard that Mr. Wang Zhen-Guo (a famous anti-cancer herbalist) would
come to Malaysia to provide free consultation for cancer patients.
I was able to consult Mr. Wang with my condition and he prescribed Tian Xian
Liquid, Tian Xian Capsule #5 and Tian Xian Plaster. He recommended the treatment
for at least one course.
The X-ray exam on June 23, 1997, indicated that
the size of the tumor was reduced by half to 1.5cm. I was shocked by the result as I did not expect this miracle.
I was very satisfied. During the course of the treatment, I felt that I was more
energetic and developed a good appetite. I followed Mr. Wang's prescription and continued with Tian Xian Liquid. I hope that
the tumor in my lung will one day disappear totally.
The X-ray as of October 25, 1997, showed that
the tumor has totally diminished. My dream was fulfilled. I am very happy that
Mr. Wang offered me a SUFFERING-FREE anti-cancer treatment.
Even though the tumor was gone, I still continue with Tian Xian Liquid at a smaller
dosage to prevent any relapse.
The X-ray on March 2, 1998, confirmed that
the cancer is not there anymore!
Is Tian Xian Liquid really effective ?
Yes, it is effective. Based on different conditions of each patient and the stages of cancer, Tian Xian Liquid will
have different level of effectiveness. It is effective when the expected effectiveness is achieved for a specific stage of
cancer.
What does "expected effectiveness for a specific stage of cancer" mean?
(1) Last stage cancer: Tian Xian Liquid can release pain and prolong life span. Most last stage cancer patients would
rest peacefully.
(2) Middle stage cancer: When combined with western medical treatment, Tian Xian
Liquid can help patients improve day by day. Patients are required to take the medicines at the dosage and time suggested
in order to achieve the expected effectiveness (control the growth of cancer, prevent metastasis and further reduce of size
of tumor).
(3) Early stage cancer: When combined with western medical treatment, Tian Xian
Liquid can destroy cancer cells and control cancer relapse effectively. In addition, it can ease the side effects resulted
from chemotherapy or radiotherapy.
In order to achieve expected effectiveness for a specific stage of cancer, patients
must have faith and courage to fight against cancer in the long term.
What does 80.2% effective rate mean?
It represented an aggregate of 80.2% among the clinical cases when standard dosage was applied.
1.2% Relief Rate: over 50% reduction in size of tumor focus which sustained for
over 4 weeks.
2% Improvement Rate: tumor focus diminished by 25% but under 50% which sustained
for at least 4 weeks.
77% Stabilization Rate: tumor focus diminished by or under 25% with no growth
or new focus.
Is Tian Xian Liquid guaranteed to be absolutely effective?
Unfortunately not. It is the most effective Chinese medicine especially when combined with western medical cancer treatment.
Based on past experience, Tian Xian Liquid is able to strengthen the immune system and prolong patient's life span. A well
kept physical condition allows patients a chance to wait for a more advanced and effective medicine and treatment for cancer
in the future.
In addition to Tian Xian Capsule #3, what other method can lessen the side effects,
such as nausea, vomiting, etc., resulted from chemotherapy or radiotherapy?
Pasting Tian Xian Plaster on the uncomfortable areas will lessen these side effects.
What is the standard dosage?
A standard dosage is suitable for early and middle stage cancer patients, and those at recovery phase. A standard dosage
requires patients to take Tian Xian Liquid 40cc a day (4 times a day), 10cc each time at 9AM, 3PM, 9PM, and 3AM. If it is
inconvenient for the patient to wake up at 3AM, patients may take 20cc at 9AM or 9PM.
What is an increased dosage?
An increased dosage is suitable for terminal stage cancer patients and those undertaking special treatment. An increased
dosage requires patients to take 60cc a day (6 times a day) 10cc each time at 6AM, 9AM, 12PM, 3PM, 6PM, and 9PM. If patients
are taking other medicines and health supplement, they can take 20cc each time at 9AM, 3PM and
9PM.
What is the difference between standard and increased dosage?
During the past few years, most of our patients were at the last or terminal stages of cancer. Some of them could not
receive western medical treatments due to various reasons. As a result, standard dosage was not effective enough for most
patients. An increased dosage is strongly recommended.
Why is it recommended to take Tian Xian Liquid at 9AM and 9PM?
Research indicates that cancer cells are most active and replicate fastest at 10 to 11 o'clock
both in the morning and at night. If patients can take Tian Xian Liquid at 9AM and 9PM, the medication will be more efficient in controlling the growth of cancer cells during this period.
Is there a maximum dosage for Tian Xian Liquid?
The maximum dosage for Tian Xian Liquid is 120cc a day. Taking too much of any medicine will burden the liver and kidney.
What is maximum number of Tian Xian Suppository to be applied each day ?
The ingredients of Tian Xian Suppository consists of strong anti-cancer
medicines. The maximum number to be used daily is 4 granules.
Should Natural Nutritious Liquid be taken constantly?
The fact is that physical condition will become less healthy as people get old. In addition, the external environment
is becoming more harmful to our body. As a result, we need health supplements to maintain physical functions. It would be
beneficial to take Natural Nutritious Liquid constantly.
Constipation may occur after taking Tian Xian Liquid. What should be done?
Since it contains animal bile (according to Chinese medicine, it is a cool medicine) if the patient has hot physique,
there is a slight chance of having constipation. This may be relieved simply by taking some saline water before breakfast
in the morning. Patients are advised to include high fiber products in their daily diet.
Diarrhea may occur after taking Tian Xian Liquid. What should be done ?
This usually happens to patients with cool and vague physique. This may be relieved by drinking red dates (5 to 7 pieces) and ginger (3 to 5 slices) water for 3 to 5 days.
Epigastric pain may occur after taking Tian Xian Liquid. What should be done?
This is due to Tian Xian Liquid's function of activating blood circulation and removing bruise. This symptom often
happens to patients whose malignancy is in the area of lungs. This symptom would disappear after one course of the dosage.
Continuous belching may occur and the stomach may feel hot after taking Tian
Xian Liquid. What should be done?
This usually happens to the patients who have chronic gastritis and peptic ulcer when they started the application
of Tian Xian Liquid. Improvement may be obtained by drinking red dates and ginger water. Gastritis may also be cured after
one course of dosage.
Gasp may occur and the heart-beat may become faster after taking Tian Xian Liquid.
What should be done?
Tian Xian Liquid has the effect of accelerating blood circulation and relief of the symptom may be obtained continuation
of dosage. This usually happens to a small minority of people with weak heart function. You may simply reduce the amount and
increase the number of dosage. Heart stimulant is not required.
Dizziness may occur after taking Tian Xian Liquid. What should be done?
This is mainly due to excessively weak physique of patients. It will be relieved after one week by simply reducing
the dosage till patients get used to the medicines. Remember to increase the dosage when the symptom is gone.
Poor appetite and nausea may occur after taking Tian Xian Liquid. What should
be done?
Taking Tian Xian Liquid will not cause poor appetite and nausea. If undertaking chemotherapy or radiotherapy, patients
will experience vomiting, nausea, and etc. They may resist the smell of the herbal medicine. You may reduce the amount of
Tian Xian Liquid and increase the use of Tian Xian Suppository till these symptoms lessen.
Blood pressure may rise after taking Tian Xian Liquid. What should be done?
Tian Xian Liquid has the function of accelerating blood circulation. This is a temporary symptom and will not cause
cardio vascular disease. If you are suffering from hypertension, please continue taking the tension-relief medicine.
If patients suffering diabetes experience increased blood sugar, what should
be done?
Tian Xian Liquid should be taken in conjunction with blood-sugar-reduction medicines. Patients should visit their doctors
on the regular basis to follow up with the reading of blood sugar level.
Patient's skin tone may become darker after taking Tian Xian Liquid. What should
be done?
This usually happens to liver cancer patients. After 2 to 3 months period of dosage, normal state will resume.
Haemorrhoids may occur after taking Tian Xian Liquid. What should be done?
This is a sign of expulsion of toxic substances out of the body for patients who originally suffer from Haemorrhoids.
It is better to ask a surgical doctor to sterilize and bandage to avoid contamination of germs. Tian Xian Suppository can
be applied to help cure haemorrhoids after the wound had healed.
What are the body reactions showing that Tian Xian Liquid has become active in
the body?
After 3 to 5 days of application, some body reactions such as pain, sore , and fatigue will occur based on the focus
and the extent of the diseases. These are improvement body reactions which will go away when patients get used to the medicines
after continuous application.
Vomiting and bloody stool may occur to a gastric cancer patient after the dosage.
What should be done ?
Vomiting: The dosage may be taken along with fresh ginger slices and red dates prepared in boiling water.
Bloody stool: If bloody stool occurs, please ask a doctor to examine whether
it is the metastasis of the cancerous cells to the large intestine or rectum.
Aching may occur throughout the body after taking Tian Xian Liquid. What should
be done?
This is the normal sign of having smooth circulation of the blood networks and a sign of medicinal herbs in fighting
against cancer cells. The dosage should be continued and relief will result in 1 or 2 weeks.
How to take Tian Xian Liquid when oral ulcer occurs after chemotherapy?
Dilute Tian Xian Liquid with the same amount of water and take the diluted medicines slowly. Tian Xian Suppository
is strongly recommended to enhance the effect of Tian Xian Liquid and to stop pain.
How to take Tian Xian Liquid when patients need the assistance of gavage?
Inject Tian Xian Liquid first and 15cc of water using syringe into gavage to make sure Tian Xian Liquid flow into stomach.
How should patients suffering from ascites utilize Tian Xian Liquid and its serial
products?
For serious ascites, western medical treatment is required to expel the water. Application of Tian Xian Liquid, Capsules,
and Suppository will be able control ascite from developing too fast at the early stage.
What should be done when cancer patients catch a cold?
When patients or family members have symptoms of flu, please add 20cc of Tian Xian Liquid to the suggested dosage for
at least 7 days to strength immunity functions to fight against virus.
Why is the taste of Tian Xian Liquid sometimes differ?
It is because of the difference in concentration and sweetness of the honey produced by the bees from different flowers
over the seasons. You may therefore feel some difference in the prescribed Tian Xian Liquid.
May Tian Xian Liquid be taken before and after a surgical operation or before,
during and after chemotherapy ?
If your doctor requires fasting, you should not take Tian Xian Liquid until you finish the therapy. If the doctor did
not require fasting, you may continue the dosage. You can resume the dose after the surgery -- with doctor's permission to
take some liquid diet.
Which Tian Xian Capsule is most suitable for patients with few new focuses of
cancer metastasis?
Patients with few new focuses of cancer metastasis may choose Tian Xian Capsule based on either the latest focus of
metastasis or the most uncomfortable part. If patients undertook many courses of chemotherapy or radiotherapy which may cause
hemopoiesis function disturbance, long-term application of Tian Xian Capsule #3 is strongly recommended to strengthen weak
physique.
If patients have difficulty to swallow the Tian Xian Capsule, what shall be done
?
Just open the capsule and mix with the medicated powder with honey water. The
curing effect is even better than swallowing the capsule.
How do rectal cancer patients who was implanted with tracheotomy (artificial
anus) use Tian Xian Suppository?
If the wound has not yet healed,
do not use the suppository. If wound has been healed for at least one month and the patients does not experience slight diarrhea,
insert suppository directly into tracheotomy.
Can Tian Xian Suppository be used for all kinds of cancer?
Yes. The medication of Tian Xian
Suppository is absorbed directly through local mucosa and blood vessel. When combined with Tian Xian Liquid and Capsule, it
can effectively control cancer growth, prevent metastasis and relieve pain.
What kinds of cancers require application of Tina Xian Plaster ?
Tian Xian Plaster can be used externally for those cancer diseases close to body surface. Tian Xian Plaster can resolve
masses and relieve pains, stop bruise and remove swells. Combined with Tian Xian Liquid and Capsule, the curing effect can
be increased by absorption of the medicine through different networks.
What should be done if the patient is too weak ?
For those patients who receive frequent chemotherapy and radiotherapy and are at last stage of cancer, in addition
to the application of Tian Xian Liquid, Capsule, Suppository and Plaster, Natural Nutritious Liquid may be taken both in the
morning and at night to strengthen the body.
A patient of nasopharyngeal carcinoma who receives repeated radiotherapy will
experience difficulty of opening his or her mouth. What should be done?
This will be improved by pasting Tian Xian Plaster on the cheeks once a day for eight hours.
Can patients undergoing hemodialysis take Tian Xian Products?
Patients are not recommended to take Tian Xian Products on the day of hemodialysis. Patients can resume application
after hemodialysis.
Is it helpful to take Tian Xian Liquid for benign tumor?
Yes. Taking it at the standard dosage for 3 to 6 months will reduce the tumor size significantly. It may be taken to
prevent it from developing into malignant tumor.
When rashes, pimples or uloncus occur after taking Natural Nutritious Liquid,
what should be done?
These are improvement reactions. If these symptoms become worse, please stop the dosage until these symptoms disappear
which usually takes 7 to 10 days. You may resume with smaller amount of the dosage and gradually increase to 20cc a day.
Are there any counterfeits for Tian Xian Liquid?
All high quality products may be imitated all over the world. Many customers bought counterfeits because they did not
know how to differentiate counterfeits. Our company have invested on the research and development on the new package for Tian
Xian Liquid which will be available starting on December 1998. Please recognize clearly the new look of Tian Xian Liquid and
consult with genuine contracted distributors.
Can patients take other Chinese medicines or supplements when they take Tian
Xian Liquid?
It is very important to take Tian Xian Liquid at the suggested time. Patients can take calcium, iron, hormone and other
Chinese medicines that are supportive to the blood and vital energy at the interval of one hour. Other anti-cancer herbal
medicines are not recommended because some of the ingredients might be overlapping or contradicting. Patients do not have
to add ginseng in the treatment because the ginseng used in Tian Xian Liquid was from Changbai
Mountain which is proved to be the most effective ginseng compared to ginsen from other areas. Patients also
need to select other supplements wisely.
Is it necessary to take Tian Xian Liquid for one's whole life ?
As long as the cancer has been stabilized, the dosage can be adjusted and reduced. It is strongly recommended that
patients conduct follow-up examination on the regular basis. Generally, the dose applications are divided into 3 stages:
a. In the case of combined application with surgery and chemotherapy, we recommend
the dosage be followed for 3 to 6 months until examination confirms that the tumor have diminished or disappeared.
b. During the next two years, please change to one month dosage per quarter.
That is, by having the dose for one month while on suspension for the next two months.
c. Owing to the high relapse rate of as much as 60% within 5 years of the cancer
disease, dosage should be taken for one month in March and September during the three subsequent years.
If taking Tian Xian Liquid continuously, patients will prevent other diseases
due to well regulated constitution and strengthened immune system.
Which cancer disease is Tian Xian Liquid most effective on ?
When destroying cancer cells, Tian Xian Liquid is able to strengthen the immunity functions of the body at the same
time. The therapeutic theory focuses on the total rebuild of body to restore health and eliminate illness. Therefore it is
very effective to numerous types of cancer disease. Since it is by oral application, it has the greatest effect to cancers
of the digestive system.
When should Tian Xian Antitussivese Capsule be used?
It is used for lung cancer patients who have acute and chronic tracheitis, hypersensitive asthma, chest distress, and
cough. Combined application of Tian Xian Antitussives and Tian Xian Plaster can ease these symptoms effectively.
When should Tian Xian Ostitis Tablet be used?
It is applied for patients who have bone cancer, osteometastasis and osteoporosis. Combined application of Tian Xian
Ostitis Tablet and Tian Xian Plaster can effectively help release pain.
Are the white spots on the surface of Tian Xian Suppository traces of mildew?
The white spots are one of the constituent medical substances, which may also prevent the Tian Xian Suppository sticking
onto the package bag.
How to use Tian Xian Suppository properly?
Tian Xian Suppository is to be inserted into anus or vagina and is dissolved by body temperature. You may apply lubricant
such as Vaseline on the surface of the Tian Xian Suppository for a smoother insert. Please insert suppository 3 to 5 cm deep
and rest on the bed for 20 minutes so that suppository will not fall out of the body.
What should be done if the affected part is sensitive and itching after application
of Tian Xian Plaster?
This indicates that you have sensitive skin. Please apply a thin film of galactic liquid or lipa before pasting the
Tian Xian Plaster. Depending on the reaction of the skin, remove it within 4 hours or if adverse sensation occurs.
Are there any laboratory tests conducted on Tian Xian Liquid?
A: Yes. Many animal experiments and clinical trials have been conducted during the research and development of Tian
Xian Liquid. Recently, Free Radical Biology & Development Center in Taipei, carried out
four experiments which were directed by different research institutes.
What are the experiments conducted by Free Radical Biology & Development Center
in Taipei?
Experiments on removal of free radical by Institute of Biophysics, Academia
Sinica, Beijing Bradford Research Institute, CA, USA.
Toxicology experiments by Institute of Biophysics, Academia Sinica, Beijing Bradford Research Institute, CA, USA.
Immunization function tests by Institute of Biophysics, Academia Sinica, Beijing Bradford Research Institute,
CA, USA.
Inhibition effect on tumor by Guangzhou Tumor Institute.
What are the results of the experiment on removal of free radical?
Tian Xian Liquid is able to effectively remove:
Superoxide free radical with clearance capacity of 300,000 unit of SOD activity per c.c.
free radical generated by white blood cells which vitamin E fails to effectuate.
hydroxyl free radical which vitamin C fails to effectuate.
capacity to remove lipide peroxide is much higher than that of vitamin E.
What are the results of the experiment on toxicology?
Based on experiments conducted on mice, Tian Xian Liquid was able to pass stringent acute toxicity test, micro-nuclear
of bone marrow cell test, sperm distortion test and Ames test respectively.
What are the results of the experiment on immunization function tests?
Animal experiments on mice showed that Tian Xian Liquid may increase the phagocytosis of macrophage, strengthen lymphatic
conversion for the spleen and raise the serum hemolysis reaction and anti-host reaction which indicated significant benefits
to immunization.
What are the results of the experiment on inhibition effect on tumor?
As evidenced in the test on mice in sarcoma and hepatocele, inhibition effect shown as not inferior to chemical (5-Fu).
Quantum effect reaction was observed which indicated that the larger the dosage, the better the inhibition effect. This was
greatly superior to a reference group of glossy ganoderma and green algaes etc..
It is said that many herbal medicines produced in China have high heavy metal contents. What are the heavy metal contents in Tian Xian Liquid?
Micro elements are essential for anti-cancer effect. However, the heavy metal contents beyond the tolerance of human
body will burden the liver and kidney. Every batch of Tian Xian Liquid is submitted to SIGs of Hong Kong for test of heavy
metal contents, including cadmium, chromium, mercury, arsenic, lead, aluminum, antimony and tin. The test result shows that
the contents are far below the standard prescribed by the Hong Kong Government and world class standard (Test report available
upon request).
What kinds of food should patients consume more?
Patients are advised to eat more mushroom, garlic, vinegar and bean products.
Patients are advised to eat less dark meats and more white meats. Dark meats are categorized as acid food. Acidified
constitution has higher possibility to lead to cancer in the future. Milk and eggs with rich protein can provide energy and
nutrition. Due to slower gastroenteric wriggle, patients need more high fiber diet such as oatmeal, fruit and vegetables to
avoid constipation and flatulence. Bean products and milk easily produce gas in the stomach. As a result, patients should
consume small amount of bean products, soy bean milk and milk each time. Variety of foods is recommended.
What kinds of food should patients avoid?
Patients should not eat crab, chicken
skin, chili and alcoholic.
Why is it more effective when Tian Xian Liquid is combined with western medicine?
Western cancer treatment has been
the most effective and direct method for curing cancer. However, western treatment faces bottleneck in body reconstruction.
The concept of Chinese medicines emphasizes on the improvement of immune system and regulating constitution which enables
body cell to be repaired and basic functions to be restored.
This will complement what western treatment fails to accomplish. According to
the past experience, taking Tian Xian Liquid for a certain period of time before the surgery can possibly reduce the size
of tumor which will make surgery easier to remove the reduced tumor. Taking Tian Xian Liquid after the surgery will shorten
patient's recovery period and prevent metastasis and relapse.
Taking Tian Xian Liquid will significantly ease the side effects, such as vomiting,
nausea, oral ulcer, decrease in white cell count, associated with chemotherapy or radiotherapy which often administered before
the surgery. It also will enhance the effectiveness of chemotherapy and radiotherapy.
Can patients take Tian Xian Liquid only for cancer treatment and not receive
chemotherapy, radiotherapy and surgery?
We strongly recommend to our patients
not to give up on western treatment. Even though most patients who considered Tian Xian Liquid could not receive surgery or
had fear of the side effects associated with chemotherapy or radiotherapy, we try to educate our patients that western medical
treatment should be the focal point to cure cancer with the complement of Tian Xian Products. Based on the past experience,
the effectiveness was enhanced for last stage cancer patients when the combination of western treatment and increased dosage
of Tian Xian Liquid and its serial products was performed. Some patients, who could not receive western treatment, applied
Tian Xian Liquid at increased dosage with the supplement of serial product properly and earned a chance to be able to receive
western treatment.
During fever, may Tian Xian Suppository be applied as antipyretic?
Tian Xian Suppository has heat relief
effect. For against fever caused by infection of virus, it is not advisable to use Tian Xian Suppository for abatement of
fever.
Can Tian Xian Suppository be used to cure feminine diseases?
Yes. Due to its antiphlogistic,
styptic and anti-itching effects, it may be used to cure vaginitis, vaginitis trichomonas, venereal disease and cervical cancer.
Can Tian Xian Suppository cure hemorrhoids?
Yes. Tian Xian Suppository may relieve
the pains of hemorrhoids. If hermorrhoids already break out and bleed, western treatment is required to stop bleeding. If
it is only swollen, continuous use of Tian Xian Suppository can heal hermorrhoids in a short period of time. What is most
important is to have regular life style and eat more fruit and vegetables.
During headache, can pain be relieved by pasting of Tian Xian Plaster ?
Yes. Paste it on the temples and
between eyebrows for 30 minutes and the pain will generally lessen.
During sore waist and backache, can pain be relieved by pasting of Tian Xian
Plaster ?
Pains may be relieved by pasting
Tian Xian Plaster on the wider area where pains occur. It is very important to visit your doctor to find out the reasons that
cause pains.
Is it helpful to have Tian Xian Plaster pasted for coughing and sore throat?
Swelling may be removed and pain
relieved. Recovery will be achieved in 3 to 5 days when used with Tian Xian Antitussives Capsules.
During toothache, can pain be relieved by pasting of Tian Xian Plaster ?
Yes. By pasting on the affected
part, pain will generally be relieved in 20 minutes. Please visit your dentist for a proper exam.
Can Tian Xian Plaster cure cracking hands and beriberi?
It has specific effect to cure cracking hands and beriberi which requires time
and patience. It is advised to combine with western treatment.
On dysmenorrhea, can pain be relieved by pasting of Tian Xian Plaster ?
Pasting it on the abdomen will result
in obvious pain relief. To have better effect, apply it on the abdomen with a hot compress.
What should be done when there is chest distress and the pectoralgia occur?
Please have your doctor find out
the causes of chest distress and pectoralgia.
Can abdominal pain be relieved by pasting Tian Xian Plaster ?
Pain can be relieved. Diagnosis
should be conducted to find out the cause of the pain to prevent a misjudge.
Is it useful to have Tian Xian Plaster pasted to relieve muscle pain caused by
exercises?
It has the effect of detumescence
and may prevent other diseases caused by stasis of blood and injury of the tissues. If you do not know the cause of the pain,
please ask your doctor for a exam.
Is it helpful to use Tian Xian Plaster for nasal obstruction?
Yes, pasting on the temples and
between eyebrows for antiseptic and soothing effects. It is important to have examination and treatment in the hospital.
For scapulohumeral periarthritis, is it helpful to paste Tian Xian Plaster to
relieve pain ?
It may be pasted on the affected
part for a week to relieve or cure the pain.
Is it helpful to use Tian Xian Plaster for stiff neck?
Yes, applying on the lower backneck.
Please refer to the Tian Xian Plaster application demonstration.
Is it helpful to paste Tian Xian Plaster for spur?
Yes. This should cope with adjustment
to the vertebra.
Can pain be relieved for rheumatalgia and arthritis by Tian Xian Plaster ?
Yes. It has the effects of expelling
the wind, relaxing muscles, and relieving pain. Please remember to take care of daily life and keep warm. The effects can
be enhanced by applying Natural Nutritious Liquid.
Is it effective for viral hepatitis A, B and C sufferers to take the Tian Xian
Liquid?
Yes. By taking Tian Xian Liquid in conjunction with Tian Xian Capsule No. 6 ,
the liver functions may be strengthened to prevent cirrhosis.
After the index has dropped after taking Tian Xian Liquid, may a viral hepatitis
A, B and C sufferer stop the dosage?
When the index has dropped to the
normal rating, the dose should be maintained but may be reduced.
Is it effective to take Tian Xian Liquid for cirrhosis?
By taking Tian Xian Liquid in conjunction with Tian Xian Capsule No. 6, the liver
functions may be strengthened to prevent against liver cancer. When improvement occurs, please take Natural Nutritious Liquid
to maintain the condition of liver.
Does Natural Nutritious Liquid have any effect on sensitive skin?
Generally, Natural Nutritious Liquid
will strengthen immune system and improve physical nature. Improvement of sensitive skin problem will be achieved through
long term application.
Can Natural Nutritious Liquid improve irritability, insomnia and dreaminess?
Yes, these symptoms will be improved
in few days. To maintain the improvement, please continue the application for at least 3 months.
Can Natural Nutritious Liquid regulate menstruation irregularity and disorder
of internal secretion and even have beautifying effect?
Taking Natural Nutritious Liquid
can stimulate metabolism, regulate endocrine imbalance and beautify skin. Better results can be achieved by continuous long
term application.
Can teenage girls take Natural Nutritious Liquid?
Yes. Natural Nutritious Liquid can smooth the circulation of blood networks.
Therefore, it can improve irregular menstruation and menoxenia.
Is Natural Nutritious Liquid effective in improving hyperthyroidism or hypothyroidism?
It is suggested to combine western and Chinese herbal treatment. The western
curing effect will be enhanced by taking Natural Nutritious Liquid.
Is Natural Nutritious Liquid effective for dim-sighted, acerbity or sensitivity
caused by prolong improper use of the eyes?
Yes, Natural Nutritious Liquid may be applied to help recover from eye fatigue.
It is important to take good care of eyes.
Is it effective to take Natural Nutritious Liquid for soreness of waist, backache,
shoulder aching pain and lumbago due to the kidney deficiency of the aged ?
It is effective. These will be improved by merely taking Natural Nutritious Liquid
and Tian Xian Plaster.
For those having weak stomach due to poor digestive system and absorption function,
is it effective to take Natural Nutritious Liquid ?
Yes, Natural Nutritious Liquid can protect stomach mucosa and therefore is very
effective for peptic ulcer. It requires long term application and regular eating habits.
Is Natural Nutritious Liquid effective for Gout?
Yes, because it can smoother the circulation of blood networks, remove swell
and bruises. It can effectively ease the pain from Gout. Western medicines are necessary in the beginning of the treatment.
When the symptoms diminish, western medicines can slowly be decreased.
Is Natural Nutritious Liquid suitable for those people who have very weak constitution
and have been ill for a long period of time?
Yes. Taking Natural Nutritious Liquid can improve immunity function and energy
during restorative period for both children and adults who are very weak, catch a cold easily, and have been through surgery.
It is a very simple, safe, convenient and effective health supplement.
Is Natural Nutritious Liquid suitable for those people who suffers from brain
nerve weakness?
Yes. Taking Natural Nutritious Liquid can increase the oxygen utilization in
the brain which will improve migraine, incapability to focus and impaired memory resulted from excessive use of brain and
brain nerve weakness.
Can Natural Nutritious Liquid improve symptoms associated with menopause?
Yes. The ingredients of Natural Nutritious Liquid can improve constitution and
maintain the level of red blood cell count. The symptoms can be lessen.
Can Natural Nutritious Liquid promote liver functions and neutralize drinking
effects?
Yes. It can prevent infection of hepatitis and increase the detoxifying function of liver. Taking Natural Nutritious
Liquid before and after drinking alcohol has an inhibitory effect on ethanol which causes drunkenness and promotes the metabolism
of alcohol.
NOTE:
1.
During treatment period, dont eat
things such as crabs, chicken skin, chili and alcoholic drink.
2.
It is beneficial to the treatment
to eat things such as garlic, mushroom, vinegar and bean products.
3.
For all kinds of TIAN XIAN CAPSULE
(WAN), if anyone after taking those pills has a stomach upset, please stop taking for several days, then continue to take
them.
4.
Pregnant women are not allowed to
take above medicines.
Cancer-herbs.com covers the China No. 1 Tian Xian range of serial products. The Tian Xian products
are herbal nutritional supplements. The natural herbal ingredients aims to strengthen the body's immune system. Our body's
internal defense will attack and destroy tumor and cancer cells. It's the body's natural defenses working. It complements
the western therapies.
Though currently produced in China, expansion plans are in progress. It will be produce simultaneously
in the United States, specifically for the American market, before the end of the year 2000.
Testimonials of cancer survivors are from USA, Japan, Hong Kong, India, China, Philippines, Taiwan, Thailand, and Malaysia. The list of testimonials are added regularly.
Two books have already been published. Detailing how Tian Xian was discovered, it's function and numerous cancer survivors
stories. The publications, beside English, are available in Chinese, Japanese, and Korean.
Some of the major awards and recognitions that were received by Professor Wang Zhen Guo:
China President Jiang Zemin (Middle) congratulates Prof. Wang Zhen Guo (Left) -- inventor of Tian Xian
products.
Prof. Wang Zhen Guo (left)
receives the Best Invention Award by Individual Research in the World at the 38th World Eureka Invention Expo in Brussels, Germany (Cancer-Herbs.com)
Vaccine Therapy in Treating Patients With Gastric Cancer, Non-Small
Cell Lung Cancer, Prostate, or Ovarian Cancer
This study is currently recruiting patients.
Sponsored by
Southwest Oncology Group
National Cancer Institute (NCI)
Purpose
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill cancer cells.
PURPOSE: Phase I trial to compare two different vaccines in treating patients who have gastric cancer, non-small cell
lung cancer, prostate, or ovarian cancer.
Condition Treatment or Intervention Phase
adult brain tumor
Gastric Cancer
Non-small cell lung cancer
ovarian epithelial cancer
Prostate Cancer
Drug: EGFR antisense DNA
Drug: keyhole limpet hemocyanin
Drug: sargramostim
Procedure: antisense therapy
Procedure: biological response modifier therapy
Procedure: non-specific immune-modulator therapy
Procedure: non-tumor cell derivative vaccine
Procedure: vaccine therapy
Phase I
MedlinePlus related topics: Brain
Cancer; Cancer; Cancer
Alternative Therapy; Lung Cancer;
Ovarian Cancer; Prostate Cancer;
Respiratory Diseases; Stomach Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase I Study of EGFRvIII Peptide Vaccine With Sargramostim (GM-CSF) Versus Keyhole Limpet Hemocyanin
as Adjuvant in Patients With EGFRvIII-Expressing Cancer
Further Study Details:
OBJECTIVES:
Determine the toxicity of EGFRvIII peptide vaccine with sargramostim (GM-CSF) or keyhole limpet hemocyanin (KLH) as
adjuvant in patients with EGFRvIII-expressing cancer.
Determine the preexisting antibody and T-cell responses to EGFRvIII in these patients.
Determine the antibody and T-cell responses to EGFRvIII peptide after immunization with this vaccine with GM-CSF or
KLH as adjuvant.
OUTLINE: Patients are assigned to one of two treatment arms.
Arm I: Patients receive a vaccine containing EGFRvIII peptide admixed with sargramostim (GM-CSF) intradermally monthly.
Patients receive a vaccine containing EGFRvIII peptide admixed with keyhole limpet hemocyanin subcutaneously monthly.
Treatment in both arms continues for 6 months in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year.
PROJECTED ACCRUAL: A total of 30 patients (15 per treatment arm) will be accrued for this study.
Eligibility
Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed diagnosis of one the following:
Stage II-III gastric cancer
Stage II-IIIA non-small cell lung cancer
Stage IIC-IV ovarian cancer in first complete remission
CA 125 normal and stable*
Grade III anaplastic astrocytoma
Stage IV (M1) prostate adenocarcinoma
No small cell variations
Must be receiving androgen blockade
Prostate-specific antigen less than 5 ng/mL and stable*
Documented EGFRvIII expression in primary tumor
Must have received prior surgery and or chemoradiotherapy for disease (except prostate cancer patients) NOTE: *Stable
defined as no increase over 2 measurements at least 28 days apart with the last measurement within the past 28 days
PATIENT CHARACTERISTICS: Age:
Not specified
Performance status:
Zubrod 0
Life expectancy:
Not specified
Hematopoietic:
WBC at least 3,000/mm^3
Platelet count at least 100,000/mm^3
Hemoglobin at least 10 g/dL
Hepatic:
SGOT no greater than 2.5 times upper limit of normal (ULN)
Alkaline phosphatase no greater than 2.5 times ULN
No hepatitis
Renal:
Not specified
Other:
No other malignancy in the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma
in situ of the cervix, or adequately treated stage I or II cancer in complete remission
No contraindication to receiving sargramostim (GM-CSF) or KLH-based vaccine products
No autoimmune disease
HIV negative
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY: Biologic therapy:
Not specified
Chemotherapy:
See Disease Characteristics
At least 1 month since prior cytotoxic chemotherapy
No concurrent chemotherapy
Endocrine therapy:
See Disease Characteristics
At least 1 month since prior treatment dose corticosteroids
No concurrent corticosteroids
Radiotherapy:
See Disease Characteristics
No concurrent radiotherapy
Surgery:
See Disease Characteristics
Other:
Recovered from all prior therapies
No concurrent enrollment on other phase I studies
No other concurrent immune modulators
EP-2101 Vaccine in Treating Patients With Stage IIB or Stage IIIA
Non-Small Cell Lung Cancer
This study is currently recruiting patients.
Sponsored by
Epimmune
Purpose
RATIONALE: Vaccines such as EP-2101 made from peptides may make the body build an immune response to kill tumor cells.
PURPOSE: Phase I trial to study the effectiveness of the EP-2101 vaccine in treating patients who have received standard
therapy for stage IIB or stage IIIA non-small cell lung cancer.
Condition Treatment or Intervention Phase
stage II non-small cell lung cancer
stage IIIA non-small cell lung cancer
Drug: EP-2101
Drug: Montanide ISA-51
Procedure: adjuvant therapy
Procedure: biological response modifier therapy
Procedure: non-specific immune-modulator therapy
Procedure: non-tumor cell derivative vaccine
Procedure: vaccine therapy
Phase I
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Lung
Cancer; Respiratory Diseases
Study Type: Interventional
Study Design: Treatment
Official Title: Phase I Study of Adjuvant EP-2101 Peptide Vaccine in Patients With Stage IIB or IIIA Non-Small Cell
Lung Cancer
Further Study Details:
OBJECTIVES:
Determine the safety and tolerability of EP-2101 peptide vaccine in patients with stage IIB or IIIA non-small cell
lung cancer.
Determine the frequency of response in patients treated with this vaccine.
Determine the breadth of tumor-associated antigen-specific cytotoxic T-lymphocyte (CTL) response in patients treated
with this vaccine.
Determine the magnitude of each epitope-specific CTL response in patients treated with this vaccine.
Determine the overall CTL response for each epitope in patients treated with this vaccine.
OUTLINE: This is an open-label, multicenter study.
Patients receive EP-2101 peptide vaccine emulsified in Montanide ISA-51 subcutaneously every 3 weeks for a total of
6 vaccinations in the absence of unacceptable toxicity.
Patients are followed at 3 weeks.
PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for this study.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed non-small cell lung cancer meeting 1 of the following staging criteria:
Stage IIB (T2, N1, M0 or T3, N0, M0)
Stage IIIA (T1, N2, M0; T2, N2, M0; T3, N1, M0; or T3, N2, M0)
No evidence of disease after prior standard treatment with curative intent
Therapy completed within the past 4 to 12 weeks
HLA-A2 positive
PATIENT CHARACTERISTICS: Age
18 and over
Performance status
ECOG 0-1
Life expectancy
Not specified
Hematopoietic
Hemoglobin at least 10 g/dL
Platelet count greater than 100,000/mm^3
WBC greater than 3,000/mm^3
Absolute neutrophil count greater than 1,500/mm^3
Absolute lymphocyte count greater than 500/mm^3
Hepatic
AST and ALT no greater than 2.5 times upper limit of normal (ULN)
Bilirubin less than 3 mg/dL
Alkaline phosphatase no greater than 2.5 times ULN
No history of hepatitis B or C
Renal
Creatinine no greater than 1.5 times ULN
Immunologic
No prior serious adverse reactions, including anaphylaxis and related symptoms such as hives or respiratory difficulty,
to any vaccines
No prior hypersensitivity to any components of the study vaccine
No history of any of the following conditions:
Systemic lupus erythematosus
Scleroderma
Connective tissue disease
Sjögren's syndrome
Rheumatoid arthritis
Inflammatory bowel disease
HIV negative
Other
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 3 weeks after study treatment
No other prior cancer except successfully excised nonmelanomatous skin cancer or surgically cured carcinoma in situ
of the cervix
No other acute medical condition that would preclude study therapy
No mental or psychiatric condition that would preclude study compliance
PRIOR CONCURRENT THERAPY: Biologic therapy
No prior vaccine therapy for cancer
More than 1 month since prior interferon therapy
More than 1 month since prior interleukin therapy
More than 1 month since prior influenza vaccine
More than 1 month since other prior immunomodulatory agents
No other concurrent immunomodulatory agents
No concurrent influenza vaccine
Chemotherapy
Not specified
Endocrine therapy
More than 1 month since prior systemic corticosteroids
Radiotherapy
Not specified
Surgery
Not specified
Other
No concurrent participation in any other investigational study
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
This study is currently recruiting patients.
Sponsored by
National Cancer Institute (NCI)
Purpose
This 2-phase study will determine the safety of treating patients with non-small cell lung cancer with the genetically
engineered HyperAcute-Lung cancer vaccine. It will establish the proper vaccine dose and will examine side effects and potential
benefits of the treatment. The vaccine contains killed lung cancer cells containing a mouse gene that causes the production
of a foreign pattern of protein-sugars on the cell surface. It is hoped that the immune response to the foreign substance
will stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern,
causing the tumor to remain stable or shrink.
Patients 18 years of age or older with non-small cell lung cancer that has recurred or no longer responds to standard
treatment may be eligible for this study. Candidates will be screened with a medical history and physical examination, blood
tests, urinalysis, chest x-rays, and lung function testing. CT, MRI, PET, and ultrasound scans of the chest may be obtained
if needed.
Participants will receive four vaccinations a month apart from each other. The vaccines will be injected under the
skin, similar to the way a tuberculosis skin test is given. Phase I of the study will treat successive groups of patients
with increasing numbers of the vaccine cells to evaluate side effects of the treatment and determine the optimum dose. Phase
II will look for any beneficial effects of the vaccine given at the highest dose found to be safe in Phase I. Weekly blood
samples will be drawn during the 4 months of vaccine treatment. In addition, patient follow-up visits will be scheduled every
2 months for the first year after vaccination and then every 3 months for the next 2 years for the following tests and procedures
to evaluate treatment response and side effects:
- Medical history and physical examination
- Blood tests
- X-rays and various scans (nuclear medicine/CT/MRI)
- FACT-L Assessment questionnaire to measure the impact of treatment on the patient's general well-being. The questionnaire
is administered before beginning treatment, before each vaccination, and during follow-up visits after completing the treatment.
It includes questions on the severity of lung cancer symptoms and the ability to perform normal activities of daily life.
In addition to the above procedures, 3 skin punch biopsies will be done at the vaccination site to look for a local
immune response. For this procedure, an area of skin is numbed with an anesthetic and a 4 mm (about 1/4-inch) circular area
is removed, using a sharp cookie cutter-type instrument. Also, one blood sample per year will be collected for the next 15
years to monitor the safety of the gene transfer. Patients whose lung cancer spreads to the skin, superficial soft tissues,
or a superficial lymph node may be asked to undergo a biopsy of the lesion to see what effect the treatment may be having
on the tumor.
Condition Treatment or Intervention Phase
Carcinoma, Non-Small-Cell Lung
Drug: Hyperacute Lung Cancer Cell Vaccine
Phase I
MedlinePlus related topics: Cancer
Study Type: Interventional
Study Design: Treatment, Safety
Official Title: A Phase I/II Study of an Antitumor Vaccination Using
Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell
Lung Cancer
Further Study Details:
According to statistics of the American Cancer Society, an estimated 169,400 individuals will be diagnosed with lung
cancer and 154,900 will die of the disease this year despite all current therapy. This protocol attempts to exploit an approach
to lung cancer gene therapy using a naturally occurring barrier to xenotransplantation in humans in attempt to vaccinate patients
against their lung cancer. The expression of the murine alpha (1,3) galactosyltransferase [alpha (1,3) GT] gene results in
the cell surface expression of alpha (1,3) galactosyl-epitopes (alpha-gal) on membrane glycoproteins and glycolipids. These
epitopes are the major target of the hyperacute rejection response that occurs when organs are transplanted from non-primate
donor species into man. Human hosts often have pre-existing anti-alpha-gal antibodies that bind alpha-gal epitopes and lead
to rapid activation of complement and cell lysis. The pre-existing anti-alpha-gal antibodies found in most individuals are
thought to be due to exposure to alpha-gal epitopes that are naturally expressed on normal gut flora leading to chronic immunological
stimulation. These antibodies may comprise up to 1% of serum IgG. In this Phase I/II trial, patients with recurrent or refractory
advanced stage non-small cell lung cancer will undergo a series of four intradermal injections with a trivalent vaccine composed
of irradiated allogeneic non-small cell lung cancer cell lines (HAL-1, HAL-2 and HAL-3) that have been transduced with a recombinant
Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha (1,3) GT gene. Endpoints of the
study include determination of dose-limiting toxicity (DLT), maximum tolerated dose (MTD), tumor and immunological responses.
Eligibility
Genders Eligible for Study: Both
Criteria
INCLUSION CRITERIA:
Histological diagnosis of non-small cell lung cancer (NSCLC). Squamous cell (epidermoid), adenocarcinoma and large
cell anaplastic lung carcinoma histologies are eligible. Bronchoalveolar carcinoma, mixed NSCLC/small cell lung carcinoma
(SCLC) and variant large and small cell lung cancer are not eligible for this study. The patient's pathology must be reviewed
by the NIH Clinical Center Department of Pathology.
AJCC Stage IV (any T, any N, M1), metastatic, or progressive or recurrent NSCLC. Patients may not be eligible for other
curative intent treatment (e.g., surgical resection).
Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2.
Serum albumin greater than or equal to 3.0 gm/dL.
Expected survival greater than or equal to 4 months.
Adequate organ function including:
A. Marrow: Hemoglobin greater than or equal to 10.0 gm/dL, absolute granulocyte count (AGC) greater than or equal 1,500/mm(3),
platelets greater than or equal to 100,000/mm(3), absolute lymphocyte count greater than or equal 475/mm(3).
B. Hepatic: Serum total bilirubin less than or equal to 1.5 x upper limit of normal (ULN), ALT (SGPT) and AST (SGOT)
less than or equal to 2.5 x ULN.
C. Renal: Serum creatinine (sCr) less than or equal to 1.5 x upper limit of normal, or creatinine clearance (Ccr) greater
than or equal to 50 mL/min.
Measurable or non-measurable disease defined as:
Measurable - those that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater
than or equal to 20 mm with conventional techniques (CT, MRI, x-ray) or as greater than or equal to 10 mm with spiral CT scan.
All tumor measurements must be recorded in millimeters (or decimal fractions of centimeters).
Non-measurable - All other lesions (or sites of disease), including small lesions (longest diameter less than 20 mm
with conventional techniques or less than 10 mm using spiral CT scan), are considered non-measurable disease. Bone lesions,
leptomeningeal disease, ascites, pleural or pericardial effusions, lymphangitis cutis or pulmonis, inflammatory breast disease,
abdominal masses (not followed by CT or MRI), and cystic lesions are all considered non-measurable.
Subjects must have negative serologies for hepatitis viruses B and C, and HIV prior to entering study.
Prior therapy for NSCLC that may include surgery, radiation therapy, immunotherapy, and/or less than or equal to 2
different chemotherapy regimens (including neoadjuvant and adjuvant treatment).
Patients receiving preoperative (neoadjuvant) and postoperative (within 12 weeks of surgery) adjuvant chemotherapy
with the same agent(s) will be considered to have received a single chemotherapy regimen.
Patients with previously treated, unresponsive or progressive disease that have failed at least one chemotherapy regimen.
Patients must be greater than or equal to 4 weeks since major surgery, radiotherapy, chemotherapy (6-weeks if they
were treated with a nitrosourea or mitomycin) or biotherapy/targeted therapies and recovered from the toxicity of prior treatment
to less than or equal to Grade 1, exclusive of alopecia or fatigue.
Patients must have the ability to understand the study, its risks, side effects, potential benefits and is able to
give written informed consent to participate. Patients may not be consented by a durable power of attorney (DPA).
Male and female subjects of child producing potential must agree to use contraception or avoidance of pregnancy measures
while enrolled on study and receiving the experimental drug, and for one month after the last immunization.
EXCLUSION CRITERIA:
Age less than 18-years-old.
Active CNS metastases or carcinomatous meningitis.
Hypercalcemia greater than 2.9 mmol/L, unresponsive to standard therapy (e.g., I.V. hydration, diuretics, calctonin
and/or bisphosphate therapy).
Pregnant or nursing women due to the unknown effects of vaccination on the developing fetus or newborn infant.
Other malignancy within five years, unless the probability of recurrence of the prior malignancy is less than 5%. Patient's
curatively treated for squamous and basal cell carcinoma of the skin and carcinoma in situ of the uterine cervix (CIN) or
patients with a history of malignant tumor in the past that have been disease free for at least five years are also eligible
for this study.
History of organ transplant, active immunosuppressive therapy or history of prior immunotherapy.
Subjects taking systemic corticosteroid therapy and/or tacrolimus for any reason including replacement therapy for
hypoadrenalism, are not eligible. Subjects receiving inhaled or topical corticosteroids are eligible. Subjects who require
systemic corticosteroids after beginning vaccinations, will be removed from the study.
Significant or uncontrolled congestive heart failure (CHF), myocardial infarction, significant ventricular arrhythmias
within the last six months or significant pulmonary dysfunction.
Active infection or antibiotics within 1-week prior to study, including unexplained fever (temp. greater than 38.1
degrees Celsius).
Autoimmune disease (e.g., systemic lupus erythematosis, active rheumatoid arthritis, etc). Patients with a remote history
of asthma or mild active asthma are eligible.
Other serious medical conditions that may be expected to limit life expectancy to less than 2 years (e.g., liver cirrhosis).
Any condition, psychiatric or otherwise, that would preclude informed consent consistent follow-up or compliance with
any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc).
A known allergy to any component of the alpha (1,3) galactosyltransferase tumor vaccine or cell lines from which it
is derived.
Expected Total Enrollment: 52
ABX-EGF (panitumumab)
Abgenix's most advanced antibody product candidate is ABX-EGF (panitumumab), a fully human monoclonal antibody generated
using XenoMouse® technology.
ABX-EGF targets the epidermal growth factor receptor (EGFr), which is over-expressed in a variety of cancers including
lung, breast, bladder, pancreatic, colorectal, kidney and head and neck cancer. Research
has demonstrated that cancer cells can become dependent on growth signals mediated through EGFr for their survival. In preclinical
research, ABX-EGF monotherapy has been shown to inhibit the growth of human tumors in mice.
Codeveloped by Abgenix and Immunex, a wholly owned subsidiary of Amgen, ABX-EGF is being evaluated in a comprehensive
clinical program in several indications. The program currently includes clinical trials to evaluate ABX-EGF in renal (kidney),
colorectal, and non-small cell lung cancers. Results of clinical studies have demonstrated single-agent activity and a good
pharmacokinetic and tolerability profile.
Clinical Development Program
Abgenix's fully human monoclonal antibody product candidate, ABX-EGF, is being tested in clinical trials as monotherapy
and in combination with standard chemotherapy in several types of cancer. This program currently includes studies in renal,
colorectal, and non-small cell lung cancers.
Abgenix and its partner Immunex, a wholly owned subsidiary of Amgen, are actively planning for commercialization of
ABX-EGF, pending results of ongoing clinical studies. In January 2004, Amgen initiated pivotal clinical trials for ABX-EGF
in third line colorectal cancer. Abgenix and Amgen expect further results from the ongoing phase 2 clinical program will emerge
in 2004 and beyond. The companies continue to evaluate additional opportunities for ABX-EGF and plan to conduct further clinical
studies.
Amgen Collaboration
Abgenix and Immunex, a wholly owned subsidiary of Amgen, are working together to develop and commercialize ABX-EGF
(panitumumab) for various oncology indications. Abgenix and Amgen also have collaborative arrangements directed to other therapeutic
antibody targets.
In October 2003, Immunex and Abgenix clarified responsibilities in the codevelopment agreement for ABX-EGF. Under the
amended agreement, development costs are shared equally by the two companies, along with any future profits from product sales
worldwide. Immunex will lead clinical development and commercialization activities, while Abgenix will be responsible for
clinical and commercial manufacturing, with some assistance from Immunex . Abgenix also retains copromotion rights. Under
the 2003 amendment, Immunex will make available to Abgenix $60 million in advances that may be used by Abgenix to fund its
share of development and commercialization costs for ABX-EGF after Abgenix has contributed $20 million toward development
costs in 2004. The amount of any advances drawn by Abgenix, plus interest, may be repaid out of profits resulting from future
product sales. However, Abgenix is not obligated to repay any portion of the loan if ABX-EGF does not reach commercialization.
Key Product Characteristics
Results of ABX-EGF studies to date suggest several important differences between ABX-EGF and drugs targeting the EGF
receptor and pathway:
ABX-EGF has not shown dose limiting toxicity, while the small-molecule drugs targeting the EGFr are dose-limited by
the occurrence of severe diarrhea.
The current dose of ABX-EGF has been set at the level that results in 100% of patients achieving an acneiform skin
rash that suggests full blockade of the EGFr on the skin.
Preliminary analysis of phase 2 studies suggests ABX-EGF has single-agent biological activity in patients with solid
tumors.
ABX-EGF has demonstrated an extremely low incidence of immunologic reactions. In studies of over 500 patients, only
two patients experienced infusion related reactions, in each case controllable by premedication.
EGF Receptor Inhibition
Relative to normal tissue, certain cancer cells that overexpress epidermal growth factor receptors (EGFr) on their
surface often depend on EGFr's activation for growth. EGFr is overexpressed in
a variety of cancers, including lung, breast, ovarian, bladder, prostate, colorectal, kidney and head and neck. EGFr activation is triggered by the binding of EGFr by EGF or transforming growth factor alpha (TGFa) and
EGFr dimerization, which trigger the cellular signalings leading to tumor cell proliferation. EGF and TGF-a are expressed
by the tumor or neighboring cells, which provide autocrine and parocrine growth support for tumor growth.
ABX-EGF is being developed based on the belief that blocking the ability of EGF and TGFa to bind with EGFr offers a
potential treatment strategy for certain cancers. ABX-EGF, a fully human monoclonal
antibody generated using XenoMouse technology, binds to EGFr with high affinity. This antibody has been shown to inhibit tumor
cell proliferation in mouse models and cause eradication of EGF-dependent human tumors in mice.
Abgenix is conducting preclinical studies and assessing which cancer types may be eligible for ABX-EGF treatment. Published
studies have shown that ABX-EGF can inhibit growth of EGF-dependent human tumors cells in mouse models. ABX-EGF has also been
shown to eradicate established tumors in mice, even when administered after significant tumor growth has occurred.
Abgenix Reports Encouraging Preclinical
Results With ABX-EGF In Cancer Research
Fully Human Antibody Eradicates Established Tumors as Monotherapy
FREMONT, Calif., March 15, 1999 -- Abgenix, Inc. (Nasdaq: ABGX) reported today in Cancer Research (Volume 59,
Issue no. 6), encouraging results of preclinical studies with its proprietary fully human monoclonal antibody, ABX-EGF. Developed
using the company's XenoMouseTM technology, ABX-EGF targets the receptor for human epidermal growth factor (EGFr) which is
overexpressed on many major human tumor types including renal, prostate, colorectal, head and neck, and breast. As reported
in a paper titled, "Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor
Receptor without Concomitant Chemotherapy," Abgenix scientists demonstrated that ABX-EGF alone, in mouse models, can both
block the growth of human tumors, is potent at comparatively low doses and, more importantly, eradicates established tumors.
Another member of the EGFr family, Her-2, is the target for a monoclonal antibody currently being marketed by Genentech, Inc.
for treatment of breast cancer.
With cancer cells, expression of EGFr is significantly increased, which increases growth stimuli and causes cells to
divide abnormally. Consequently, many cancer cells require EGFr for their survival. ABX-EGF binds with high affinity to the
EGFr and selectively targets these cancer cells by blocking the binding of important tumor growth factors to the receptor.
A key finding of the Abgenix studies was that relatively low doses of ABX-EGF, without concomitant chemotherapy, could eradicate
human tumors with a size of up to 1.2cm3 in mice. Although the treatment period was relatively short, no recurrence of tumors
was seen in these mice out to 250 days after the last dose of antibody. Abgenix plans to begin clinical trials with ABX-EGF
around midyear.
"We believe that these results indicate the potential of ABX-EGF as a monotherapy for the treatment of multiple EGF-dependent
human solid tumors, including those for which no effective chemotherapy is available," stated R. Scott Greer, president and
chief executive officer of Abgenix. "Because EGFr is overexpressed on many types of cancer, ABX-EGF has the potential to be
a broad cancer treatment."
As a fully human antibody generated with XenoMouseTM technology, ABX-EGF is expected to have minimal immunogenicity
and a longer half-life than antibody products containing mouse protein, thus potentially allowing repeat administration at
lower doses in patients with competent immune systems. This potential was observed in a Phase I clinical trial in psoriasis
of ABX-IL8, the first fully human antibody generated in transgenic mice to be tested in humans. ABX-IL8 demonstrated a three
week half life, equivalent to that of naturally occuring human antibodies and no immune reaction to ABX-IL8 was observed.
Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapeutic products for
the treatment of a variety of disease conditions, including transplant-related diseases, inflammatory and autoimmune disorders,
cardiovascular disease and cancer. Abgenix has developed XenoMouse technology, which it believes enables quick generation
of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy.
Abgenix has collaborative arrangements with multiple pharmaceutical and biotechnology companies involving its XenoMouse technology.
In addition, Abgenix has four proprietary antibody product candidates that are under development internally, two of which
are in human clinical trials.
Statements made in this press release about the potential of ABX-EGF as a monotherapy, Abgenix's XenoMouse technology,
product development activities and collaborative arrangements other than statements of historical fact, are forward looking
statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements
made, including risks associated with the success of clinical trials, the progress of research and product development programs,
the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix's
patent portfolio. Please see Abgenix's public filings with the Securities and Exchange Commission for information about risks
which may affect Abgenix.
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney),
Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
This study is currently recruiting patients.
Sponsored by
Jonsson
Comprehensive Cancer Center
National Cancer Institute (NCI)
Purpose
RATIONALE: Monoclonal antibodies such as ABX-EGF can locate tumor cells and either kill them or deliver tumor-killing
substances to them without harming normal cells.
PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody ABX-EGF in treating patients who have either
renal (kidney), prostate, pancreatic, non-small cell lung, colon, rectal, esophageal, or gastroesophageal junction cancer.
Condition Treatment or Intervention Phase
Colorectal Cancer
Esophageal Cancer
kidney tumor
Lung Cancer
Pancreatic Cancer
Prostate Cancer
Drug: monoclonal antibody ABX-EGF
Procedure: antibody therapy
Procedure: biological response modifier therapy
Procedure: monoclonal antibody therapy
Phase I
MedlinePlus related topics: Colorectal
Cancer; Esophageal Cancer;
Kidney Cancer; Lung Cancer;
Pancreatic Cancer; Prostate Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase I Study of Monoclonal Antibody ABX-EGF in
Patients With Renal, Prostate, Pancreatic, Non-Small Cell Lung, Colorectal, Esophageal, or Gastroesophageal Junction Cancer
Further Study Details:
OBJECTIVES:
Determine the safety of monoclonal antibody ABX-EGF in patients with renal, prostate, pancreatic, non-small cell lung,
colorectal, esophageal, or gastroesophageal junction cancer.
Determine the pharmacokinetics and the dose-response relationship of this drug in this patient population.
Evaluate the clinical effect of this drug in this patient population.
OUTLINE: This is an open-label, dose-escalation, multicenter study.
Patients receive monoclonal antibody ABX-EGF IV over 1 hour once weekly on weeks 0-3* (enrollment for the weekly dosing
schedule completed as of 4/21/03 [with the exception of patients undergoing full pharmacokinetic analyses, described below])
OR once every 2 weeks on weeks 0, 2, 4, and 6* OR once every 3 weeks on weeks 0, 3, 6, and 9*. Patients undergoing full pharmacokinetic
analyses receive a loading dose on week 0 and the subsequent 3 doses on weeks 3-5.
NOTE: *All patients receive a total of 4 doses.
Cohorts of 2-8 patients receive escalating doses of monoclonal antibody ABX-EGF until the maximum tolerated dose (MTD)
is determined. The MTD is defined as the dose preceding that at which at least 2 or 3 patients experience dose-limiting toxicity.
Patients are followed every 2 weeks for 5 weeks.
PROJECTED ACCRUAL: A total of 76 patients will be accrued for this study within approximately 14 months.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed diagnosis of 1 of the following:
Renal cell cancer (RCC)
Prior nephrectomy required
Prostate cancer
Failed prior primary therapy (e.g., surgery, radiotherapy, or chemotherapy)
Failed prior hormonal therapy (e.g., antiandrogen, luteinizing hormone-releasing hormone inhibitor, or orchiectomy)
Pancreatic cancer
Failed at least 1 prior standard therapy regimen for unresectable metastatic disease
Non-small cell lung cancer
Failed at least 1 prior standard therapy regimen for unresectable metastatic disease
Colorectal cancer
Received 1 or more prior chemotherapy regimen(s) for advanced metastatic disease
Esophageal cancer
Failed prior primary therapy (e.g., surgery, radiotherapy, or chemotherapy)
Gastroesophageal junction cancer
Evaluable disease
Epidermal growth factor receptor overexpression
Tumor tissue must yield the sum of 1+, 2+, or 3+ staining in at least 10% of evaluated tumor cells
No uncontrolled brain metastases
No evidence of disease progression or regression after a 30-day washout period
PATIENT CHARACTERISTICS: Age:
18 and over
Performance status:
Karnofsky 70-100% OR
ECOG 0-1
Life expectancy:
Not specified
Hematopoietic:
Absolute neutrophil count greater than 1,000/mm^3
Platelet count greater than 100,000/mm^3
Hepatic:
AST/ALT no greater than 2 times upper limit of normal (ULN) (3 times ULN for liver metastases)
Alkaline phosphatase no greater than 2 times ULN (3 times ULN for liver metastases)
Renal:
Creatinine less than 2.2 mg/dL
NCI renal toxicity no greater than grade 2
No hypercalcemia (antihypercalcemic therapy allowed)
Cardiovascular:
Ejection fraction at least 45% by MUGA
No abnormal ECG or MUGA
No myocardial infarction within the past year
Pulmonary:
No abnormal chest x-ray
FEV_1 greater than 50% of predicted
Other:
No known allergy to ingredients of study drug
No known allergy to Staphylococcus aureus Protein A
HIV negative
No chronic medical or psychiatric condition that would preclude study compliance
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 2 months after study participation
PRIOR CONCURRENT THERAPY: Biologic therapy:
At least 30 days since prior biologic therapy (e.g., antibodies, cytokines, or co-stimulatory pathway inhibitors)
No other concurrent biologic therapy
Chemotherapy:
See Disease Characteristics
At least 6 weeks since prior chemotherapy and recovered
No prior chemotherapy for RCC
No prior anthracyclines
No concurrent chemotherapy
Endocrine therapy:
See Disease Characteristics
Concurrent steroids allowed
Concurrent hormonal therapy allowed
Radiotherapy:
See Disease Characteristics
No prior mediastinal radiotherapy
No concurrent radiotherapy
Surgery:
See Disease Characteristics
Recovered from any recent prior surgery
Other:
At least 30 days since prior investigational drug or device
At least 30 days since prior systemic therapy
No other concurrent investigational drugs
No other concurrent systemic agents or cancer therapy
Drugs Approved by the FDA Drug Name: CEA-Scan
The following information is obtained from various newswires, published medical journal articles, and medical conference
presentations.
Company: Immunomedics
Approval Status: Approved April 1996
Treatment for: colorectal cancer
General Information
CEA is expressed by more than 90% of colorectal cancers, as well as by a large number of other carcinomas, including
esophageal, stomach, lung, breast, pancreas, uterus, and ovarian cancer. It has been shown that this tumor marker can serve
as a useful target for radiolabeled antibodies. Since CEA-Scan uses a small antibody fragment at a low dose, there is virtually
no immune reaction by subjects to the foreign protein. In addition, linking the fragment with technetium-99m, a common radioisotope
in nuclear medicine, permits tumor detection within a few hours, using conventional gamma cameras.
Mechanism of Action
CEA-Scan comprises an antibody fragment (Fab') against the tumor marker, carcinoembryonic antigen ("CEA").
Additional Information
Each year there are approximately 134,000 new cases of colorectal cancer in the United States; colorectal cancer is estimated to kill over 55,000 Americans annually. Trials are also under way for
lung and breast cancer indications.
Drug listing last updated on October 26, 2001
Clinical Overview
Immunomedics has a broad clinical research program involving diagnostic imaging and therapeutic agents. The Company
is unique in having companion imaging and therapeutic agents based upon similar antibodies and disease indications (Table
1). For example, CEA-Scan® (arcitumomab) targets cancers expressing carcinoembryonic antigen (CEA), which comprise about 80
percent of all solid cancers, and is currently approved in the U.S., Canada, and Europe, for the detection of colorectal cancer
spread, in conjunction with other standard diagnostic tests. Publications in the medical literature have also shown that CEA-Scan
can image lung and breast cancers.
CEA-Cide (labetuzumab) is the therapeutic counterpart, also involving a specific antibody against CEA, but in this
case the antibody has been humanized, a process that depletes by about 90% all murine components in the antibody by replacement
with human immunoglobulin, or antibody, structures. This antibody is in clinical studies as a naked (unlabeled) and a radiolabeled
conjugate, for the therapy of diverse cancers expressing CEA, including colorectal, pancreatic and breast cancers. The Company
believes that the therapeutic use of CEA-Cide may create a market interest in the use of CEA-Scan for improved patient management,
such as earlier staging of cancer and earlier identification of residual disease following therapy.
Another example of companion imaging and therapy products is LymphoScan® ~ LymphoCide. LymphoScan consists of the fragment
of an antibody against the CD22 determinant on B-cells, and targets B-cell tumors, such as non-Hodgkin's lymphoma (NHL). The
product is in Phase III trials to stage NHL patients and to assess residual disease following therapy.
A humanized version of this antibody constitutes LymphoCide (epratuzumab), which is being studied clinically both as
a naked (unlabeled) and a radiolabeled (yttrium-90 or 90Y) form. The unlabeled epratuzumab is now entering Phase III trials
for the therapy of NHL, while the 90Y-version is in Phase I trials.
Imaging Therapy Potential Disease Target
CEA-Scan CEA-Cide
Stomach, colorectal, pancreatic,
medullary thyroid, head/neck, lung,
breast, ovarian, uterine, bladder
cancers
LymphoScan LymphoCide
Non-Hodgkin's lymphoma
AFP-Scan AFP-Cide
Liver and germ-cell cancers
(testis and ovary)
MyelomaScan MyelomaCide
Multiple Myeloma
LeukoScan LeukoCide
Infection imaging /
Acute and chronic myeloid leukemia
ProstaScan
ProstaCide
Clinical Development of a Novel Cancer Vaccine: A Multi-Epitope Vaccine
for Lung and Colorectal Cancer
Introduction/Background
In order to create multi-epitope cancer vaccines, Epimmune has developed a highly efficient strategy which can be applied
universally to tumour-associated antigens for the identification of cytotoxic T cell and helper T cell epitopes, the know-how
for modifying epitopes to create analogues with enhanced immunogenicity, and proprietary methods to optimally configure these
epitopes for delivery using DNA, viral or recombinant protein delivery strategies.
Aims/Hypothesis
Epimmune's EP-2101 is in development as a breast, colon and lung cancer vaccine constructed with natural and modified
epitopes derived from four well-characterised, tumour-associated antigens, CEA, HER2/neu, p53 and MAGE 2/3.
Research
Delivered as synthetic peptides in adjuvant, EP-2101 includes PADRE®, Epimmune's proprietary T cell epitope, to improve
the immunogenicity of disease-specific epitopes. The epitopes utilised in EP-2101 are the actual peptides responsible for
the induction of an anti-cancer immune response, which increases both safety and potency of the vaccine as compared to vaccines
using whole antigens or poorly defined, cell-derived antigen mixtures. Additionally, EP-2101 includes multiple epitope analogues
modified to increase immune response potency, a competitive advantage facilitated by the epitope approach. EP-2101 is appropriate
for treatment of HLA-A2 patients, which represent approximately 45% of most ethnic groups.
Epimmune Inc. received clearance from the United States Food and Drug Administration to start Phase
I/II clinical trials of its EP-2101 therapeutic, multi-epitope vaccine in lung and colorectal cancer patients. Two separate
Phase I/II trials are currently being conducted, one in colorectal cancer and one in non-small cell lung cancer, at various
sites in the US. The trials involve an aggregate of approximately 25 patients who have had surgery to remove the majority of the cancer
cells. These patients generally have normal immune system function. The vaccine candidate includes proprietary, native epitopes
as well as a number of modified, or analogue, epitopes that are designed to enhance the potency of the T cell response. Primary
endpoints of the trials will be safety and immunogenicity, as measured by the quantity and breadth of cytotoxic T cells, or
CTLs generated. Safety and immunogenicity results from the current trials are expected in the first half of 2004.
Conclusion
A novel multi-epitope vaccine is undergoing Phase I/II clinical development for lung and colorectal cancer.
Relevance/Opportunity
Epimmune is seeking licensing and collaborative partnership opportunities with companies interested in the development
of T cell epitope-based vaccines for the treatment of colorectal and non-small cell lung cancer. The opportunity for EP-2101
also includes access to Epimmune's second-generation epitope package. Derived from the same four tumour-associated antigens
this clinical research-stage epitope portfolio targets multiple HLA supertypes for universal patient population coverage.
Please enquire below if you are interested in this opportunity.
Epimmune gets FDA okay to start studies of cancer vaccines
Reuters Health Posting Date: January 13, 2003 Last Updated:
2003-01-13 15:19:10 -0400 (Reuters Health)
WASHINGTON (Reuters Health) - Epimmune Inc. said on Monday that it has received clearance from the US Food and Drug
Administration (FDA) to start phase I/II clinical trials of its EP-2101 therapeutic, multi-epitope vaccine in lung and colorectal
cancer patients.
The company said that it plans to conduct two separate trials for the individual indications, involving an aggregate
of approximately 25 patients who have had surgery to remove the majority of the tumor. These patients generally have normal
immune system function, the company noted.
Assuming patient enrollment proceeds on schedule, Epimmune said the first patients are expected to begin treatment
in approximately four weeks and the final data analysis is expected to be complete in the first half of 2004. The company
said the primary endpoints of the trials would be safety and immunogenicity, as measured by the quantity and breadth of cytotoxic
T cells generated.
According to Epimmune, EP-2101 includes proprietary, native epitopes and a number of modified, or analog, epitopes
that were designed to enhance the potency of the T cell response.
Cell Genesys' GVAX® lung cancer vaccine is a patient-specific vaccine designed to induce a systemic immune response against the patient's
lung cancer. The vaccine is made by directly modifying the patient's tumor cells using a semi-automated closed system designed
to enable safe and sterile manufacturing of each patient's vaccine. After surgical removal of a patient's tumor, the GVAX®
cancer vaccine is prepared by culturing and genetically modifying the patient's tumor cells to secrete GM-CSF, an immune stimulatory
hormone. The cells are then irradiated for safety prior to vaccinating the patient.
Based on encouraging data from the companys initial trial of GVAX® lung cancer vaccine, Cell Genesys will conduct two
Phase 2 clinical trials evaluating GVAX® lung cancer vaccine. The first of these Phase 2 trials, initiated in April 2003,
is sponsored by Cell Genesys and is enrolling patients with all subtypes of non small-cell lung cancer. Patients are being
randomized to receive GVAX® lung cancer vaccine with or without low-dose cyclophosphamide, a chemotherapeutic agent which
in the doses to be employed has been shown to enhance the immune response. The second Phase 2 trial, which is expected to
be sponsored and partially funded by the Southwest Oncology Group (SWOG), a cooperative clinical trials group of the National
Cancer Institute (NCI), will focus on patients with the bronchoalveolar carcinoma (BAC) subtype of non small-cell lung cancer.
This trial is expected to begin in the second quarter of 2004. The two trials may enroll up to approximately 75 patients each.
At the International Conference on Gene Therapy of Cancer in December 2002, final data were reported from the company's
initial Phase 1/2 trial of GVAX® lung cancer vaccine in patients with advanced non small-cell lung cancer. Patients received
the treatment vaccine in an outpatient clinical setting over a three-month period and were monitored for the subsequent six
months. Of the 33 advanced stage patients, most of whom had failed prior chemotherapy and/or radiation therapy, three patients
(9 percent) experienced complete responses (complete disappearance of all tumors) with a median duration of response of 17.8
months. The median survival of all 33 treated patients was 11.6 months (measured from the initiation of vaccine manufacturing),
which compares favorably to the approved second-line taxane chemotherapy for such patients. Of these three patients, two were
noted to have the BAC subtype of lung cancer. In addition to these complete responses, seven patients (21 percent) achieved
stable (non progressive) disease with a median response duration of 7.7 months. Median survival was significantly longer in
patients whose vaccine products secreted higher levels of GM-CSF which all GVAX® vaccines are engineered to produce (median
survival of 17.1 months for GM-CSF >40 ng./106 cells/24 hr. versus median survival of 7.4 months for GM-CSF <40ng./106
cells/24 hr., p= .04).
Cell Genesys constructed a 35,000 square-foot manufacturing facility in Memphis, TN,
which is being used for the manufacturing of the company's patient-specific GVAX® lung cancer vaccines for the ongoing Phase
2 clinical trial, and is also expected to be used for the Phase 3 clinical trial and potential market launch.
(The data referenced in the preceding paragraphs represent the most recently announced data pertaining to this program.)
Information About GVAX® Lung Cancer Vaccine Clinical Trials Currently Under Way:
D-0031: A Phase 2 Randomized Study of GM-CSF Gene-Modified Autologous Tumor Vaccine (CG8123) ("GVAX® Lung Cancer Vaccine")
with and without Low-Dose Cyclophosphamide in Advanced Stage Non Small-Cell Lung Cancer.
Cell Genesys, Inc. (CEGE) Reacquires Full Commercial Rights To GVAX
Lung Cancer Vaccines From Japan Tobacco; License Agreement Terminated
FOSTER CITY, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE - News) today announced that
the company has reacquired full commercial rights to GVAX® lung cancer vaccines following the termination of its remaining
license agreement with the pharmaceutical division of Japan Tobacco Inc. (JT). As a result, Cell Genesys now holds all worldwide
commercial rights to its entire portfolio of GVAX® cancer vaccine products. Given the scope of the company's plans for the
next clinical trials of GVAX® lung cancer vaccine, as well as the anticipated funding from the National Cancer Institute for
one of those trials, Cell Genesys expects the near-term revenue impact from ending the agreement with JT to be minimal.
"We believe that holding full commercial rights to all of our GVAX® cancer vaccines, particularly as these products
advance toward Phase III trials, will enhance our flexibility in pursuing an optimal worldwide commercialization strategy
for GVAX® products," stated Robert H. Tidwell, senior vice president, corporate development of Cell Genesys. "We, of course,
appreciate JT's support during the early phase of our GVAX® cancer vaccine program and understand their business circumstances
which have led to this decision."
In June of this year at the International Lung Cancer Congress, Cell Genesys presented the final results of a multicenter
Phase I/II trial of GVAX® lung cancer vaccine. These results demonstrated complete tumor regressions in three of 33 patients
(nine percent) with advanced non small- cell lung cancer (NSCLC) who received the vaccine after failing prior radiation and/or
chemotherapy, as well as stable disease or minor responses in another seven patients (21 percent). The median survival of
all treated patients was approximately eight months compared to 5.7 - 7 months reported for taxol chemotherapy and approximately
4.6 months for best supportive care. In addition, patients with the bronchoalveolar carcinoma (BAC) subtype of NSCLC appeared
to be particularly responsive to GVAX® lung cancer vaccine treatment. As a result, the company recently announced its intention
to conduct two Phase II trials in patients with BAC prior to initiating a broad Phase III trial in all types of NSCLC. One
of the two BAC trials will be sponsored and conducted by the National Cancer Institute's Southwest Oncology Group (SWOG).
Both BAC studies are expected to begin in the late 2002/early 2003 timeframe. A Phase III study of all types of NSCLC is targeted
to begin in late 2003.
Cell Genesys and JT entered into the collaboration agreement for GVAX® cancer vaccines in December
1998. The agreement, which originally focused on the development of GVAX® prostate cancer and lung cancer vaccines, was significantly
reduced in scope in November 2001 to focus primarily on GVAX® lung cancer vaccines. Under the modified agreement, Cell Genesys
would pay JT an undisclosed royalty on GVAX® lung cancer vaccine sales in all territories except Japan, Taiwan and Korea where JT would pay the
same royalty to Cell Genesys, and JT would provide partial development funding for GVAX® lung cancer vaccine products.
Cell Genesys' GVAX® cancer vaccines are comprised of tumor cells which have been irradiated and genetically modified
to secrete granulocyte- macrophage colony stimulating factor (GM-CSF), a hormone which plays a key role in stimulating the
body's immune response to vaccines. The genetically modified tumor cells are used to vaccinate patients to stimulate an immune
response against their tumor. GVAX® cancer vaccines have demonstrated antitumor effects against every type of human cancer
against which they have been tested to date. Currently, Cell Genesys is evaluating non patient- specific, off-the-shelf GVAX®
vaccines for prostate cancer and pancreatic cancer and patient-specific, individualized vaccines for lung cancer, leukemia
and myeloma. With all tumor types and vaccine formats tested, GVAX® cancer vaccines have demonstrated a favorable side effect
profile and have been safely administered to over 400 patients to date. GVAX® prostate cancer vaccine, Cell Genesys' lead
product candidate, is expected to enter Phase III clinical trials by mid-2003.
Cell Genesys is focused on the development and commercialization of innovative therapeutic products
for cancer based on gene therapy technologies. The company is pursuing three cancer product platforms -- GVAX® cancer vaccines,
oncolytic virus therapies and in vivo cancer gene therapies. Clinical trials of GVAX® vaccines are under way in prostate cancer,
lung cancer, pancreatic cancer, leukemia and myeloma. Clinical trials of oncolytic virus therapies include CG7060 and CG7870
in prostate cancer. Preclinical stage programs include oncolytic virus therapies and gene therapies for multiple types of
cancer. Cell Genesys' majority-owned subsidiary, Ceregene, is focused on gene therapies for neurologic disorders. Cell Genesys
also continues to hold approximately nine million shares of common stock in its former subsidiary, Abgenix, an antibody products
company. Cell Genesys is headquartered in Foster
City, CA and has manufacturing operations
in San Diego, CA, Hayward, CA and Memphis, TN. For additional information, please visit the company's website at www.cellgenesys.com.
Statements made herein about Cell Genesys and its subsidiaries, other than statements of historical fact, including
statements about the progress and reports of clinical trials, timelines and future plans for clinical programs, marketability
and success of potential products and nature of product pipelines, licensing agreements, partnering expectations and revenue
expectations are forward-looking statements and are subject to a number of uncertainties that could cause actual results to
differ materially from the statements made, including risks associated with the success of research and development programs,
the success and results of clinical trials, the regulatory approval process, competitive technologies and products, patents
and additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's
Annual Report on Form 10-K dated April 1, 2002 as well as Cell Genesys' reports on Form 10-Q and 8-K and other reports filed
from time to time with the Securities and Exchange Commission.
Cell Genesys reports antitumor activity in Phase I/II GVAX lung
cancer vaccine trial
SAN FRANCISCO, Calif., May 13, 2001Cell Genesys, Inc. (Nasdaq: CEGE) today reported interim clinical
data from its multicenter Phase I/II GVAX® lung cancer vaccine trial which demonstrates objective evidence of antitumor activity
including a major response rate of 18 percent in patients with advanced non small-cell lung cancer who have failed chemotherapy
and/or radiation therapy. These data were presented on behalf of the GVAX® Lung Cancer Clinical Investigators by John Nemunaitis,
M.D. of U.S. Oncology at the American Society of Clinical Oncology (ASCO) Meeting in San Francisco, Calif. The presentation was one of 17 selected for ASCOs Official Press Program from the more than 3,300 submitted to the
meeting.
The interim clinical trial data includes results on 30 currently evaluable patients with advanced or early-stage lung
cancer. Of 22 patients with advanced-stage lung cancer, three patients, two of whom had failed chemotherapy and one who failed
radiation therapy, showed a complete disappearance of metastatic tumors following treatment with GVAX® lung cancer vaccine.
One other patient who failed radiation and chemotherapy had partial (greater than 50 percent) reduction in his tumor. In addition
to these major responses, four patients currently have stable (non-progressive) disease. All of these responses are continuing
with a median follow-up time of approximately five months. In addition to the responses in patients with advanced disease,
seven of eight patients with early-stage lung cancer who received GVAX® vaccine following surgery, currently remain free of
disease with a median follow-up time of seven months.
We are very encouraged by what we have seen to date with GVAX® lung cancer vaccine, particularly with respect to the
major tumor responses in patients with metastatic lung cancer who have failed chemotherapy, stated Dr. Nemunaitis. These findings
are all the more noteworthy given that lung cancer patients who fail chemotherapy have little chance of responding to further
chemotherapy or other treatment.
These exciting clinical results with our GVAX® lung cancer vaccine are yet another reason we have increased our investment
in the clinical and manufacturing development required to bring a GVAX® product to market, stated Joseph J. Vallner, Ph.D.,
executive vice president and chief operating officer of Cell Genesys. GVAX® vaccines have demonstrated objective evidence
of antitumor activity in all five types of cancer in which they have been testedlung, prostate, pancreatic, kidney and melanomaas
well as a very favorable safety profile compared to chemotherapy which has been documented in over 300 patients treated to
date.
The currently ongoing Phase I/II trial of GVAX® lung cancer vaccine for which the interim results were reported has
recently completed enrollment. A final report on the trial is expected during the next year. In this trial, patients were
administered up to six vaccine treatments every other week for three months as an intradermal (under the skin) injection.
Patients received no other anticancer treatments during the trial evaluation period. As has been demonstrated in all GVAX®
cancer vaccine trials to date, the vaccine was shown to be safe and well tolerateda side effect profile which compares favorably
to other cancer treatments such as chemotherapy. No dose limiting toxicities have been observed. In addition to the antitumor
activity noted above, the interim trial results also demonstrate that GVAX® lung cancer vaccine induces an anti-lung cancer
cellular immune response as well as the formation of new anti-lung cancer antibodies in the blood.
Update on Initial Trial of GVAX® Lung Cancer Vaccine
An earlier Phase I/II trial of GVAX® lung cancer vaccine in patients with advanced non small-cell lung cancer which
was conducted by Dr. Glenn Dranoff and colleagues at Dana-Farber/Partners Cancer Care, an affiliate of Harvard Medical School,
was reported at the Ninth World Conference on Lung Cancer in Tokyo, Japan in September 2000. This trial demonstrated antitumor
immunity in 18 of 25 patients. In addition, two patients who received GVAX® lung cancer vaccine following surgery remain in
complete remission more than three years after GVAX® treatment.
Future Clinical Trials for GVAX® Lung Cancer Vaccine
The GVAX® lung cancer vaccine trials to date, including the current study, have employed a patient-specific product
format in which the vaccine is directly prepared from the patients own tumor cells in an overnight process. In the near future,
Cell Genesys plans to launch a clinical trial in advanced lung cancer to evaluate a non patient-specific GVAX® product which
will be centrally manufactured by Cell Genesys and then mixed with patients own irradiated tumor cells prior to vaccination.
This new product format for GVAX® lung cancer vaccine is expected to have significant development and commercialization advantages
compared to the first generation product used in the trial reported today. Given the encouraging results demonstrated in ongoing
clinical trials for prostate and pancreatic cancer, Cell Genesys is emphasizing non patient-specific GVAX® products which
can be developed and commercialized as off-the-shelf pharmaceuticals.
Background on GVAX® Cancer Vaccines
GVAX® cancer vaccines are comprised of tumor cells which have been genetically modified to secrete granulocyte-macrophage
colony stimulating factor (GM-CSF), a hormone which plays a key role in stimulating the body's immune response to vaccines.
The genetically modified tumor cells are then irradiated for safety and used to vaccinate patients to stimulate an immune
response against their tumor. The company's lead GVAX® cancer vaccine program targets patients with recurrent hormone refractory
prostate cancer and is currently being evaluated in two multicenter Phase II trials. A series of Phase I/II trials was recently
initiated utilizing the companys new high-potency GVAX® prostate cancer vaccine. Additionally, a Phase I/II trial for GVAX®
vaccine for myeloma was recently initiated, and a Phase II trial of GVAX® pancreatic cancer vaccine and a Phase I/II trial
of GVAX® vaccine for leukemia are expected to commence in mid 2001.
Cell Genesys Profile
Cell Genesys is focused on the development and commercialization of cancer vaccines and gene therapies to treat major,
life-threatening diseases. The company is conducting clinical trials of GVAX® cancer vaccines in prostate cancer, pancreatic
cancer, lung cancer and myeloma and expects to initiate new studies in acute leukemia during 2001. Preclinical stage programs
include gene therapies for cancer, hemophilia and cardiovascular disorders. Cell Genesys majority-owned subsidiary, Ceregene,
is focused on gene therapies for central nervous system disorders. Cell Genesys also continues to hold a 10.5 percent equity
interest in its former subsidiary, Abgenix, an antibody product company. For additional information, please visit the company's
web site at www.cellgenesys.com.
Promising Lung Cancer Vaccine Trial Results Reported
A lung cancer vaccine Phase I/II trial that demonstrates objective evidence of antitumor activity was announced Sunday.
The activity reported included a major response rate of 18 percent in patients with advanced non small-cell lung cancer who
had failed chemotherapy and/or radiation therapy.
The data were presented on behalf of Cell Genesys, Inc. GVAX® Lung Cancer Clinical Investigators
by John Nemunaitis, M.D. of U.S. Oncology at the American Society of Clinical Oncology (ASCO) Meeting in San Francisco,
Calif.
The presentation was one of 17 selected, from the more than 3,300 submitted to the meeting, for ASCO's Official Press
Program.
The interim clinical trial data includes results on 30 currently evaluable patients with advanced or early-stage lung
cancer. Of 22 patients with advanced-stage lung cancer, three patients, two of whom had failed chemotherapy and one who failed
radiation therapy, showed a complete disappearance of metastatic tumors following treatment with GVAX® lung cancer vaccine.
One other patient who had failed radiation and chemotherapy had partial (greater than 50 percent) reduction in his
tumor. In addition to these major responses, four patients currently have stable (non-progressive) disease.
All of these responses are continuing, with a median follow-up time of approximately five months. In addition to the
responses in patients with advanced disease, seven of eight patients with early-stage lung cancer who received GVAX® vaccine
following surgery currently remain free of disease, with a median follow-up time of seven months.
"We are very encouraged by what we have seen to date with GVAX® lung cancer vaccine, particularly with respect to the
major tumor responses in patients with metastatic lung cancer who have failed chemotherapy," stated Dr. Nemunaitis. "These
findings are all the more noteworthy given that lung cancer patients who fail chemotherapy have little chance of responding
to further chemotherapy or other treatment."
"These exciting clinical results with our GVAX® lung cancer vaccine are yet another reason we have increased our investment
in the clinical and manufacturing development required to bring a GVAX® product to market," stated Joseph J. Vallner, Ph.D.,
executive vice president and chief operating officer of Cell Genesys.
Dr. Vallmer added, "GVAX® vaccines have demonstrated objective evidence of antitumor activity in all five types of
cancer in which they have been tested -- lung, prostate, pancreatic, kidney and melanoma -- as well as a very favorable safety
profile compared to chemotherapy, which has been documented in over 300 patients treated to date."
The currently ongoing Phase I/II trial of GVAX® lung cancer vaccine has recently completed enrollment. A final report
on the trial is expected during the next year.
In this trial, patients were administered up to six vaccine treatments every other week for three months as an intradermal
(under the skin) injection. Patients received no other anticancer treatments during the trial evaluation period.
As has been demonstrated in all GVAX® cancer vaccine trials to date, the vaccine was shown to be safe and well tolerated
-- a side effect profile that compares favorably to other cancer treatments such as chemotherapy. No dose-limiting toxicities
have been observed.
In addition to the antitumor activity noted above, the interim trial results also demonstrate that GVAX® lung cancer
vaccine induces an anti-lung cancer cellular immune response and formation of new anti-lung cancer antibodies in the blood.
An earlier Phase I/II trial of GVAX® lung cancer vaccine in patients with advanced non small-cell lung cancer, conducted
by Dr. Glenn Dranoff and colleagues at Dana-Farber/Partners Cancer Care, an affiliate of Harvard Medical School, was reported
at the Ninth World Conference on Lung Cancer in Tokyo, Japan in September 2000.
This trial demonstrated antitumor immunity in 18 of 25 patients. In addition, two patients who received GVAX® lung
cancer vaccine following surgery remain in complete remission more than three years after GVAX® treatment.
The GVAX® lung cancer vaccine trials to date, including the current study, have employed a patient-specific product
format in which the vaccine is prepared directly from the patient's own tumor cells in an overnight process.
In the near future, Cell Genesys plans to launch a clinical trial in advanced lung cancer to evaluate a non patient-specific
GVAX® product which will be centrally manufactured by Cell Genesys and then mixed with patients' own irradiated tumor cells
prior to vaccination.
This new product format for GVAX® lung cancer vaccine is expected to have significant development and commercialization
advantages compared to the first-generation product used in the trial reported yesterday.
Given the encouraging results demonstrated in ongoing clinical trials for prostate and pancreatic cancer, Cell Genesys
is emphasizing non patient-specific GVAX® products which can be developed and commercialized as "off-the-shelf" pharmaceuticals.
GVAX® cancer vaccines are comprised of tumor cells which have been genetically modified to secrete granulocyte-macrophage
colony stimulating factor (GM-CSF), a hormone which plays a key role in stimulating the body's immune response to vaccines.
The genetically modified tumor cells are then irradiated for safety and used to vaccinate patients to stimulate an
immune response against their tumor.
The company's lead GVAX® cancer vaccine program targets patients with recurrent hormone refractory prostate cancer
and is currently being evaluated in two multicenter Phase II trials.
A series of Phase I/II trials was recently initiated utilizing the company's new high-potency GVAX® prostate cancer
vaccine. Additionally, a Phase I/II trial for GVAX® vaccine for myeloma was recently initiated, and a Phase II trial of GVAX®
pancreatic cancer vaccine and a Phase I/II trial of GVAX® vaccine for leukemia are expected to commence in mid 2001.
Cell Genesys is focused on the development and commercialization of cancer vaccines and gene therapies to treat major
life-threatening diseases. The company is conducting clinical trials of GVAX® cancer vaccines in prostate cancer, pancreatic
cancer, lung cancer and myeloma and expects to initiate new studies in acute leukemia during 2001.
Preclinical stage programs include gene therapies for cancer, hemophilia and cardiovascular disorders. Cell Genesys'
majority-owned subsidiary, Ceregene, is focused on gene therapies for central nervous system disorders. Cell Genesys also
continues to hold a 10.5 percent equity interest in its former subsidiary, Abgenix, an antibody product company.
|